Document:

Exhibit 10.1

EXECUTION
VERSION

 

AMENDED
AND RESTATED BUY-IN LICENSE AGREEMENT

 

between

 

ARIAD
Pharmaceuticals, Inc.

 

and

 

ARIAD
Pharmaceuticals (Europe) Sarl

 

and

 

Incyte
Corporation (as guarantor)

 

 

 

    	 	 	 

     

    

 

TABLE
OF CONTENTS

 

	ARTICLE
    1 – DEFINITIONS	2
	ARTICLE 2
    – GRANT OF LICENSES	18
	ARTICLE 3
    – RESERVED TERRITORIES AND NON-COMPETITION	19
	ARTICLE 4
    – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES	23
	ARTICLE 5
    – DEVELOPMENT	25
	ARTICLE 6
    - EXCHANGE OF OTHER KNOW-HOW	31
	ARTICLE 7
    – PRICING AND REIMBURSEMENT	32
	ARTICLE 8
    – REGULATORY MATTERS	32
	ARTICLE 9
    – PHARMACOVIGILANCE	35
	ARTICLE 10
    – SUPPLY, FORECASTS AND ORDERING	37
	ARTICLE 11
    – SHIPMENT AND DELIVERY	39
	ARTICLE 12
    – MANUFACTURING OF THE PRODUCT	41
	ARTICLE 13
    – QUALITY ASSURANCE	43
	ARTICLE 14
    - RECALLS AND PRODUCT WITHDRAWAL	44
	ARTICLE 15
    – COMMERCIALIZATION OF THE PRODUCT	45
	ARTICLE 16
    – BUY-BACK OPTION	47
	ARTICLE 17
    – MEDICAL AFFAIRS ACTIVITIES	48
	ARTICLE 18
    – TRADEMARKS	49
	ARTICLE 19
    – CONSIDERATION AND PAYMENTS	51
	ARTICLE 20
    – REPRESENTATIONS AND WARRANTIES	56
	ARTICLE 21
    – COMPLIANCE WITH LAW; DATA PRIVACY; ANTI-BRIBERY AND ANTI-CORRUPTION	59
	ARTICLE 22
    – INDEMNIFICATION, LIMITATIONS OF LIABILITY AND INSURANCE	60
	ARTICLE 23
    – THE PATENTS	63
	ARTICLE 24
    – CONFIDENTIALITY	69
	ARTICLE 25 – TERM	71
	ARTICLE 26
    – TERMINATION	71
	ARTICLE 27
    – FORCE MAJEURE	73
	ARTICLE 28
    – LAW TO GOVERN	74
	ARTICLE 29
    – DISPUTE RESOLUTION	74
	ARTICLE 30
    – MISCELLANEOUS	75

 

appendices

APPENDIX
1.18 – ARIAD US TRADEMARKS

APPENDIX
1.21 – BCR-ABL INHIBITOR COMPOUND ASSAY

APPENDIX
1.35 – COMMERCIALIZATION PLAN

APPENDIX
1.40 – PONATINIB STRUCTURE

APPENDIX
1.62 – DISTRIBUTION AGREEMENTS

APPENDIX
1.128 – PATENTS

APPENDIX
1.134 – PRIMARY EFFICACY ENDPOINT

APPENDIX
1.138 – PROPOSED STUDIES

APPENDIX
1.161 – SUPERIORITY

APPENDIX
1.167 – TERRITORY

APPENDIX
1.175 – TRANSITION BACK ARRANGEMENTS

APPENDIX
17.3 – ISTs

APPENDIX
19.8.2 – OFFSET

APPENDIX
20 - DISCLOSURE SCHEDULES

APPENDIX
20.1.17 – POST-MARKETING REQUIREMENTS

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

THIS
AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT (“Agreement”) dated as of June 1, 2016 (the “Effective
Date”), between ARIAD Pharmaceuticals, Inc., (“ARIAD US”), a Delaware corporation and ARIAD Pharmaceuticals
(Europe) Sarl, (“ARIAD SWISSCO”), a Swiss limited liability company registered in Lausanne (together, the “Parties”
and, individually, each a “Party”) and Incyte Corporation, a Delaware corporation (“Incyte Corporation”)
solely in its capacity as guarantor under Section 30.19. This Agreement only comes into effect on the Effective Date (as defined
below) and shall be of no force or effect if there is no Closing (as defined below). 

 

RECITALS

 

		a.	The Parties are engaged in the
                                         business of discovering, developing, manufacturing and selling the Product (as defined
                                         below);

 

		b.	The Parties entered into a Buy-In
                                         License Agreement on August 7, 2012 (“Buy-In License Agreement”),
                                         whereby ARIAD US granted to ARIAD SWISSCO a perpetual and exclusive license to the Ponatinib
                                         Intangibles (as therein defined) for the purposes of development and commercialization
                                         of the Product in certain territories. The Parties also entered into a Development Cost
                                         Sharing Agreement on August 7, 2012 (the “CSA Agreement”) pursuant
                                         to which they agreed to share the costs and risks of further developing the Product.

 

		c.	ARIAD SWISSCO is an Affiliate of ARIAD
                                         Pharmaceuticals (Luxembourg) S.a.r.l. (“ARIAD LUXCO”), a Luxembourg
                                         limited liability company registered in Luxembourg. Pursuant to a Share Purchase Agreement
                                         (“Share Purchase Agreement”) entered into on May 9, 2016 among ARIAD
                                         Pharmaceuticals (Cayman) L.P., a Cayman Limited Partnership, ARIAD US (with respect to
                                         selected provisions only), Incyte Europe S.a.r.l, an entity formed under the laws of
                                         Switzerland (“Incyte Europe”) and Incyte Corporation (with respect
                                         to selected provisions only), Incyte Europe will acquire the entire issued share capital
                                         in ARIAD LUXCO and, in connection therewith, the parties thereto agreed that the Buy-in
                                         License Agreement would be amended and restated on the terms of this Amended and Restated
                                         Buy-In License Agreement. The CSA Agreement will terminate effective on the Effective
                                         Date and the costs of development will now be on the terms set out in this Agreement.

 

		d.	The Parties entered into a Loan Agreement
                                         on August 7, 2012 (the “Loan Agreement”) pursuant to which ARIAD US
                                         loaned the monies to ARIAD SWISSCO to enable it to pay the consideration under the Buy-In
                                         License Agreement. In consideration of ARIAD SWISSCO entering into this Agreement, ARIAD
                                         US has hereby agreed to reduce all of the amount outstanding under the Loan Agreement
                                         and, effective as of the Effective Date, the loan is no longer outstanding.

 

		e.	ARIAD SWISSCO wishes to continue to
                                         purchase the Product from ARIAD US for the Territory, as further set forth herein.

 

		f.	The Parties agree that this preamble
                                         constitutes an integral part of this Agreement and that all capitalized terms used in
                                         this preamble shall have the respective meanings given above or in ARTICLE 1 or elsewhere
                                         in this Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 1

     

    

 

NOW,
THEREFORE, in consideration of the above premises and the mutual promises set forth below, the Parties hereby agree as follows:

 

ARTICLE
1 – DEFINITIONS

 

Capitalized terms used
in this Agreement shall have the meanings specified below or elsewhere herein.

 

		1.1	“Acquired
                                         Party” has the meaning set forth in Section 3.3.2.

 

		1.2	“Acquiring
                                         Party” has the meaning set forth in Section 3.3.2.

 

		1.3	“Adverse
                                         Ruling” has the meaning set forth in Section 26.1.

 

		1.4	“Affiliate”
                                         means any corporation or business entity that, whether now or in the future, controls,
                                         is controlled by or is under common control with a Party. For the purposes of this definition,
                                         the terms “controls”, “controlled by” and “under common
                                         control with” as used with respect to any Party, means (i) to possess (directly
                                         or indirectly) the power to direct the management or affairs of a corporation or other
                                         business entity, whether through ownership of voting securities or other equity rights
                                         or by contract relating to voting rights or corporate governance or otherwise, or (ii)
                                         to own, directly or indirectly, more than [***] of the outstanding voting securities
                                         or other ownership interest of such corporation or other business entity. For purposes
                                         of this Agreement, as of the Effective Date, ARIAD SWISSCO and ARIAD US are no longer
                                         Affiliates of one another.

 

		1.5	“Agreement”
                                         has the meaning set forth in the Preamble.

 

		1.6	“Alliance
                                         Manager” has the meaning set forth in Section 4.6.

 

		1.7	“Ancillary
                                         Research” means research other than Basic Research, in the case of ARIAD SWISSCO
                                         conducted under the licenses granted to ARIAD SWISSCO pursuant to this Agreement and
                                         in the case of ARIAD US, comparable research conducted by ARIAD US, other than in connection
                                         with a clinical trial under this Agreement.

 

		1.8	“Anti-Corruption
                                         Laws” means all Applicable Laws for the prevention of fraud, kickbacks, bribery,
                                         corruption, racketeering, money laundering or terrorism, including the FCPA, each, as
                                         amended from time to time.

 

		1.9	“API”
                                         means the Compound in the active pharmaceutical ingredient form set forth in the Specifications.

 

		1.10	“Applicable
                                         Laws” means the applicable provisions of any and all national, regional, state
                                         and local laws, treaties, statutes, rules, regulations, administrative codes, and ordinances,
                                         and any and all directives, and orders or administrative decisions of any governmental
                                         agency or authority (including Regulatory Authorities) having jurisdiction over or related
                                         to the subject matter in question, including Regulatory

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 2

     

    

 

Requirements,
Regulatory Laws, Export Control Laws, and the FCPA and other Anti-Corruption Laws, which are applicable to the subject matter
of this Agreement.

 

		1.11	“ARIAD
                                         LUXCO” has the meaning set forth in the Recitals.

 

		1.12	“ARIAD
                                         SWISSCO” has the meaning set forth in the Preamble.

 

		1.13	“ARIAD
                                         SWISSCO Improvements” means Know-how (for purposes of this definition Know-how
                                         shall be the Know-how definition without clause (b) thereof and references to ARIAD US
                                         therein shall be references to ARIAD SWISSCO) and any associated Intellectual Property
                                         Rights arising after the Effective Date and resulting from Development or Manufacturing
                                         activity conducted by ARIAD SWISSCO, its Affiliates or Subcontractors but excluding Development
                                         Data.

 

		1.14	“ARIAD
                                         SWISSCO Trademarks” means any word, name, symbol, color, designation or device
                                         or any combination thereof that functions as a source identifier, including any trademark,
                                         trade dress, brand mark, service mark, trade name, brand name, logo, business symbol
                                         or domain names, whether or not registered, to be used by ARIAD SWISSCO or its Affiliates
                                         or its or their respective Sublicensees (as an alternative to the ARIAD US Trademark)
                                         and any registrations thereof or any pending applications relating thereto (excluding,
                                         in any event, any trademarks, service marks, names or logos that include any corporate
                                         name or logo of the Parties or their Affiliates). The ARIAD SWISSCO Trademarks exclude
                                         the ARIAD US Trademarks.

 

		1.15	“ARIAD
                                         US” has the meaning set forth in the Preamble.

 

		1.16	“ARIAD
                                         US Improvements” means (i) Know How and any associated Intellectual Property
                                         Rights arising after the Effective Date and resulting from Development or Manufacturing
                                         activity conducted by ARIAD US, its Affiliates or Subcontractors, but excluding Development
                                         Data ; and (ii) Know How and any associated Intellectual Property Rights arising after
                                         the Effective Date and resulting from the conduct of Basic Research by ARIAD US, its
                                         Affiliates or Subcontractors; and (iii) any new technologies Controlled by ARIAD US or
                                         its Affiliates and used by them in relation to Product during the Term.

 

		1.17	“ARIAD
                                         US Successor” has the meaning set forth in Section 16.1.

 

		1.18	“ARIAD
                                         US Trademarks” means any word, name, symbol, color, designation or device or
                                         any combination thereof that functions as a source identifier, including any trademark,
                                         trade dress, brand mark, service mark, trade name, brand name, logo, business symbol
                                         or domain names, whether or not registered, for the Product in the Territory used by
                                         ARIAD US for the Product in USA including (a) the trademarks applications and registrations
                                         set forth in Appendix 1.18 and (b) all registered and unregistered rights in such trademarks
                                         set forth in Appendix 1.18, including all current and future registrations and applications
                                         for registration of the same in the Territory and all renewals and extensions thereto,
                                         in each case that are Controlled by ARIAD US or its Affiliates.

 

		1.19	“Basic
                                         Research” means research on the Compound’s [***], [***], [***] and all
                                         other research the objective of which is a product [***] from the Product. 

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 3

     

    

 

		1.20	“BCR-ABL”
                                         means the chromosomal translocation designated as t(9;22)(q34;q11) in the International
                                         System for Human Cytogenetic Nomenclature (or a mutated or modified form thereof).

 

		1.21	“BCR-ABL
                                         Inhibitor Compound” means any compound that inhibits BCR-ABL with an [***]
                                         (measured as average [***] at an ATP concentration equal to the Km for [***] in an enzyme
                                         assay when assayed [***] using the assay method set forth in [***].

 

		1.22	“Breaching
                                         Party” has the meaning set forth in Section 26.1.

 

		1.23	“Business
                                         Day” means a day other than a Saturday or Sunday or any public holiday in the
                                         United States or Switzerland or any other day on which banks are required or authorized
                                         by Applicable Law to be closed in the United States or Switzerland.

 

		1.24	“Business
                                         Entity” means any corporation, general or limited partnership, trust, joint
                                         venture, unincorporated organization, limited liability entity or other entity.

 

		1.25	“Buy-Back
                                         Option” has the meaning set forth in Section 16.1.

 

		1.26	“Buy-In
                                         License Agreement” has the meaning set forth in the Recitals.

 

		1.27	“CDA”
                                         means the Confidential Disclosure Agreement by and between ARIAD US and Incyte Corporation
                                         dated January 19, 2016.

 

		1.28	“cGMP”
                                         means all Applicable Laws, guidance, directives, standards, practices and procedures
                                         relating to the Manufacture of Compound or Product, including (i) the U.S. Code of Federal
                                         Regulations and FDA’s guidance documents, and all successor applicable regulations
                                         and guidance documents thereto, (ii) the EUDRALEX Vol. 4 “Medicinals for Human
                                         and Veterinary Use: Good Manufacturing Practice”, in particular Part II “Basic
                                         Requirements for Active Substances used as Starting Materials” (03 October 2005),
                                         and applicable Annexes to Vol.4, and (iii) the ICH (International Conference on Harmonisation
                                         of Technical Requirements for the Registration of Pharmaceuticals for Human Use) guidelines,
                                         including without limitation, ICH Q7A "ICH Good Manufacturing Practice Guide for
                                         Active Pharmaceutical Ingredients.

 

		1.29	“Change
                                         of Control” means in respect of a Party the occurrence after the Effective
                                         Date of any of the following: (i) the sale, conveyance or disposition, in one or a series
                                         of related transactions, of all or substantially all of the assets of such Party to a
                                         Third Party that is not an Affiliate of such Party prior to such transaction or the first
                                         of such related transactions; (ii) the consolidation, merger or other business combination
                                         of ARIAD US with or into any other Business Entity, immediately following which the then-current
                                         stockholders of the Party, as such, fail to own in the aggregate at least Majority Voting
                                         Power of the surviving Party in such consolidation, merger or business combination or
                                         of its ultimate publicly-traded parent Business Entity; or (iii) a transaction or series
                                         of transactions in which any Person or “group” (as such term is used in Sections
                                         13(d) and 14(d) of the Exchange Act) acquires Majority Voting Power of such Party (other
                                         than (a) a reincorporation or similar corporate transaction in which each of such Party’s
                                         stockholders owns, immediately thereafter, interests in

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 4

     

    

 

the new
parent company in substantially the same percentage as such stockholder owned in such Party immediately prior to such transaction,
or (b) in connection with a transaction described in (ii), which shall be governed by such (ii)), For the Purposes of this definition
“Majority Voting Power” means a majority of the ordinary voting power in the election of directors or a majority
of all the outstanding voting securities of the resulting Business Entity or of the Party, respectively.

 

		1.30	“Claim
                                         Notice” has the meaning set forth in Section 22.3.1.

 

		1.31	“Closing”
                                         has the meaning set forth in the Share Purchase Agreement.

 

		1.32	“CML”
                                         means chronic myeloid leukemia.

 

		1.33	“Combination
                                         Product” means a Product that is comprised of or contains Compound as an active
                                         ingredient together with one (1) or more other active ingredients and is sold either
                                         as a fixed dose or as separate doses in one (1) product.

 

		1.34	“Commercialize”
                                         means all activities directed to importing (into, or within, the Territory), exporting
                                         (to or within the Territory), storing, marketing, promoting, selling, offering for sale
                                         and distributing the Product in the Territory. “Commercializes,” “Commercialized,”
                                         “Commercialization” and other forms of the word “Commercialize”
                                         shall have the correlative meaning. For clarity, “Commercialize” excludes
                                         Manufacture.

 

		1.35	“Commercialization
                                         Plan” means (i) a [***] plan prepared by ARIAD SWISSCO for the Product in the
                                         Field in the Territory setting out the Commercialization [***],[***] and activities,
                                         in each case for the following calendar year; and (ii) a [***] plan prepared by ARIAD
                                         US for the Product in the Field in the Reserved Territory setting out the Commercialization
                                         [***],[***] and activities, in each case for the following calendar year. The Commercialization
                                         Plan for 2016 is attached at [***], it being understood that the contents of future Commercialization
                                         Plans shall be in accordance with this Section 1.35 without regard to [***].

 

		1.36	“Commercially
                                         Reasonable Efforts” means, in respect of ARIAD SWISSCO, [***] and in respect
                                         of ARIAD US, [***], in each case, to [***] and [***] a [***] such party or [***], which
                                         [***] is [***] or [***] and is [***] taking into [***] and other relevant factors.

 

		1.37	“Competitive
                                         Product” means any pharmaceutical product (other than a Product, but including
                                         a generic version of the Product) that is a [***] other than an Excluded Compound. 
                                         

 

		1.38	“Compliance
                                         Event” has the meaning set forth in Section 21.5.

 

		1.39	“Composition
                                         Patent” means any Patent Controlled by ARIAD US or its Affiliates in the Territory
                                         that contains a Valid Claim that covers the Product and/or Compound.

 

		1.40	“Compound”
                                         means the active pharmaceutical ingredient known as ponatinib having the structure set
                                         forth on Appendix 1.40, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer,
                                         free acid form, free base form, crystalline form, co-crystalline form, amorphous form,
                                         pro-drug (including ester pro-drug) form,

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 5

     

    

 

racemate,
polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing, including crystalline ponatinib monohydrochloride.

 

		1.41	“Confidential
                                         Information” has the meaning set forth in Section 24.1.

 

		1.42	“Control”
                                         (including any variations such as “Controlled” and “Controlling”)
                                         means, with respect to any item of Know-how, Regulatory Documentation, material, Patent,
                                         or other Intellectual Property Right, the possession of the right, whether directly or
                                         indirectly, and whether by ownership, license or otherwise (other than by operation of
                                         the license granted under this Agreement), to grant a license, sublicense or other right
                                         (including the right to reference Regulatory Documentation) to or under such Know-how,
                                         Regulatory Documentation, material, Patent, or other Intellectual Property Right as provided
                                         for herein without violating the terms of any then-existing agreement with any Third
                                         Party; provided, that Intellectual Property Rights of an acquirer of a Party or
                                         its Affiliates in existence prior to the acquisition date, or developed after the acquisition
                                         date solely by such acquirer without use of or reference to such Party’s preexisting
                                         Know-how, Regulatory Documentation, material, Patent, or other Intellectual Property
                                         Right and without contribution from employees of a Party or its Affiliates other than
                                         the acquirer, shall not be deemed to be “Controlled” by such Party or Affiliate.

 

		1.43	“Cost
                                         of Manufacture” means in relation to any aspect of the Manufacture either (i)
                                         Direct Cost and Indirect Cost where the Party is undertaking the manufacture; or (ii)
                                         Third Party Manufacturing Costs where a Party has appointed a contract manufacturing
                                         organization or toll manufacturer.

 

		1.44	“CRO”
                                         means a contract research organization to which certain Development services are contracted.

 

		1.45	“CSA
                                         Agreement” has the meaning set forth in the Recitals.

 

		1.46	“CSR”
                                         means a written clinical study report containing the results of an Ongoing Study or other
                                         clinical study, as applicable.

 

		1.47	“CSR
                                         Payment” has the meaning set forth in Section 5.3.1.

 

		1.48	“Current
                                         Manufacturing Process” has the meaning set forth in Section 6.2.

 

		1.49	“Customer”
                                         means any entity or person that is authorized to purchase and dispense or sell the Product
                                         in the Territory under Applicable Law.

 

		1.50	“Data
                                         Protection Laws” has the meaning set forth in Section 21.4.

 

		1.51	“Default
                                         Notice” has the meaning set forth in Section 26.1.

 

		1.52	“Defending
                                         Party” has the meaning set forth in Section 23.5.1.

 

		1.53	“Delivery”
                                         has the meaning set forth in Section 11.1.3.

 

		1.54	“Delivery
                                         Documents” means those documents specified and listed as such in the Interim
                                         Quality Agreement

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 6

     

    

 

		1.55	“Development”
                                         and “Develop” means the conduct of Pre-clinical Research, test method
                                         development and stability testing, process development, manufacturing scale-up, qualification
                                         and validation, quality assurance/quality control, any clinical studies carried out in
                                         relation to the Product leading to a Marketing Authorization or an extension of such
                                         Marketing Authorization, including Manufacturing in support thereof, statistical analysis
                                         and report writing, the preparation and submission of Registrations, regulatory affairs
                                         with respect to the foregoing and all other activities necessary or reasonably useful
                                         or otherwise requested or required by a Regulatory Authority as a condition to or in
                                         support of obtaining or maintaining a Registration. For clarity, Development does not
                                         include Basic Research.

 

		1.56	“Development
                                         Costs” means the costs and expenses associated with Development activities
                                         and shall include, unless stated otherwise, [***], [***] and [***].

 

		1.57	“Development
                                         Data” means data resulting from Development activity being Pre-clinical Research
                                         or clinical studies.

 

		1.58	“Development
                                         Register” has the meaning set forth in Section 5.1.

 

		1.59	“Development
                                         Territory” means the Reserved Territory less [***].

 

		1.60	“Developing
                                         Party” means the Party conducting or proposing to conduct the applicable clinical
                                         study itself or through its Affiliates, Sublicensees or Third Parties.

 

		1.61	“Direct
                                         Costs” include direct labor costs, based on actual hours consumed by personnel
                                         charged at an average hourly wage rate which is designed to approximate actual cost for
                                         each employee’s position and direct labor fringe benefit costs, including compensation
                                         expense (other than direct labor costs already included), payroll taxes and benefits
                                         allocated based on a proportionate percentage of direct labor costs charged to Development
                                         or Manufacture (including Manufacturing Technology Transfer) of the Product (as the case
                                         may be) in comparison to all development or manufacturing activity undertaken during
                                         the period.

 

		1.62	“Distribution
                                         Agreements” means the existing Distribution Agreements entered into as of the
                                         Effective Date in respect of the Commercialization of the Product in the Territory, a
                                         list of which is set out in Appendix 1.62 to this Agreement and any additional distribution
                                         agreements entered into by ARIAD SWISSCO or its Affiliates in respect of the Commercialization
                                         of the Product during the Term.

 

		1.63	“Distribution
                                         Agreement Milestone Payments” means any and all outstanding milestone payments
                                         [***] under Article 13.2 of the [***] between [***].

 

		1.64	“Drug
                                         Product” means Product in bulk finished (not labeled or packaged) form.

 

		1.65	“Effective
                                         Date” has the meaning set forth in the Preamble.

 

		1.66	“Escalation
                                         Notice” has the meaning set forth in Section 5.6.

 

		1.67	“Exchange
                                         Act” means the U.S. Securities Exchange Act of 1934, as amended, together with
                                         the rules and regulations promulgated thereunder.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 7

     

    

 

		1.68	“Excluded
                                         Compound” means a (i) [***] that is [***] or more potent on the enzyme for
                                         that compound’s primary (biologically relevant) target compared to BCR-ABL where
                                         the selectivity is assessed by the relative IC50s in enzyme assays conducted at [***]
                                         ATP for each of the two kinases (i.e. BCR-ABL and the primary target kinase of interest)
                                         or (ii) a BCR-ABL Inhibitor Compound that is more potent with respect to a target other
                                         than BCR-ABL and is not being developed as an inhibitor of BCR-ABL or for an indication
                                         for which there is an active Development program ongoing with the Product or for which
                                         the Product is then being Commercialized.

 

		1.69	“Export
                                         Control Laws” means all applicable U.S. laws and regulations relating to (a)
                                         economic and trade sanctions and embargoes imposed by the Office of Foreign Assets Control
                                         of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies,
                                         or services, including the Export Administration Act of 1979, 24 U.S.C. §§
                                         2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706,
                                         the International Traffic in Arms Regulations, 22 C.F.R. parts 120-130, the Trading with
                                         the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C.
                                         §§ 2778 and 2779, and the International Boycott Provisions of Section 999 of
                                         the U.S. Internal Revenue Code of 1986 (as amended) or such equivalent laws of any other
                                         country.

 

		1.70	“FCPA”
                                         means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.)
                                         as amended.

 

		1.71	“FDA”
                                         means the U.S. Food and Drug Administration.

 

		1.72	“Field”
                                         means the diagnosis, treatment and prevention of all diseases in humans.

 

		1.73	“Final
                                         Manufacturing” means all activities occurring anywhere in the world required
                                         to prepare the Product for commercial sale in the Territory, including secondary packaging
                                         and labeling with the approved packaging and label for the country in the Territory in
                                         which it is to be sold; stability or other testing; quality control; and release of the
                                         Product for sale in the Territory.

 

		1.74	“First
                                         Commercial Sale” means the first sale to a Third Party of Product for use or
                                         consumption by an end-user in the Field in a given country in the Territory after all
                                         aspects of Registration have been obtained in such country. A First Commercial Sale shall
                                         not include a sale of Product for use in clinical trials, for research or for other non-commercial
                                         uses, or supply of Product as part of a Named Patient Program or similar program.

 

		1.75	“Forecast”
                                         has the meaning set forth in Section 10.3.

 

		1.76	“Full
                                         Royalty Term” means, on a country-by-country basis within the Territory, the
                                         period from the Effective Date expiring on the later of (i) the expiry date (including
                                         the expiry of any patent term extensions, supplementary protection certificates or pediatric
                                         extensions) of the Composition Patent in such country or (ii) the expiration of any regulatory
                                         marketing exclusivity period or other statutory designation that provides similar exclusivity
                                         for the Commercialization of the Product in such country, or (iii) seven (7) years after
                                         the date of First Commercial Sale in such country.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 8

     

    

 

		1.77	“Generic
                                         Product” means in any particular country any Third Party product that contains
                                         Compound and either (i) for which equivalence with Product has been demonstrated to the
                                         satisfaction of the Regulatory Authority in that country or which can be substituted
                                         for Product by a dispenser or (ii) which is approved in reliance, in whole or in part,
                                         on the prior approval (or on safety or efficacy data submitted in support of the prior
                                         approval) of such Product as determined by the applicable Regulatory Authority.

 

		1.78	“Global
                                         Product Positioning” has the meaning set forth in Section 15.3.

 

		1.79	“Global
                                         Study(ies)” means a multi-centre clinical trial carried out at clinical research
                                         sites located both in the Territory and in the Development Territory.

 

		1.80	“Global
                                         Third Party License” has the meaning set forth in Section 23.6.2(a).

 

		1.81	“Government
                                         Official” means (a) any officer or employee of a government or any department,
                                         agency or instrumentality of a government; (b) any person acting in an official capacity
                                         for or on behalf of a government or any department, agency, or instrumentality of a government;
                                         (c) any officer or employee of a company or business owned or controlled by a government;
                                         (d) any officer or employee or person acting in an official capacity for or on behalf
                                         of a public international organization or any department, agency, or instrumentality
                                         of such public international organization such as the World Bank or United Nations; (e)
                                         any political party or official thereof; and/or (f) any candidate for political office.

 

		1.82	“Healthcare
                                         Professional” means any member of the medical, pharmacy or nursing professions
                                         or any other person who in the course of his or her professional activities may prescribe,
                                         administer or dispense to an end-user a medicinal product.

 

		1.83	“IC50”
                                         means the half maximal inhibitory concentration.

 

		1.84	“Incyte
                                         Corporation” has the meaning set forth in the Preamble.

 

		1.85	“Incyte
                                         Europe” has the meaning set forth in the Recitals.

 

		1.86	“IND”
                                         means an investigational new drug application filed with, and accepted by, the FDA prior
                                         to beginning clinical trials in humans in the US, or any comparable application to and
                                         acceptance by the Regulatory Authority of a country or group of countries other than
                                         the US including a request for authorization of clinical trial to be conducted in the
                                         Territory made to EMA.

 

		1.87	“Indemnified
                                         Party” has the meaning set forth in Section 22.3.1.

 

		1.88	“Indemnifying
                                         Party” has the meaning set forth in Section 22.3.1.

 

		1.89	“Indirect
                                         Costs” include (i) within Development or Manufacture or Manufacturing Technology
                                         Transfer (as the case may be), facility and occupancy costs for development personnel,
                                         such cost to be allocated pro-rata to the percent occupancy represented by development
                                         personnel on the overall facility and (ii) the cost of allocable overhead, being an amount
                                         added to an item of cost to reflect central or other overhead costs incurred by a Party
                                         being such costs normally allocated by such

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 9

     

    

 

Party to
its departments or project groups based on space occupied or headcount or other activity based method, consistently applied in
accordance with US GAAP.

 

		1.90	“Industry
                                         Guidelines” means voluntary industry codes or guidelines to which a Party has
                                         publically stated it adheres as of the Effective Date, or subsequently during the Term
                                         (as such codes or guidelines are revised from time to time by their promulgating organization).

 

		1.91	“Inferiority”
                                         means the circumstance in relation to the results of the [***] where [***] has been demonstrated
                                         to be [***] to either ponatinib dosing arm of the study (according to the [***]).

 

		1.92	“Intellectual
                                         Property Rights” means all rights in, to and under patents, trademarks, copyrights,
                                         databases, data, domain names, inventions, trade secrets and confidential information,
                                         and all other intellectual or industrial property and other analogous proprietary rights
                                         throughout the world.

 

		1.93	“Interim
                                         Quality Agreement” has the meaning set out in Section 13.1.

 

		1.94	“IST”
                                         means an investigator sponsored clinical trial.

 

		1.95	“JCC”
                                         has the meaning set forth in Section 4.4.

 

		1.96	“JSC”
                                         has the meaning set forth in Section 4.1.

 

		1.97	“Know-how”
                                         means all information regarding the Compound or Product, including documentation, processes,
                                         data and other information, and further including (a) all information on file with any
                                         competent Regulatory Authority in support of a Marketing Authorization; and (b) ARIAD
                                         US Improvements, which information and ARIAD US Improvements are Controlled by ARIAD
                                         US or its Affiliates as of the Effective Date or at any time during the Term. Know-how
                                         includes all unpatented Intellectual Property Rights licensed to ARIAD US pursuant to
                                         a Global Third Party License.

 

		1.98	“Knowledge”
                                         shall mean, with respect to a fact or matter, that the applicable Party’s [***]
                                         employee directly responsible for such fact or matter is [***] of such fact or matter
                                         [***] with respect to such fact or matter of the persons directly reporting to him or
                                         her.  “Known” has a correlative meaning.

 

		1.99	“Labeled
                                         Bottles” means Drug Product in labeled bottle form as set forth in the Specifications.

 

		1.100	“Label
                                         Payment” has the meaning set forth in Section 5.3.1.

 

		1.101	“Latent
                                         Defect” means a Non-Conformance that is not discoverable or actually discovered
                                         upon reasonable visual inspection performed pursuant to Section 11.2.1, but that is discovered
                                         at a later time (e.g., a failure to comply with the shelf-life set forth in the Specification
                                         that is identified as a result of long-term stability studies conducted by ARIAD US or
                                         its Affiliates or a Third Party authorized by ARIAD US or its Affiliates).

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 10

     

    

 

		1.102	“Liability”
                                         means any liability or obligation, whether known or unknown, absolute or contingent,
                                         accrued or unaccrued, liquidated or unliquidated, due or to become due.

 

		1.103	“Loan
                                         Agreement” has the meaning set forth in the Recitals.

 

		1.104	“Local
                                         Currencies” means the currency used in each of the respective countries in
                                         the Territory.

 

		1.105	“Losses”
                                         has the meaning set forth in Section 22.1.

 

		1.106	“MAH”
                                         means the Marketing Authorization holder for the Product in each country in the Territory.

 

		1.107	“Manufacture”
                                         means, as applicable, Final Manufacturing and the manufacturing of the Product up to
                                         and including Drug Product in Unlabeled Bottles or blister packages, and all activities
                                         related to such manufacturing of Product, or any ingredient thereof, either directly
                                         or through a contract manufacturer, including in-process and semi-finished Product testing,
                                         ongoing stability tests and regulatory activities related to any of the foregoing. “Manufactured”
                                         or “Manufacturing” and other forms of the word “Manufacture”
                                         shall have correlative meaning.

 

		1.108	“Manufacturing
                                         Process” has the meaning set forth in Section 12.3.

 

		1.109	“Manufacturing
                                         Technology Transfer” has the meaning set forth in Section 6.2.

 

		1.110	“Marketing
                                         Authorization” means a marketing authorization for the Product granted by the
                                         European Medicines Agency or by any other Regulatory Authority.

 

		1.111	“Named
                                         Patient Program” means a compassionate use, named patient use, or similar program
                                         for the supply of the Product in the Field in the Territory prior to obtainment of Registrations,
                                         to the extent permitted by and in accordance with Applicable Laws.

 

		1.112	“Net
                                         Sales” means, with respect to a Product, the [***] by ARIAD SWISSCO, its Affiliates
                                         or its Sublicensees for such Product in the Field in the Territory to [***] (such [***],
                                         including, for the purposes of this definition, the [***] under (x) the [***] and (y)
                                         any [***] where [***] is [***] of such Product to [***], in each case of (x) or (y) which
                                         [***]), less the following deductions relating to sales of the Product:

 

		(a)	[***]
                                         and/or other [***] and [***] with respect to such sales;

 

		(b)	[***];

 

		(c)	[***]
                                         or other [***] and paid with respect to the [***] of such Product [***];

 

		(d)	the
                                         amount of [***] and amounts [***] by reason of [***];

 

		(e)	charges
                                         for [***] directly related to the [***], to the extent not already deducted or excluded
                                         from the gross amount invoiced; and

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 11

     

    

 

		(f)	[***]
                                         payable to any [***];

 

		(g)	any
                                         other similar and customary deductions that are consistent with US GAAP (not including
                                         bad debt).

 

Notwithstanding
the foregoing, no [***], or any similar amount, however designated, that is given or associated with the purchase by [***] of
any product or service in addition to the Products shall be [***] allocated to the Product.

 

Such amounts
invoiced and such deductions shall be determined from the books and records of ARIAD SWISSCO and its Sublicensees maintained in
accordance with US GAAP, consistently applied throughout such party’s organization.

 

In the case
of any sale of such Product for consideration other than (or in addition to) cash, such as barter or countertrade, Net Sales shall
be calculated on the [***] of the [***] received.

 

In the case
of a sale under a [***] by [***] to a [***] that is a [***] for purposes of this definition of Net Sales, Net Sales will be based
on the [***] of Product; provided, however, that if the royalty payable based on such [***] to ARIAD US is less than [***] of
the royalty that would be applicable under this Agreement if the Net Sales had been by [***] or [***], then any other consideration
received by [***] or [***] under such [***], such as upfront or milestone payments (and not legitimate compensation for other
services or products) will be included in Net Sales on an equitable pro-rata basis.

 

If such
Product is sold to any [***] together with other products or services, the price of such Product, solely for purposes of the calculation
of Net Sales, shall be deemed to be no less than the price at which such Product would be [***] to a [***] not also [***].

 

The Net
Sales of any Combination Product:

 

(x)     for
which the [***] and other [***] of such Combination Product are sold separately by ARIAD SWISSCO, or any of its Affiliates or
their Sublicensees, or the relevant Third Party, in such country, then Net Sales for such Combination Product in such country
shall be calculated by multiplying [***] of such Combination Product in such country by the fraction A/(A+B), where A is [***];

 

(y)     for
which the other [***] in the Combination Product is/are not sold separately by ARIAD SWISSCO or any of its Affiliates or their
Sublicensees or the relevant Third Party, in such country, then Net Sales for such Combination Product in such country shall be
calculated by multiplying [***] of such Combination Product in such country by the fraction A/D, where A is the [***], and D is
the [***]; and

 

(z)     for
which neither clause (x) nor clause (y) above is applicable, the Parties shall determine Net Sales for such Combination Product
in such country by [***] based on the [***] and the [***] in the Combination Product.

 

		1.113	“New
                                         Indication” means any indication in the Field, being any disease, condition
                                         or syndrome other than CML or Philadelphia chromosome positive ALL. For clarity, new
                                         lines of therapy within an already approved indication or for another subset of patients
                                         within an already approved indication (e.g., pediatric Ph+ ALL) would not qualify as
                                         a New Indication.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 12

     

    

 

		1.114	“Non-Breaching
                                         Party” has the meaning set forth in Section 26.1.

 

		1.115	“Non-Conformance”
                                         means a failure of the Product supplied hereunder to comply with any of the Product warranties
                                         set forth in Section 20.1.5. For clarity, a Latent Defect is an instance of Non-Conformance.
                                         The adjective “Non-Conforming” shall have the correlative meaning. “Non-Conformance”
                                         does not include damage caused to Products caused by actions of or on behalf of ARIAD
                                         SWISSCO following Delivery by ARIAD US to ARIAD SWISSCO, including Manufacture, where
                                         applicable.

 

		1.116	“Non-Developing
                                         Party” means the Party that is not the Developing Party.

 

		1.117	“Non-Inferiority”
                                         means the circumstance in relation to the results of the [***] where neither [***] nor
                                         [***] has been demonstrated.

 

		1.118	“Notified
                                         Party” has the meaning set forth in Section 21.5.

 

		1.119	“Notifying
                                         Party” has the meaning set forth in Section 21.5.

 

		1.120	“Objection
                                         Notice” has the meaning set forth in Section 11.2.2.

 

		1.121	“OMNI
                                         Study” means the postmarketing observational study to evaluate the incidence
                                         and risk factors for vascular occlusive events associated with Iclusig®

 

		1.122	“Ongoing
                                         Studies” means the OPTIC Clinical Trial, OPTIC-2L Clinical Trial and OMNI Study
                                         each of which were started prior to the Effective Date and are scheduled to be completed
                                         after the Effective Date.

 

		1.123	“Ongoing
                                         Studies Budget” has the meaning set forth in Section 5.3.1

 

		1.124	“OPTIC
                                         Clinical Trial” means the Phase 2 dose-ranging OPTIC (Optimizing Ponatinib
                                         Treatment in CML) trial being conducted by ARIAD US in respect of the Product as at the
                                         Effective Date.

 

		1.125	“OPTIC
                                         2L Clinical Trial” means the randomized Phase 3 OPTIC 2L (Optimizing Ponatinib
                                         Treatment in CML, Second Line) trial versus nilotinib being conducted by ARIAD US in
                                         respect of the Product as at the Effective Date.

 

		1.126	“Party”
                                         has the meaning set forth in the Preamble.

 

		1.127	“Payment”
                                         has the meaning set forth in Section 19.7.

 

		1.128	“Patents”
                                         means (a) all patents and patent applications that are Controlled by ARIAD US or its
                                         Affiliates as of the Effective Date and at any time during the Term that are necessary
                                         or useful (or, with respect to patent applications, would be necessary or useful if such
                                         patent applications were to issue as patents), a list of which as at the Effective Date
                                         is included in Appendix 1.128 hereto, or are licensed to ARIAD US pursuant to a Global
                                         Third Party License; (b) all patents issuing from the applications in subsection (a);
                                         (c) any additions, divisions, continuations, continuations-in-part, counterparts, amendments,
                                         amalgamations, reissues and re-examinations of such applications or patents; (d) any
                                         confirmation, importation and registration patents

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 13

     

    

 

thereof;
and (e) any extensions and renewals of all such patents and patent applications in whatever legal form and by whatever legal title
they are granted.

 

		1.129	“PDL
                                         Agreements” mean the (i) Revenue Interest Assignment Agreement between ARIAD
                                         US and PDL BioPharma, Inc., dated July 28, 2015, and (ii) the Security Agreement among
                                         ARIAD US, ARIAD Pharma Ltd. and PDL BioPharma, Inc., dated July 28, 2015, in each case
                                         as amended in connection with this Agreement. 

 

		1.130	“Pharmacovigilance
                                         Agreement” has the meaning set forth in Section 9.4.

 

		1.131	“Pre-clinical
                                         Research” means (i) research preparatory to the filing of an IND to conduct
                                         clinical studies including studies on the toxicological, pharmacological, metabolic or
                                         clinical aspects of the Product and testing in-vivo in animal models in relation to a
                                         New Indication, a line extension of an existing approved indication, or a Global Study
                                         or a Territory-specific study; and (ii) research conducted in relation to a clinical
                                         study under this Agreement. Pre-clinical Research excludes Basic Research.

 

		1.132	“Presentation”
                                         means each stock-keeping unit of Product differentiated by dosage strength, bottle count,
                                         packaging presentation, and/or country-specific labeling for the Product for which Marketing
                                         Authorization has been received in a country in the Territory (e.g., a 60 count bottle
                                         of 15mg tablets labeled for a specific country in the Territory).

 

		1.133	“Pricing
                                         and Reimbursement Approval” means any official, final, binding and non-appealable
                                         determination of the reimbursable price of the Product in accordance with Applicable
                                         Laws and approval by relevant Regulatory Authorities pertaining to the reimbursement
                                         of the Product, as applicable in each country in the Territory in which a Regulatory
                                         Authority approves or determines the price and/or reimbursement of pharmaceutical products.

 

		1.134	“Primary
                                         Efficacy Endpoint” has the meaning set forth on Appendix 1.134.

 

		1.135	“Proceeding”
                                         means any (i) Third Party private action, claim or lawsuit (including in arbitration)
                                         or (ii) governmental, judicial, administrative or adversarial proceeding, hearing, probe
                                         or inquiry brought by any Third Party public entity, including whistleblower complaints.
                                         Proceedings shall not include any action, claim or lawsuit brought by one Party or its
                                         Affiliates against the other Party or its Affiliates.

 

		1.136	“Product”
                                         means any pharmaceutical product containing Compound as an active chemical entity in
                                         any and all forms, presentations, and dosages

 

		1.137	“Product
                                         Withdrawal” means removal of Product from the market in any country on grounds
                                         of public health or safety resulting in discontinuation of all or substantially all distribution
                                         of Product in such country. Product Withdrawal does not include a Recall.

 

		1.138	“Proposed
                                         Studies” means the list of clinical studies proposed to be undertaken by ARIAD
                                         US in the Territory and the Reserved Territory, the name, protocol synopses for which
                                         are as set forth in Appendix 1.138.

 

		1.139	“Protected
                                         Personal Information” has the meaning set forth in Section 21.4.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 14

     

    

 

		1.140	“Quality
                                         Agreement” has the meaning set out in Section 13.1.

 

		1.141	“Raw
                                         Materials” means any raw materials, components, or other ingredients required
                                         for the Manufacture of the Drug Product.

 

		1.142	“Recall”
                                         means a recall or retrieval of Product on grounds of Non-Conformance, public health or
                                         safety which is limited as to lot(s) or batch(es) of Product.

 

		1.143	“Reduced
                                         Royalty Term” has the meaning set forth in Section 19.2.2.

 

		1.144	“Registrations”
                                         means (a) Marketing Authorizations, (b) Pricing and Reimbursement Approval, (c) receipt
                                         of any license required to import or export Product(s), and (d) any other official license
                                         or approval which is legally required to (i) Develop or Manufacture Compound or Product
                                         anywhere in the world for purposes of Commercialization in the Field in the Territory
                                         or (ii) Commercialize Product in the Field in the Territory (e.g., wholesale licenses).

 

		1.145	“Regulatory
                                         Authority” means the European Medicines Agency, FDA or any other government
                                         agency that is a competent authority for the issuance of any of the Registrations, or
                                         any part of them, throughout the Term.

 

		1.146	“Regulatory
                                         Documentation” means all letters, correspondence, applications and other documents
                                         and information submitted to Regulatory Authorities or received from Regulatory Authorities
                                         in writing, including in electronic format, as well as any supporting documentation.

 

		1.147	“Regulatory
                                         Laws” means all laws, and all orders, determinations, regulations, licenses
                                         and directions made or issued under such laws, in respect of the Registrations, Manufacturing
                                         and Commercialization of the Product.

 

		1.148	“Regulatory
                                         Requirements” means all licenses, registrations, mandatory standards, conditions,
                                         manufacturing principles, directions, orders and determinations in force from time to
                                         time set out in the Regulatory Laws and all other Applicable Laws that apply to the manufacture
                                         (including Manufacture), supply, packaging, labeling and/or Commercialization of medicinal
                                         products.

 

		1.149	“Reserved
                                         Territory” shall have the meaning set forth in Section 3.1.

 

		1.150	“Royalty
                                         Term” means, with respect to a country in the Territory, the Full Royalty Term
                                         and the Reduced Royalty Term, collectively.

 

		1.151	“Safety
                                         Improvement” means the circumstance in relation to the results of the [***]
                                         where (i) [***]; but (ii) there is at least a [***] reduction in the [***] in either
                                         ponatinib arm of the study compared to the rate set forth in [***] for the Product as
                                         of the Effective Date (ie [***]).

 

		1.152	“Safety
                                         Information” has the meaning set forth in Section 9.5.

 

		1.153	“SEC”
                                         means the U.S. Securities and Exchange Commission or any successor agency.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 15

     

    

 

		1.154	“Second
                                         Line CML” means the treatment of second line CML (post-imatinib) based on demonstration
                                         of the Product’s [***] in the ongoing OPTIC 2L Clinical Trial or any other study
                                         sponsored by either ARIAD US or ARIAD SWISSCO.

 

		1.155	“Segregate”
                                         means, with respect to a Competitive Product to use Commercially Reasonable Efforts to
                                         segregate the Development, Manufacture, and Commercialization activities relating to
                                         such Competitive Product from Development, Manufacture, and Commercialization activities
                                         for Compounds or Products under this Agreement, including using Commercially Reasonable
                                         Efforts to ensure that: (i) no personnel involved in performing the Development, Manufacture,
                                         or Commercialization of such Competitive Product have access to non-public plans or non-public
                                         information relating to the Development, Manufacture, or Commercialization of Compounds
                                         or Products or any other Confidential Information of the applicable Party; and (ii) no
                                         personnel involved in performing the Development, Manufacture, or Commercialization of
                                         Compounds or Products have access to non-public plans or information relating to the
                                         Development, Manufacture, or Commercialization of such Competitive Product; provided,
                                         that, in either case of (i) or (ii), senior management personnel may review and evaluate
                                         plans and information regarding the Development, Manufacture, and Commercialization of
                                         such Competitive Product, solely in connection with portfolio decision-making among product
                                         opportunities.

 

		1.156	“Senior
                                         Officer” means, (i) with respect to ARIAD US, its Chief Executive Officer,
                                         and (ii) with respect to ARIAD SWISSCO, the Chief Executive Officer of Incyte Corporation.

 

		1.157	“Specifications”
                                         means the specifications for the Product in Unlabeled Bottle or API form, as applicable,
                                         as defined by the Parties and incorporated into the Interim Quality Agreement and future
                                         Quality Agreements, together with changes to such specifications made in accordance with
                                         Section 12.3.

 

		1.158	“Share
                                         Purchase Agreement” has the meaning set forth in the Recitals.

 

		1.159	“Sublicensee”
                                         means any Affiliate of ARIAD SWISSCO or Third Party appointed by ARIAD SWISSCO as a sublicensee
                                         under this Agreement in accordance with the terms of this Agreement.

 

		1.160	“Subcontractor”
                                         means a Third Party appointed by ARIAD SWISSCO, subject to Section 2.3, to perform activities
                                         under this Agreement on behalf of ARIAD SWISSCO. For clarity, a Subcontractor does not
                                         include a Sublicensee.

 

		1.161	“Superiority”
                                         has the meaning set forth on Appendix 1.161.

 

		1.162	“Supply
                                         Agreement” has the meaning set forth in Section 10.1.

 

		1.163	“Target
                                         Enrollment” has the meaning set forth in Section 5.3.2.

 

		1.164	“Taxes”
                                         has the meaning set forth in Section 19.7. The terms “Taxable”
                                         and “Tax” have correlative meanings.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 16

     

    

 

		1.165	“Term”
                                         means the period beginning on the Effective Date and continuing unless and until terminated
                                         in accordance with its terms.

 

		1.166	“Termination
                                         Notice” has the meaning set forth in Section 16.1.

 

		1.167	“Territory”
                                         means the area within the geographic boundaries as set forth in Appendix 1.167. Appendix
                                         1.167 sets forth the status of Product in the Territory as of the Effective Date.

 

		1.168	“Territory-Only
                                         Third Party License” has the meaning set forth in Section 23.6.1.

 

		1.169	“Third
                                         Party” means any Person other than ARIAD US, ARIAD SWISSCO and their respective
                                         Affiliates. For purposes of this definition, “Person” means any (i) natural
                                         person, (ii) partnership, company, corporation or other form of business organization
                                         or legal entity, and (iii) any governmental or administrative entity.

 

		1.170	“Third
                                         Party Development Costs” mean within Development, the actual invoiced amounts
                                         paid by a Party to a CRO, excluding recoverable taxes such as VAT.

 

		1.171	“Third
                                         Party Infringement Claim” has the meaning set forth in Section 23.5.1.

 

		1.172	“Third
                                         Party License” has the meaning set forth in Section 23.5.6.

 

		1.173	“Third
                                         Party Manufacturing Costs” mean within or relating to Manufacture or Manufacturing
                                         Technology Transfer, the actual invoiced amounts paid by a Party to a contract manufacturing
                                         organization, excluding recoverable taxes such as VAT.

 

		1.174	“Transaction”
                                         has the meaning set forth in Section 3.3.2.

 

		1.175	“Transition
                                         Back Arrangements” means the arrangements set out in Appendix 1.175.

 

		1.176	“Transitional
                                         Supply Arrangements” has the meaning set forth in Section 10.1.

 

		1.177	“Unlabeled
                                         Bottles” means Drug Product in unlabeled bottle form as set forth in the Specifications.

 

		1.178	“US
                                         GAAP” means generally accepted accounting provisions in force in USA from time
                                         to time.

 

		1.179	“Valid
                                         Claim” means a claim of an issued and unexpired Patent to the extent such claim
                                         has not been revoked, held invalid or unenforceable by a patent office, court or other
                                         governmental agency of competent jurisdiction in a final order, from which no further
                                         appeal can be taken, and which claim has not been disclaimed, denied or admitted to be
                                         invalid or unenforceable through reissue, re-examination or disclaimer or otherwise.

 

		1.180	“Year-End
                                         Compensating Payment” has the meaning set forth in Appendix 19.8.2.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 17

     

    

 

ARTICLE
2 – GRANT OF LICENSES 

 

		2.1	Grant
                                         of licenses.

 

		2.1.1	Subject
                                         to the terms and conditions of this Agreement, including any reservation of ARIAD US’s
                                         rights expressly set forth herein, ARIAD US hereby grants to ARIAD SWISSCO, and ARIAD
                                         SWISSCO hereby accepts, an exclusive (even as to ARIAD US and its Affiliates, except
                                         in the case of clause (i) below), perpetual, license under the Patents, the Know-how,
                                         the ARIAD US Trademarks and any other Intellectual Property Rights of ARIAD US and its
                                         Affiliates in and to the Compound or Product to (i) conduct Ancillary Research anywhere
                                         in the world, (ii) Develop Product in the Territory (subject to ARIAD US’s rights
                                         to Develop under Sections 5.3, 5.4 and 5.7) and, in connection with a Global Study, in
                                         the Development Territory, (ii) Manufacture Product anywhere in the world for purposes
                                         of Commercialization in the Field in the Territory, and (iv) Commercialize Product in
                                         the Field in the Territory, in each case in accordance with the terms of this Agreement.

 

		2.1.2	Subject
                                         to the terms and conditions of this Agreement, including any reservation of ARIAD US’s
                                         rights expressly set forth herein (including payment for use of Development Data as required
                                         under Sections 5.5, 5.7.3 and 5.9), ARIAD US hereby grants to ARIAD SWISSCO, and ARIAD
                                         SWISSCO hereby accepts, an exclusive (even as to ARIAD US and its Affiliates, except
                                         in the case of clause (i) below) license and right of reference under the Registrations
                                         and all other Regulatory Documentation that ARIAD US or its Affiliates may Control with
                                         respect to the Compound or Product as necessary for ARIAD SWISSCO to (i) [***]
                                         anywhere in the world, (ii) Develop Product in the Territory (subject to ARIAD US’s
                                         rights to Develop under Sections 5.3, 5.4 and 5.7) and, in connection with a Global Study,
                                         in the Development Territory, (iii) Manufacture Product anywhere in the world for purposes
                                         of Commercialization in the Field in the Territory, and (iv) Commercialize Product in
                                         the Field in the Territory. ARIAD US shall sign, and shall cause its Affiliates to sign,
                                         any documents or instruments requested by ARIAD SWISSCO in order to effectuate the foregoing
                                         grant and enable ARIAD SWISSCO to exercise its rights under this Agreement.

 

		2.1.3	The
                                         licenses set forth in Section 2.1.1 and 2.1.2 shall be sublicensable through multiple
                                         tiers by ARIAD SWISSCO without ARIAD US’s consent except where the applicable Sublicense
                                         is to be granted in respect of the Commercialization of the Product in all or substantially
                                         all of the countries within the Territory, such consent not to be unreasonably withheld,
                                         conditioned or delayed ([***]). Prior to the grant of any such sublicense ARIAD SWISSCO
                                         shall give ARIAD US not less than [***] of the intent to enter into such a sublicense,
                                         of the identity of the proposed sublicensee and seeking consent and ARIAD US shall have
                                         the right to grant or not grant such consent in its sole discretion; provided, however,
                                         that if ARIAD US does not provide written notice that it does not consent within [***]
                                         of receipt of notice from ARIAD SWISSCO, such consent shall be deemed

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 18

     

    

 

given. ARIAD
SWISSCO shall be liable for all acts or omissions of its Sublicensees in connection with this Agreement. Any act or omission by
any Sublicensee that would constitute a breach of this Agreement if done, or omitted to be done, by ARIAD SWISSCO, shall be deemed
to be a breach of this Agreement by ARIAD SWISSCO. Any Sublicense shall contain a provision that it shall be assignable to ARIAD
US in the event of termination of this Agreement.

 

		2.2	ARIAD
                                         US and its Affiliates agree that they shall not, and they shall not appoint any Third
                                         Party (i) to [***] in the Territory other than pursuant to Sections 5.3, 5.4 and 5.7)
                                         or in connection with a [***]; or (ii) [***] (other than for purposes of supplying to
                                         ARIAD SWISSCO pursuant to this Agreement or the Supply Agreement) anywhere in the world
                                         if it is intended for Commercialization in the Territory or (iii) to [***] the [***]
                                         or Product in the Territory or (iv) otherwise in contravention of the licenses set forth
                                         in Section 2.1.1. Other than the Distribution Agreements, as at the Effective Date no
                                         rights to develop, [***] or [***] the Product has been granted to Third Parties for the
                                         Territory.

 

		2.3	ARIAD
                                         SWISSCO shall be entitled to engage Subcontractors with respect to the performance of
                                         its rights under Section 2.1 without ARIAD US’ consent provided that such sub-contract
                                         shall be assignable to ARIAD US in the event of termination of this Agreement.

 

ARTICLE
3 – RESERVED TERRITORIES AND NON-COMPETITION

 

		3.1	Development
                                         of the Compound and/or Product for and Commercialization of the Product in all countries
                                         other than those in the Territory (the “Reserved Territory”) are reserved
                                         exclusively to ARIAD US or its Affiliates, or to Third Parties appointed by ARIAD US
                                         or its Affiliates, as the case may be. In consideration of the licenses granted to ARIAD
                                         SWISSCO by ARIAD US under Section 2.1, ARIAD SWISSCO shall refrain from [***]
                                         in the Reserved Territory and/or (ii) [***] to Customers located in any country within
                                         the Reserved Territory or to Third Parties with the knowledge that such Third Party may
                                         be intending to sell the Product into the Reserved Territory. Without limiting the foregoing,
                                         ARIAD SWISSCO shall use Commercially Reasonable Efforts to refrain from the following
                                         activities solely with respect to the Product, except for permitted activities under
                                         this Agreement:

 

		(a)	sales
                                         or marketing visits or details in the Reserved Territory;

 

		(b)	direct
                                         mail, including the sending of unsolicited e-mails, to persons or entities located in
                                         the Reserved Territory;

 

		(c)	advertising
                                         in media, on the internet or other promotions, where such advertising or promotion is
                                         specifically targeted at potential purchasers in the Reserved Territory;

 

		(d)	online
                                         advertisements addressed to potential purchasers in the Reserved Territory and other
                                         efforts specifically designed to be found by potential purchasers in the Reserved Territory,
                                         including the use of in the Reserved Territory based banners on Third Party websites
                                         and paying a search engine or

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 19

     

    

 

online advertisement
provider to have advertisements or higher search rankings displayed specifically to potential purchasers outside in the Reserved
Territory; and

 

		(e)	advertising
                                         or promotion in any form, or translation of ARIAD SWISSCO’s website into a language
                                         other than an official language of any country forming part of the Territory, that in
                                         each case ARIAD SWISSCO would not reasonably carry out but for the likelihood that it
                                         will reach potential Customers in countries in the Reserved Territory.

 

Notwithstanding the foregoing, if an activity
is occurring as of the Effective Date, it shall not be a breach of this Section 3.1 if it continues after the Effective Date.

 

		3.2	For
                                         purposes of clarity, Development of the Compound and/or Product for and Commercialization
                                         of the Product in the Territory are reserved exclusively to ARIAD SWISSCO or its Affiliates,
                                         or to Third Parties appointed by ARIAD SWISSCO or its Affiliates, as the case may be.
                                         ARIAD US shall refrain from (i) [***] and/or (ii) [***] to Customers located in any country
                                         within the Territory or to Third Parties [***]. Without limiting the foregoing, ARIAD
                                         US shall use Commercially Reasonable Efforts to refrain from the following activities
                                         solely with respect to the Compound and Product, except for permitted activities under
                                         this Agreement:

 

		(a)	sales
                                         or marketing visits or details in the Territory;

 

		(b)	direct
                                         mail, including the sending of unsolicited e-mails, to persons or entities located in
                                         the Territory;

 

		(c)	advertising
                                         in media, on the internet or other promotions, where such advertising or promotion is
                                         specifically targeted at potential purchasers in the Territory;

 

		(d)	online
                                         advertisements addressed to potential purchasers in the Territory and other efforts specifically
                                         designed to be found by potential purchasers in the Territory, including the use of in
                                         the Territory based banners on Third Party websites and paying a search engine or online
                                         advertisement provider to have advertisements or higher search rankings displayed specifically
                                         to potential purchasers outside in the Territory; and

 

		(e)	advertising
                                         or promotion in any form, or translation of ARIAD US’ website into a language other
                                         than an official language of any country forming part of the Reserved Territory, that
                                         in each case ARIAD US would not reasonably carry out but for the likelihood that it will
                                         reach potential Customers in countries in the Territory.

 

		3.3	Competitive
                                         Product.

 

		3.3.1	As
                                         of the Effective Date and for [***] thereafter, neither Party nor its Affiliates shall
                                         research (other than [***], which may be conducted worldwide), develop, register, file
                                         for registration, manufacture, purchase, sell, promote, distribute, commercialize or
                                         otherwise exploit any Competitive Product in the Field anywhere in the Territory nor
                                         enable or

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 20

     

    

 

authorize
any Third Party to do so. The foregoing shall not preclude either Party from conducting research related to [***] that are not
[***]; provided that any such research shall not continue should such [***] become [***].

 

		3.3.2	Notwithstanding
                                         Section 3.3.1, if a Party or any of its Affiliates, either as a result of a merger, acquisition,
                                         change of control or similar transaction (including an acquisition of assets) (the “Transaction”)
                                         acquires (such Party being referred to as the “Acquiring Party”) or
                                         is acquired (such Party being referred to as the “Acquired Party”)
                                         by or otherwise merges with an entity that owns, has a license to, or a right to distribute,
                                         a Competitive Product that would otherwise result in a violation of Section 3.3.1, then
                                         the following shall apply:

 

		(a)	The
                                         Acquiring Party shall (i) promptly, and in any event no later than [***] following
                                         the date of the Transaction, notify the other Party in writing of the Transaction and
                                         the Competitive Product, (ii) promptly [***] the Competitive Product, and (iii) divest,
                                         or cause its relevant Affiliate to divest, all rights (including distribution rights)
                                         to the Competitive Product in accordance with this Section 3.3.2. The Acquiring Party
                                         shall promptly, and in any event no later than [***] following the date of the Transaction,
                                         notify the other Party that it or its Affiliate, as the case may be, intends to undertake
                                         good faith efforts to divest the Competitive Product, such divestiture shall be completed
                                         within [***] after the date of the Transaction and shall occur by (1) a termination of
                                         or an outright sale or assignment to a Third Party of all of the Acquiring Party’s
                                         or its Affiliate’s rights and interest in and to the Competitive Product (including
                                         all rights under any contract, such as a license or distribution agreement) or (2) an
                                         out license arrangement under which the Acquiring Party and its Affiliates have no ongoing
                                         involvement in the development or commercialization of the Competitive Product and derive
                                         no material ongoing financial return following the effective date of divestiture and
                                         no financial benefit tied to sales or success of the divested Competitive Product. Should
                                         such divestiture not have occurred with respect to any country in the Territory within
                                         such [***] period, and provided that the Acquiring Party has been using good faith efforts
                                         to divest the owned Competitive Product in such country during such [***] period, then
                                         the Acquiring Party shall discontinue (and cause its Affiliates to discontinue) developing
                                         or commercializing the Competitive Product (i.e., withdraw the Competitive Product and/or
                                         the relevant marketing authorization and, to the extent applicable, cease all promotion,
                                         marketing and other commercialization activities with respect to the Competitive Product)
                                         in such country.

 

		(b)	If
                                         the Acquired Party is ARIAD US, it shall (i) promptly, and in any event no later
                                         than [***] following the date of the Transaction, notify ARIAD SWISSCO in writing of
                                         the Transaction and the Competitive Product, (ii) promptly [***] the Competitive Product,
                                         and (iii) either (A) continue such [***] for the remainder of the Term or (B) divest,
                                         or cause its relevant Affiliate to divest, all rights (including 

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 21

     

    

 

distribution rights)
                                         to the Competitive Product in the Territory. ARIAD US shall promptly, and in any event
                                         no later than [***] following the date of the Transaction, notify ARIAD SWISSCO that
                                         it or its Affiliate, as the case may be, intends to (x) continue such [***] for the remainder
                                         of the Term or (y) undertake good faith efforts to divest the Competitive Product, such
                                         divestiture to be completed within [***] after the date of the Transaction and to occur
                                         by (1) an outright sale or assignment to a Third Party of all of ARIAD US’s or
                                         its Affiliate’s rights and interest in the Territory in and to the Competitive
                                         Product (including all rights under any contract, such as a license or distribution agreement),
                                         or (2) an out license arrangement.

 

		(c)	If
                                         the Acquired Party is ARIAD SWISSCO, it shall (i) promptly, and in any event no
                                         later than [***] following the date of the Transaction, notify ARIAD US in writing of
                                         the Transaction and the Competitive Product, (ii) promptly [***] the Competitive Product,
                                         and (iii) divest, or cause its relevant Affiliate to divest, all rights (including distribution
rights) to either the Product or the Competitive Product in the Territory. ARIAD SWISSCO shall promptly, and in any event no later
than [***] following the date of the Transaction, notify ARIAD US that it or its Affiliate, as the case may be, intends to undertake
good faith efforts to divest either the Product or the Competitive Product, such divestiture to be completed within [***] after
the date of the Transaction and to occur by (1) an outright sale or assignment to a Third Party of all of ARIAD SWISSCO’s
or its Affiliate’s rights and interest in the Territory in and to the Product or the Competitive Product, as the case may
be (including all rights under any contract, such as a license or distribution agreement), or (2) an out license arrangement.

  

		3.4	Nothing
                                         in this Agreement shall be construed as prohibiting either Party or any of their respective
                                         Affiliates either themselves or through a Third Party from developing or commercializing
                                         any Excluded Compound in any field anywhere in the world.

 

		3.5	Nothing
                                         in this Agreement shall be construed as giving ARIAD SWISSCO any right to use or otherwise
                                         exploit the Know-how, the Patents, the ARIAD US Trademarks, ARIAD US’s other Intellectual
                                         Property Rights in the Compound or Product and/or any other information received hereunder
                                         for purposes other than to perform ARIAD SWISSCO’s obligations and exercise its
                                         rights under this Agreement, including for purposes of meeting its responsibilities as
                                         the MAH in the Territory, solely in accordance with the terms and conditions of this
                                         Agreement. Except as expressly set forth in this Agreement, neither Party grants to the
                                         other Party any right or license to any of its Intellectual Property Rights.

 

		3.6	The
                                         Parties acknowledge and agree that the restrictions imposed on and accepted by the Parties
                                         in this ARTICLE 3 are restrictions that each Party has independently and unilaterally
                                         determined are necessary in order to protect such Party’s Intellectual Property
                                         Rights and ensure such Party is able to effectively commit and apply its skills, resources,
                                         networks and qualified personnel so that the other Party may comply with and perform
                                         its obligations under this Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 22

     

    

 

ARTICLE
4 – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES 

 

		4.1	Joint
                                         Steering Committee. The Parties shall, within [***] of the Effective Date, establish
                                         a Joint Steering Committee (the “JSC”), comprised of three (3) representatives
                                         of ARIAD US and three (3) representatives of ARIAD SWISSCO. The JSC shall be co-chaired
                                         by a representative of each of ARIAD US and ARIAD SWISSCO.

 

		4.2	General
                                         Responsibilities. The JSC shall coordinate and monitor progress of the activities
                                         taking place under this Agreement.

 

		4.3	Development-Related
                                         Responsibilities. The JSC shall coordinate, liaise, review and discuss matters related
                                         to the Development of the Product in the Territory, the Reserved Territory and the Global
                                         Studies to be undertaken in accordance with this Agreement. Without limitation to the
                                         generality of the foregoing, it shall prepare and approve annual (or, if needed, more
                                         frequent) updates and revisions to the Development Register, will discuss and attempt
                                         to resolve disagreements escalated by any subcommittees or project teams that may be
                                         set up from time to time to discuss any specific issues in relation to Development and
                                         assume such other responsibilities as are set forth in this Agreement, or as mutually
                                         agreed in writing by duly authorized representatives of the Parties from time to time.

 

		4.4	Commercialization-related
                                         Responsibilities. The JSC shall establish a subcommittee called Joint Commercialization
                                         Committee (“JCC”) to coordinate the activities of the Parties in connection
                                         with Commercialization of the Product in the Territory and the Reserved Territory in
                                         accordance with the terms of this Agreement. Without limitation to the generality of
                                         the foregoing, the JSC will discuss and attempt to resolve disagreements escalated by
                                         JCC and assume such other responsibilities as are set forth in this Agreement with regard
                                         to Commercialization, or as mutually agreed in writing by duly authorized representatives
                                         of the Parties from time to time. For clarity, [***] shall be [***], to [***] in the
                                         Territory, including the [***] Third Parties with respect to the sale of the Product
                                         in the Territory and neither [***] shall have any right to [***].

 

		4.5	Committee
                                         Administration.

 

		4.5.1	Subcommittees.
                                         The JSC may form subcommittees or project teams as it deems appropriate to fulfill its
                                         responsibilities. The Parties intend to establish joint pharmacovigilance (PV) and supply
                                         chain subcommittees or project teams as soon as practicable after the Effective Date
                                         in order to facilitate discussions and coordination of the Parties’ efforts and
                                         activities relating to Product PV and manufacture, supply and quality assurance (including
                                         Manufacture) under this Agreement. If a subcommittee or project team cannot reach agreement
                                         on any matter within its remit, such matter shall be submitted to the JSC for discussion
                                         and resolution prior to any further dispute resolution action being taken.

 

		4.5.2	Changes
                                         to Representatives. A Party may change any one or more of its representatives to
                                         the JSC or to a subcommittee or project team at any time upon written notice to the other
                                         Party. The number of representatives

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 23

     

    

 

appointed
by each Party to the JSC or to a subcommittee or project team may be modified by mutual agreement of the Parties; provided, that
at all times the number of representatives from each Party shall be equal.

 

		4.5.3	Schedule
                                         and Minutes. The representatives of the JSC shall mutually agree on the schedule
                                         for meetings, provided that there shall be at least one (1) meeting per calendar quarter.
                                         Either Party may schedule an emergency meeting of the JSC upon reasonable advance written
                                         notice to the other Party. A representative of the Party hosting a meeting of the JSC
                                         shall serve as secretary of that meeting. The secretary of the meeting shall prepare
                                         and distribute to all members of the JSC: (a) agenda items at least [***] in advance
                                         of the applicable meeting and (b) draft minutes of the meeting within [***] following
                                         the meeting to allow adequate review and comment. Such minutes shall provide a description
                                         in reasonable detail of the discussions held at the meeting and a list of any actions,
                                         decisions or determinations approved by the JSC. Minutes of the JSC meeting shall be
                                         approved or disapproved, and revised as necessary, within [***] after their initial circulation
                                         in draft form. Minutes for any subcommittees shall be prepared in the same manner and
                                         in accordance with the same timelines. The final minutes of any subcommittee shall be
                                         provided to the JSC.

 

		4.5.4	Location
                                         and Attendance. The location of JSC meetings shall alternate between ARIAD US’s
                                         principal place of business and ARIAD SWISSCO’s principal place of business, or
                                         as otherwise agreed by the Parties. The JSC may also meet by means of telephone conference
                                         call or videoconference, provided that at least one (1) meeting per calendar year shall
                                         be held in person. Each Party shall use reasonable efforts to cause its representatives
                                         to attend JSC meetings. If a Party’s representative to the JSC or any subcommittee
                                         is unable to attend a meeting, such Party may designate an alternate to attend such meeting
                                         in place of the absent representative. In addition, each Party may, at its discretion,
                                         invite non-voting employees, and, with the consent of the other Party, consultants or
                                         scientific advisors, to attend JSC meetings.

 

		4.6	Alliance
                                         Managers. Each Party shall appoint a business representative who possesses a general
                                         understanding of the relevant technical, business and legal issues to act as its Alliance
                                         Manager (each, an “Alliance Manager”).  The Alliance Managers
                                         shall be responsible for creating and maintaining collaborative, efficient and responsive
                                         communication within and between the Parties, and for day-to-day management of operational
                                         matters other than matters within the remit of the JSC. The Alliance Managers shall have
                                         no authority to modify this Agreement or waive any non-compliance with its terms. Alliance
                                         Managers may attend JSC and subcommittee meetings as observers.

 

		4.7	Decision
                                         Making Process.

 

		4.7.1	Development.
                                         For clarity, the veto rights set out in Sections 5.6 and 5.7.2 are to be exercised
                                         by the Parties but [***] pursuant to the first sentence of Section 29.2 and are not subject
                                         to [***].

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 24

     

    

 

		4.7.2	Commercialization.
                                         In the event of any dispute relating to Commercialization of the Product in a Party’s
                                         respective territory, the first sentence of Section 29.2 shall apply. If [***] are not
                                         able to agree upon such dispute, [***] shall have the final decision in relation to the
                                         Reserved Territory and [***] shall have the final decision in relation to the Territory.

 

ARTICLE
5 – DEVELOPMENT 

 

		5.1	Development
                                         Liaison. ARIAD US and ARIAD SWISSCO shall use good faith efforts to coordinate and
                                         liaise, through the JSC, concerning continued Development of the Product with respect
                                         to (i) Development being Global Studies, Ongoing Studies and Proposed Studies and (ii)
                                         each Party’s separate plans for Development in its respective territory. Each Party
                                         will disclose its Development activities, Ancillary Research activities and Basic Research
                                         activities, giving updates at each JSC meeting. The Proposed Studies and, if a Party
                                         does not veto a clinical study under Sections 5.6 or 5.7.2, the clinical studies the
                                         subject of (ii), in each case once initiated, shall be listed in a Development register
                                         (“Development Register”) maintained by the JSC. The Development Register
                                         shall be updated by the JSC as required to reflect changes and additions to include all
                                         new clinical studies performed under this Agreement. As of the Effective Date, the Development
                                         Register lists only the Ongoing Studies.

 

		5.2	Registration
                                         of the Product in Territory. ARIAD SWISSCO shall, or shall procure that its Sublicensees
                                         shall, [***], use Commercially Reasonable Efforts to seek Registration of the Product
                                         in the Territory taking into account the countries in which it has not obtained Registration
                                         as of the Effective Date. If ARIAD US applies for a Marketing Authorization (or equivalent)
                                         of the Product in the U.S. for a New Indication, ARIAD US will disclose full details
                                         at the JSC and may request that ARIAD SWISSCO seek Registration of the Product for the
                                         New Indication in the Territory using the Development Data provided by ARIAD US (if not
                                         already available to ARIAD SWISSCO under the terms of this Agreement. ARIAD SWISSCO will
                                         consider such request in good faith, including analyzing the commercial viability of
                                         Commercializing the Product with the New Indication in the Territory. ARIAD SWISSCO will
                                         share the results of this analysis with JSC. ARIAD US will provide reasonable assistance
                                         as appropriate to and requested by ARIAD SWISSCO as it conducts such analysis. The final
                                         decision regarding whether to seek registration for such New Indication in the Territory,
                                         or at least some countries of the Territory, shall be in [***] sole discretion.

 

		5.3	Ongoing
                                         Studies. 

 

		5.3.1	ARIAD
                                         US shall be responsible for the conduct of the Ongoing Studies. For clarity, if the Ongoing
                                         Studies are Global Studies they are not subject to Section 5.7. ARIAD SWISSCO shall reimburse
                                         ARIAD US for ongoing Third Party Development Costs incurred by ARIAD US in the Ongoing
                                         Studies, subject to a maximum aggregate amount of US$7,000,000 for the period from the
                                         Effective Date until December 31, 2016 and US$7,000,000 for the calendar year 2017 (together,
                                         the “Ongoing Studies Budget”). ARIAD SWISSCO shall reimburse the actual,
                                         undisputed Third Party Development Costs quarterly within [***] of receipt of ARIAD US’s

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 25

     

    

 

quarterly
invoice and supporting evidence of the Third Party Development Costs having been incurred. Payment shall be made into such bank
account as ARIAD US shall specify from time to time. For the period ending [***], no invoice shall be in excess of [***] (provided
that for [***] in which the Effective Date occurs the invoice shall be for a pro-rated amount) and no invoice shall be delivered
before [***]. For clarity if a [***] invoice during the calendar year ending [***] does not include the maximum of [***] any excess
may be included in a subsequent invoice for calendar year [***], provided however that no excess at the end of the calendar year
[***] may be rolled over to the calendar year [***]. If either the OPTIC Clinical Trial or the OPTIC 2L Clinical Trial is terminated
prior to [***], then the maximum aggregate amount owed by ARIAD SWISSCO with effect from the date of termination of the relevant
Ongoing Study, shall be [***] of the remaining Ongoing Studies Budget. If both the OPTIC Clinical Trial and the OPTIC 2L Clinical
Trial are terminated prior to [***], then no further amounts will be payable by ARIAD SWISSCO after the date of termination of
the last of the OPTIC Clinical Trial and the OPTIC 2L Clinical Trial. In addition to the Ongoing Studies Budget, ARIAD SWISSCO
shall pay ARIAD US (i) [***] and (ii) [***] upon either (a) [***]; or (b) [***]. For clarity, [***] will not be [***] in the event
of [***]. For clarity, [***] will not be [***]. For clarity, ARIAD US shall continue to control the conduct of the Ongoing Studies
and shall continue to be listed as the sponsor until completion. ARIAD US will be responsible for collection and reporting of
all serious adverse events from these trials to the regulatory agencies in which the trials are being conducted. No amounts will
be due under this Section 5.3.1 and payable by ARIAD SWISSCO if the Buy-Back Option has been exercised.

 

		5.3.2	In
                                         relation to the OPTIC Clinical Trial, ARIAD US shall pay to ARIAD SWISSCO on calendar
                                         [***] basis an amount equal to (i) the number of patients greater than [***] enrolled
                                         (the “Target Enrollment”) in the OPTIC Clinical Trial in countries
                                         in the Territory in which the Product has a Marketing Authorization multiplied by (ii)
                                         [***], multiplied by (iii) [***]. ARIAD US may deduct [***] from the amount of such payment
                                         and pay the net amount to ARIAD SWISSCO. Such payments shall be made within [***] after
                                         the end of each [***] for amounts accrued in such [***]. If the OPTIC Clinical Study
                                         projected enrollment of [***] subjects is changed, the Target Enrollment shall be adjusted
                                         proportionally.

 

		5.3.3	ARIAD
                                         US shall provide to ARIAD SWISSCO within [***] of the end of each calendar month, [***]
                                         for the Ongoing Studies (other than the Optic 2L Clinical Trial, for which reports shall
                                         be provided quarterly) including the following for such calendar month: [***]. In addition,
                                         ARIAD US shall within [***] of receipt, provide ARIAD SWISSCO with copies of all (i)
                                         material communications and safety reports to or from Regulatory Authorities and minutes
                                         from meetings with Regulatory Authorities related to the Ongoing Studies and (ii) any
                                         related material post-marketing requirements communications to or from Regulatory Authorities.
                                         Subject to ARIAD SWISSCO making the applicable payments due to ARIAD US

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 26

     

    

 

under Section
5.3.1 ARIAD SWISSCO shall have the right to use all Development Data (including any needed right of reference) from the Ongoing
Studies as necessary or useful for Registration in the Territory.

 

		5.3.4	ARIAD
                                         US shall report the results of each of the Ongoing Studies to ARIAD SWISSCO by sending
                                         a substantially complete draft of the CSR as soon as practicable and a copy of the draft
                                         of the final CSR to ARIAD SWISSCO within [***] of database lock for the applicable study.
                                         ARIAD SWISSCO will provide ARIAD US with any comments within [***] of its receipt of
                                         the draft of the final CSR. ARIAD US shall consider in good faith such comments, but
                                         it shall be in the sole discretion of ARIAD US whether to make changes to CSR Report
                                         to accommodate ARIAD SWISSCO comments. If the final CSR for the OPTIC 2L Clinical Trial
                                         demonstrates Superiority on the Primary Efficacy Endpoint, ARIAD SWISSCO shall submit
                                         a variation application to the Regulatory Authority to support the approval of the Second
                                         Line CML indication within [***] of ARIAD SWISSCO’S receipt of the final CSR.

 

		5.3.5	Should
                                         ARIAD US elect to discontinue one or more of the Ongoing Studies, ARIAD US shall promptly,
                                         but in all cases prior to such discontinuance, notify ARIAD SWISSCO of such decision.

 

		5.4	Proposed
                                         Studies. ARIAD US may in its sole discretion commence and conduct the Proposed Studies
                                         and the provisions of Sections 5.6 or 5.7.2 shall not apply to the Proposed Studies but
                                         otherwise all provisions of this ARTICLE 5 shall apply as appropriate to a Proposed Study.
                                         ARIAD US shall submit for discussion by the JSC the draft and final detailed budget,
                                         draft and final protocol and overview of the clinical trial design prior to study initiation.
                                         ARIAD US shall report the results of each of the Proposed Studies to ARIAD SWISSCO by
                                         sending a substantially complete draft of the CSR as soon as practicable and a copy of
                                         the draft of the final CSR to ARIAD SWISSCO within six (6) months of database lock for
                                         the applicable study. ARIAD SWISSCO will provide ARIAD US with any comments within fifteen
                                         (15) days of its receipt of the draft of the final CSR. ARIAD US shall consider in good
                                         faith such comments but it shall be in the sole discretion of ARIAD US whether to make
                                         changes to CSR Report to accommodate ARIAD SWISSCO comments.

 

		5.5	Territory
                                         and Reserved Territory Specific Development. If ARIAD SWISSCO or Sublicensee wishes
                                         to carry out Development activity comprising a clinical study that is proposed to be
                                         conducted solely at clinical research sites in the Territory, then ARIAD SWISSCO shall
                                         submit for consideration by the JSC the proposed detailed budget, protocol and clinical
                                         trial design. If ARIAD US, either itself or through an Affiliate wishes to carry out
                                         Development activity comprising a clinical study that is proposed to be conducted solely
                                         at clinical research sites in the Reserved Territory, then ARIAD US shall provide the
                                         JSC with the proposed detailed budget, protocol and clinical trial design. Subject to
                                         Section 5.6, both Parties shall be entitled to carry out such Development activity and
                                         the provisions of Section 5.7.3 and 5.9 shall apply mutatis mutandis to this Section
                                         5.5.

 

		5.6	Territory
                                         and Reserved Territory Veto Right. In connection with any clinical study proposed
                                         to be conducted by the Developing Party pursuant to Section 5.5, the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 27

     

    

 

Non-Developing
Party shall have the right, by providing written notice to the Developing Party of the grounds for such objections, to object
to the study taking place on the grounds that, in its reasonable opinion, the protocol design is reasonably likely to create a
safety risk or otherwise have a material adverse impact on the Commercialization of the Product in the Non-Developing Party’s
territory. In the event of dispute on this subject, either Party shall have the right to escalate the matter by written notice
to the other Party (“Escalation Notice”). The Senior Officers of both Parties shall use good faith efforts
to resolve any matter referred to them as soon as practicable. Any final decision that the Senior Officers mutually agree to in
writing shall be conclusive and binding on the Parties. If the Senior Officers fail to resolve the dispute, the decision of the
Non-Developing Party shall be final on all issues.

 

		5.7	Global
                                         Studies.

 

		5.7.1	If,
                                         after the Effective Date, either Party proposes to undertake a Global Study, then it
                                         shall provide the JSC with the (i) proposed detailed budget, protocol and clinical trial
                                         design, details of the sites and the key investigators, (ii) a detailed breakdown and
                                         budget of the proposed Development Costs and (iii) any other relevant information and
                                         plans relating to such study, including template patient consent forms that are reasonably
                                         requested by the other Party.

 

		5.7.2	Veto
                                         of Global Studies. In connection with any Global Study proposed to be conducted by
                                         the Developing Party, the Non-Developing Party shall have the right, by providing written
                                         notice to the Developing Party of the grounds for such objection, to object to the study
                                         taking place on the grounds that, in its reasonable opinion, the protocol design or conduct
                                         of the Global Study is reasonably likely to create a safety risk or otherwise have a
                                         material adverse impact on the Commercialization of the Product in the territory of the
                                         Non-Developing Party. In the event of dispute on this subject, either Party may refer
                                         the matter for escalation to the Senior Officers under the procedures in Section 5.6.
                                         If the Senior Officers fail to resolve the dispute, the decision of the Non-Developing
                                         Party shall be final on all issues.

 

		5.7.3	Subject
                                         to the veto right set out in Section 5.7.2, the Non-Developing Party shall determine
                                         if it wishes to co-fund the Global Study by electing to [***] and shall confirm such
                                         determination by notice in writing to the other Party. The Developing Party shall be
                                         sponsor of any such co-funded Global Study. Subject to the Pharmacovigilance Agreement,
                                         the Developing Party will be responsible for ensuring the collection and reporting of
                                         all serious adverse events from these trials to the regulatory agencies in countries
                                         and territories in which the co-funded global trials are being conducted. In relation
                                         to such Global Study, the Development Costs will be [***] ARIAD US and ARIAD SWISSCO.
                                         Each Party shall have the right to the Development Data from such Global Study as more
                                         particularly set out in Sections 5.11 and ARTICLE 6. No amounts under this Section 5.7.3
                                         will be due and payable by ARIAD SWISSCO if the Buy-Back Option has been exercised.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 28

     

    

 

		5.7.4	Subject
                                         to the veto right set out in Section 5.7.2, if the Non-Developing Party does not wish
                                         to co-fund pursuant to Section 5.7.3, the Developing Party shall have the right to conduct
                                         the Global Study [***]. To the extent that the study is being conducted in an on-label
                                         indication, the Developing Party shall pay to the Non-Developing Party on calendar quarter
                                         basis an amount equal to (i) [***], multiplied by (ii) [***], multiplied by (iii) [***].
                                         If ARIAD US is the Developing Party, it may deduct [***] from the amount of such payment
                                         and pay the net amount to ARIAD SWISSCO. Such payments shall be made within [***] after
                                         the end of each [***] for amounts accrued in such [***]. For purposes of clarity, the
                                         payments under this Section 5.7.4 shall apply to any of the Proposed Studies that are
                                         Global Studies.

 

		5.8	If
                                         either Party proceeds with a Global Study under Section 5.7.4, the Developing Party shall,
                                         at least quarterly, provide to the Non-Developing Party a detailed written report (which
                                         obligation may be satisfied by means of reports prepared by or for the Developing Party
                                         for internal use) that includes the then-current development status, the results achieved,
                                         the problems being encountered, summary of material clinical data generated, Development
                                         Costs incurred and other pertinent information relating to the Global Study. For each
                                         Global Study, the Developing Party shall provide to the Non-Developing Party a substantially
                                         complete draft of the CSR as soon as practicable and a draft of the final CSR within
                                         [***] of database lock for the study. The Non-Developing Party will provide the Developing
                                         Party with comments within [***] of its receipt of the draft final CSR. The Developing
                                         Party shall consider in good faith such comments but it shall be in the sole discretion
                                         of the Developing Party whether to make changes to CSR Report to accommodate the Non-Developing
                                         Party comments. The Developing Party shall send a copy of the final CSR of the Global
                                         Study to the Non-Developing Party in the form of a written notice.

 

		5.9	The
                                         Non-Developing Party shall, at any time prior to [***] after the final CSR of a Global
                                         Study is issued, have the right, by giving written notice to the Developing Party exercising
                                         this right, to use the Development Data from such Global Study in relation to Registration
                                         in its territory, provided that the Non-Developing Party reimburses the Developing Party
                                         [***] of the Developing Party’s Third Party Development Costs incurred in the conduct
                                         of such Global Study to date and continues to pay directly, or reimburse to the Developing
                                         Party on a [***] basis, [***] of the Third Party Development Costs paid for the conduct
                                         of such Global Study. The Non-Developing Party shall have the right, at reasonable times
                                         during business hours and upon reasonable notice to the Developing Party to access the
                                         Developing Party’s books, records and accounts for inspection and audit by the
                                         Non-Developing Party or its Affiliates or their respective duly authorized representatives
                                         or by an independent auditor to be nominated by the Non-Developing Party and reasonably
                                         acceptable to the Developing Party, to ensure the accuracy of all reports and payments
                                         made hereunder and in respect of all Development Costs. Such audit shall be covered by
                                         confidentiality obligations of the auditor. No amounts under this Section 5.9 will be
                                         due and payable by ARIAD SWISSCO if the Buy-Back Option has been exercised.

 

		5.10	Each
                                         Party hereby acknowledges and agrees that neither Party makes any warranty, and nothing
                                         in this Agreement may or shall be construed as a warranty by either

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 29

     

    

 

Party, that
the Product will obtain Registrations in any or all of the countries in or outside the Territory and neither Party shall have
claims against the other Party arising out of any delay or refusal by Regulatory Authorities to issue Registrations or to issue
Registrations that are acceptable to the Parties in or outside the Territory.

 

		5.11	Each
                                         Party shall own all title right and interest in and to all Development Data generated
                                         by them from Development activity in their respective territory and in relation to Global
                                         Studies in relation to which they have been the Developing Party. Access and the right
                                         to use Development Data for the other Party is governed by this ARTICLE 5.

 

		5.12	ARIAD
                                         US shall own all ARIAD US Improvements and ARIAD SWISSCO shall own all ARIAD SWISSCO
                                         Improvements. ARIAD SWISSCO is licensed to use ARIAD US Improvements on the terms of
                                         the license set out in Section 2.1. Throughout the Term, ARIAD US shall supply ARIAD
                                         SWISSCO with all ARIAD US Improvements that are necessary or useful for ARIAD SWISSCO
                                         to Develop, use, Commercialize, Manufacture Product in the Territory in accordance with
                                         this Agreement. Notwithstanding the foregoing, nothing in this Agreement shall require
                                         ARIAD US to develop additional Know-how or to obtain additional Know-how from Third Parties.
                                         Subject to the terms and conditions of this Agreement, including payment under Sections
                                         5.7.3 and 5.9, ARIAD SWISSCO shall have the right to use, cross-reference, file or incorporate
                                         by reference any Development Data disclosed to ARIAD SWISSCO by or on behalf of ARIAD
                                         US or its Affiliates relating to the Product for purposes of performing under this Agreement,
                                         including in order to support any regulatory filings relating to the Product and in interactions
                                         with any Regulatory Authority in connection with the development and Registration of
                                         the Product in the Territory.

 

		5.13	ARIAD
                                         SWISSCO shall promptly disclose to ARIAD US all ARIAD SWISSCO Improvements resulting
                                         from Development or Manufacturing activities conducted by ARIAD SWISSCO or its Sublicensees
                                         or Subcontractors pursuant to this Agreement. ARIAD US shall have a perpetual, irrevocable,
                                         exclusive license under the Intellectual Property Rights covering such ARIAD SWISSCO
                                         Improvements and Ancillary Research of ARIAD SWISSCO to use the same in any way whatsoever
                                         in the Reserved Territory (subject to the other terms of this Agreement) [***] provided
                                         always that in the case of ARIAD SWISSCO Improvements directly resulting from studies
                                         conducted in the Territory by ARIAD SWISSCO or from Global Studies conducted by them
                                         where ARIAD US has first paid to use the corresponding Development Data.

 

		5.14	Each
                                         Party shall ensure that all necessary notifications are made and/or necessary consents
                                         are obtained and/or agreements are entered into, under applicable data protection or
                                         privacy regulations in its respective territory such that all personal information obtained
                                         in the course of the conduct of development activities under this Agreement by either
                                         Party, its respective Affiliates or any Third Party subcontractor of such Party can be
                                         lawfully processed including being transmitted to, and used by, the other Party and its
                                         Affiliates for development work relating to the Compound and/or the Product as provided
                                         for in this Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 30

     

    

 

ARTICLE
6 - EXCHANGE OF OTHER KNOW-HOW 

 

		6.1	Subject
                                         to the terms and conditions of this Agreement, throughout the Term and/or upon either
                                         Party’s reasonable request, each Party shall supply the other in writing or by
                                         any other appropriate means at JSC meetings commercial and medical affairs information
                                         and data relating to the Product to the extent it is Controlled by the disclosing Party
                                         or its Affiliates, including relevant market analyses and assessments of the competitive
                                         landscape for the Product, and, subject to Applicable Laws, any patient or physician
                                         feedback relating to Product. The receiving Party shall be free to use such information
                                         and data for the purpose of its business and to disclose the same to its Affiliates and
                                         distributors in the Territory (if ARIAD SWISSCO is the receiving Party) or in the Reserved
                                         Territory (if ARIAD US is the receiving Party), provided that no Confidential Information
                                         pertaining to the disclosing Party’s business shall be disclosed by the receiving
                                         Party to such other distributors.

 

		6.2	Beginning
                                         immediately after the Effective Date, ARIAD US shall [***], effect a [***] to ARIAD SWISSCO
                                         or its designee (which designee may be an Affiliate or a Third Party manufacturer) of
                                         all Know-How and any other information regarding Intellectual Property Rights of ARIAD
                                         US and its Affiliates relating to the then-current process for the [***] and [***] (the
                                         “Current Manufacturing Process”) and to implement the Current Manufacturing
                                         Process at facilities designated by ARIAD SWISSCO (such transfer and implementation,
                                         as more fully described in this Section 6.2, the “Manufacturing Technology Transfer”).
                                         ARIAD US shall provide, and shall cause its Affiliates and Third Party manufacturers
                                         to provide, [***] to enable ARIAD SWISSCO (or its Affiliate or designated Third Party
                                         manufacturer, as applicable) to implement the Current Manufacturing Process at the facilities
                                         designated by ARIAD SWISSCO. If requested by ARIAD SWISSCO, such assistance shall include
                                         [***]. Without limitation to the foregoing, in connection with each Manufacturing Technology
                                         Transfer, ARIAD US shall, and shall cause its Affiliates and Third Party manufacturers
                                         to:

 

		6.2.1	make
                                         available to ARIAD SWISSCO (or its Affiliate or designated Third Party manufacturer,
                                         as applicable) from time to time as ARIAD SWISSCO may request, all [***] of ARIAD US
                                         and its Affiliates relating to the Current Manufacturing Process, and all [***], that
                                         are reasonably necessary or useful to enable ARIAD SWISSCO (or its Affiliate or designated
                                         Third Party manufacturer, as applicable) to use and practice the Current Manufacturing
                                         Process;

 

		6.2.2	cause
                                         [***] to assist with the working up and use of the Current Manufacturing Process and
                                         with the [***] to the extent reasonably necessary or useful to enable ARIAD SWISSCO (or
                                         its Affiliate or designated Third Party manufacturer, as applicable) to use and practice
                                         the Current Manufacturing Process;

 

		6.2.3	Without
                                         limiting the generality of Section 6.2.2 above, cause appropriate [***] and make available
                                         necessary [***], to support and execute the transfer of all applicable analytical methods
                                         and the validation thereof (including, all [***] of ARIAD US and its Affiliates relating
                                         to the Current Manufacturing Process, [***]);

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 31

     

    

 

		6.2.4	take
                                         such steps as are reasonably necessary or useful to assist in [***] with respect to the
                                         Manufacture of Product at the applicable facilities; and

 

		6.2.5	provide
                                         such other assistance as ARIAD SWISSCO (or its Affiliate or designated Third Party manufacturer,
                                         as applicable) may reasonably request to enable ARIAD SWISSCO (or its Affiliate or designated
                                         Third Party manufacturer, as applicable) to use and practice the Current Manufacturing
                                         Process and otherwise to Manufacture Product.

 

		6.3	Within
                                         [***] of the end of each [***] during the period of the [***] ARIAD US shall report to
                                         ARIAD SWISSCO [***] incurred in such period, and shall invoice ARIAD SWISSCO for the
                                         same. ARIAD SWISSCO shall pay each such invoice within [***] of receipt of such invoice.

 

		6.4	Without
                                         limiting the foregoing, if ARIAD US or its Affiliates makes any invention, discovery,
                                         or improvement relating to the Manufacture of Product during the Term, ARIAD US shall,
                                         [***], promptly disclose such invention, discovery, or improvement to ARIAD SWISSCO,
                                         and shall, at ARIAD SWISSCO’s request, [***] with respect to such invention, discovery,
                                         or improvement in the same manner as provided in Section 6.2. Neither Party will (nor
                                         cause its Third Party Manufacturers to) implement any process improvement that may impact
                                         the Specifications of the Product or the relevant sections of the Marketing Authorization
                                         or that would require approval of any Regulatory Authority, without the prior written
                                         approval of the other Party.

 

ARTICLE
7 – PRICING AND REIMBURSEMENT 

 

		7.1	With
                                         respect to: (i) all countries within [***] and (ii) each country outside [***] in the
                                         Territory if a Marketing Authorization of the Product has been obtained in each such
                                         country in the Territory, ARIAD SWISSCO shall use Commercially Reasonable Efforts to
                                         obtain Pricing and Reimbursement Approval in such countries as soon as reasonably possible.

 

		7.2	In
                                         accordance with Applicable Law, the Parties shall discuss and exchange information and
                                         documentation (including health economic data, analyses and argumentation) to develop
                                         and support the pricing and reimbursement strategy for the Product within the Territory.
                                         ARIAD SWISSCO shall provide ARIAD US with periodic updates and, upon reasonable request,
                                         copies of material communications with, and submissions to, pricing and reimbursement
                                         authorities with respect to Products in the Field in the Territory. For clarity, ARIAD
                                         SWISSCO shall be solely responsible for determining the actual selling price to Customers
                                         and all other conditions of sale in the Territory.

 

ARTICLE
8 – REGULATORY MATTERS

 

		8.1	Marketing
                                         Authorizations.

 

		8.1.1	ARIAD
                                         SWISSCO shall oversee, monitor and coordinate all regulatory actions, communications
                                         and filings with, and submissions to, Regulatory Authorities with respect to Products
                                         in the Field in the Territory. ARIAD

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 32

     

    

 

US shall
provide ARIAD SWISSCO with reasonable assistance, information, and access to ARIAD US’s personnel, to support ARIAD SWISSCO’s
or the relevant ARIAD SWISSCO Sublicensees’ applications for Marketing Authorizations and other interactions with Regulatory
Authorities in the Territory relating to Product and ARIAD SWISSCO shall reimburse ARIAD US for [***] in connection therewith.
Each Party shall use appropriately qualified personnel for such activities, including personnel with local regulatory expertise.
In accordance with its responsibilities as the MAH in the Territory, ARIAD SWISSCO or the relevant ARIAD SWISSCO Sublicensee shall
act as the authorized contact for the Regulatory Authorities in the Territory in connection with obtaining and maintaining Marketing
Authorizations (subject to ARIAD US’s involvement as provided in Section 8.3), as well as in connection with the Development,
Manufacturing (if applicable) or Commercialization of the Product. [***].

 

		8.1.2	ARIAD
                                         US shall be responsible for maintaining the Company Core Data Sheet (“CCDS”)
                                         / Company Core Safety Information (“CCSI”) / core Risk Management
                                         Plan (“RMP”) for the Product.  In the event that a change to
                                         the CCDS/CCSI/RMP necessitates a change to the local labeling in a country within the
                                         Territory, ARIAD SWISSCO shall be responsible for developing a proposed revised draft
                                         product label or package insert for each country in the Territory.  ARIAD US shall
                                         provide ARIAD SWISSCO with information and reasonable access to ARIAD US’s personnel,
                                         to support ARIAD SWISSCO’s changes to the Marketing Authorizations to modify the
                                         revised draft labeling provided that ARIAD SWISSCO shall reimburse ARIAD US for [***].
                                         ARIAD SWISSCO or the relevant ARIAD SWISSCO Sublicensee shall promptly submit a change
                                         to applicable Marketing Authorizations in the Territory to modify the labeling.

 

		8.2	Subject
                                         to Section 4.7, ARIAD SWISSCO shall review and approve the prescribing information, label
                                         and final packaging of the Product for the Territory to be submitted in connection with
                                         applications for Marketing Authorizations, and shall subsequently review and approve
                                         any modifications thereto required by a Regulatory Authority or proposed by either Party.
                                         ARIAD SWISSCO or the relevant ARIAD SWISSCO Sublicensee shall prepare and submit the
                                         relevant documentation related to Marketing Authorizations and other Registrations in
                                         compliance with Applicable Laws.

 

		8.3	Each
                                         Party or its relevant Sublicensee or licensee (as applicable) shall prepare for and conduct
                                         meetings with the local Regulatory Authorities for which it is responsible in consultation
                                         with the other Party, and shall, to the extent such meetings are reasonably likely to
                                         be material to the other Party’s rights and obligations under this Agreement:

 

		(a)	notify
                                         the other Party in advance of such planned scheduled interactions with Regulatory Authorities
                                         relating to the Product and invite the other Party to attend such interactions, at the
                                         other Party’s cost, if permitted by the Regulatory Authority;

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 33

     

    

 

		(b)	notify
                                         the other Party of such spontaneous interactions with the Regulatory Authorities relating
                                         to the Product as soon as reasonably possible after the interaction;

 

		(c)	prepare
                                         meeting minutes of such interactions with Regulatory Authorities and circulate the same
                                         to the other Party, accompanied by a translation into English if the original minutes
                                         are not in English; and

 

		(d)	address
                                         such questions and requests from the Regulatory Authorities relating to the Product following
                                         consultation with the other Party.

 

		8.4	Without
                                         limiting the foregoing, in connection with regulatory activities for which a Party has
                                         responsibility or authority under this Agreement, each Party or its relevant Sublicensee
                                         or licensee (as applicable) shall (i) provide advance copies to the other Party’s
                                         representatives on the JSC of any proposed material submission to, or material communication
                                         with, any Regulatory Authority to the extent they relate to the Marketing Authorization
                                         or otherwise to the Product, and shall consider in good faith, and accommodate when reasonably
                                         appropriate, any requests by the other Party’s JSC representatives to make any
                                         modification thereto, and (ii) keep the other Party fully and promptly informed, throughout
                                         the Term, about all material communications received from the local [***] concerning
                                         the Product and/or the Compound, including providing the other Party with a copy of all
                                         such material communications (without translation) no later than [***] after receipt
                                         by ARIAD SWISSCO and with a copy thereof translated into English as soon as practicable
                                         thereafter. Without prejudice to full compliance by both Parties with any obligations
                                         established by Applicable Laws of each country in the Territory, any and all material
                                         communications to local Regulatory Authorities concerning the Product as described above
                                         shall be submitted by the responsible Party only after the relevant contents have been
                                         discussed with and approved by the JSC; provided, however, that the responsible Party
                                         shall not be required to delay any communication with or regulatory submission to any
                                         applicable Regulatory Authority in a manner that affects the responsible Party’s
                                         ability to comply with Regulatory Requirements or Applicable Laws. The responsible Party
                                         shall provide English translation of all material documents relating to the Product to
                                         be submitted by the responsible Party or its Sublicensees or licensees (as applicable)
                                         to, or that are received by responsible Party or its Sublicensees or licensees (as applicable)
                                         from, Regulatory Authorities in a language other than English. On a semi-annual basis,
                                         each Party shall provide the other Party with an itemized list of (a) all material written
                                         communications received from the local Regulatory Authorities concerning the Product
                                         during the prior [***] and (b) all material documents and written communications relating
                                         to the Product submitted by such Party or its Sublicensees or licensees (as applicable)
                                         to any Regulatory Authority during the prior [***]. Upon the request of a Party, the
                                         other Party shall provide the requesting Party with copies of any such communications
                                         or documentation itemized on such list, including where reasonably requested, English
                                         translations of all material communications or documentation. For clarity, (1) any communications
                                         with Regulatory Authorities or documents submitted to Regulatory Authorities that relate
                                         to Product quality shall not be governed by this Section 8.4 and shall be subject to
                                         the Quality Agreements, and (2) any communications with Regulatory Authorities or documents
                                         and written communications submitted to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 34

     

    

 

Regulatory
Authorities that relate to pharmacovigilance shall not be governed by this Section 8.4 and shall be subject to ARTICLE 9 until
the Pharmacovigilance Agreement becomes effective and thereafter shall be subject to the Pharmacovigilance Agreement.

 

		8.5	If
                                         any material alterations, modifications or amendments of this Agreement or modification
                                         of the Product are required to comply with the request of any Regulatory Authority as
                                         prerequisites for the continuation of the Marketing Authorization or the grant or the
                                         continuation of the Registration of the Product, or if the Marketing Authorization or
                                         Registrations are suspended or withdrawn by any said Regulatory Authority, each Party
                                         shall notify the other Party immediately and the Parties shall use Commercially Reasonable
                                         Efforts to agree upon a reasonable and mutually acceptable resolution thereof.

 

		8.6	ARIAD
                                         US may retain a copy of, and have ongoing access to, the Marketing Authorization for
                                         the Product granted by the European Medicines Agency existing as at the Effective Date,
                                         together with the certificates of pharmaceutical product and full dossier relating thereto
                                         (the “EMA MA”) and to all supplements, amendments and revisions occurring
                                         after the Effective Date (“EMA MA Updates”), provided that in the
                                         case of any supplement, amendment or revision that is made as a result of Development
                                         for which ARIAD US is to pay costs pursuant to Sections 5.5, 5.7.3 or 5.9, then ARIAD
                                         US shall only receive such EMA MA Updates provided ARIAD US has made such payments under
                                         Section 5.5, 5.7.3 or 5.9 (as applicable). Subject to the foregoing, ARIAD SWISSCO, on
                                         behalf of itself and its Affiliates, hereby grants to ARIAD US and its Affiliates a right
                                         of reference, with the right to grant further rights of reference to ARIAD US licensees
                                         of rights to register and commercialize the Product in the Reserved Territory, under
                                         suchEMA MA and any EMA MA Updates, in each case to enable ARIAD US and its Affiliates
                                         to exercise its rights and perform its obligations under this Agreement and to register
                                         and commercialize the Product in the Reserved Territory.

 

ARTICLE
9 – PHARMACOVIGILANCE 

 

		9.1	ARIAD
                                         US shall own and manage the global safety database for the Product and ARIAD US or its
                                         Affiliates shall be responsible for the timely reporting of all relevant adverse drug
                                         reactions/experiences, including those associated with Product quality complaints, and
                                         aggregate safety data relating to the Product, outside the Territory. ARIAD US shall
                                         provide ARIAD SWISSCO with extracts from the global safety database upon request of ARIAD
                                         SWISSCO. Reconciliation between the data contained in the ARIAD SWISSCO and ARIAD US
                                         safety databases shall be conducted periodically in accordance with the separate Pharmacovigilance
                                         Agreement. ARIAD SWISSCO will procure that the MAH in each country within the Territory
                                         shall be responsible for the timely reporting of all relevant post marketing adverse
                                         drug reactions/experiences, including those associated with Product quality complaints,
                                         and aggregate safety data relating to the Product, in accordance with local pharmacovigilance
                                         legislation within the Territory. ARIAD SWISSCO will have the right to independently
                                         audit the global safety database to ensure that their MAH obligations can be fulfilled.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 35

     

    

 

		9.2	ARIAD
                                         US shall be responsible for global medical surveillance, risk management, global medical
                                         literature review and monitoring, and responses for the Product to the appropriate Regulatory
                                         Authorities outside the Territory. ARIAD US shall be responsible for the interpretation,
                                         in light of ARIAD US’s global pharmacovigilance data, of adverse events in the
                                         Territory of which ARIAD US becomes aware, including adverse events reported to ARIAD
                                         US by ARIAD SWISSCO or the relevant ARIAD SWISSCO Sublicensee. ARIAD SWISSCO will procure
                                         that the MAH in each country in the Territory shall be responsible for local medical
                                         surveillance, risk management, medical literature review and monitoring within such country
                                         of the Territory, and responses to the appropriate Regulatory Authorities within the
                                         Territory. ARIAD SWISSCO will procure that the MAH in each country in the Territory shall
                                         provide an English-translated copy of the final responses to Regulatory Authorities to
                                         ARIAD US.

 

		9.3	ARIAD
                                         SWISSCO shall, and shall procure each MAH in each country in the Territory, implement
                                         and execute local Product-specific risk management activities, in collaboration with
                                         ARIAD US’s PV department, that are aligned with ARIAD US’s global risk management
                                         strategies.

 

		9.4	Further
                                         details of the Parties’ respective pharmacovigilance obligations and responsibilities
                                         (e.g., signal management, case processing and reporting, aggregate reporting, risk management,
                                         health authority responses, safety data exchange, etc.) shall be set forth in a pharmacovigilance
                                         agreement that will be agreed to by the Parties (and their respective Affiliate(s), as
                                         appropriate) within [***] after the Effective Date (as it may be amended from time to
                                         time, the “Pharmacovigilance Agreement”). In the event of a conflict
                                         between the terms of the Pharmacovigilance Agreement and the terms of this Agreement,
                                         the provisions of this Agreement shall govern; provided, however, that the Pharmacovigilance
                                         Agreement shall govern in respect of pharmacovigilance, including safety and risk management,
                                         matters.

 

		9.5	Prior
                                         to executing the Pharmacovigilance Agreement, the Parties agree to work together in good
                                         faith to coordinate activities regarding pharmacovigilance with respect to the Product
                                         in accordance with this ARTICLE 9, including by exchanging standard operating procedures
                                         and other information relevant to such pharmacovigilance activities as mutually agreed
                                         by the Parties. ARIAD US shall provide ARIAD SWISSCO with access to all pharmacovigilance
                                         related standard operating procedures (local and global) required in Territory and ARIAD
                                         SWISSCO shall procure that such standard operating procedures shall remain in place and
                                         be used by ARIAD SWISSCO until ARIAD SWISSCO transitions all pharmacovigilance standard
                                         operating procedures in accordance with the Pharmacovigilance Agreement. Without limiting
                                         the foregoing, prior to executing the Pharmacovigilance Agreement, in the event ARIAD
                                         SWISSCO or the relevant ARIAD SWISSCO Sublicensee receives reports of adverse drug reactions/experiences
                                         or safety data relating to the Product (“Safety Information”) ARIAD
                                         SWISSCO shall send the Safety Information to ARIAD US on source documents, or other mutually
                                         agreed format, via email or fax as soon as practicable, but, in any event, after it receives
                                         the Safety Information, and, in the event ARIAD SWISSCO or a Sublicensee receives any
                                         information concerning any investigation, inquiry or other action by any Regulatory Authority
                                         concerning the safety of the Product, ARIAD SWISSCO shall send such information to ARIAD
                                         US via email or

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 36

     

    

 

fax as soon
as possible, but in any event, after ARIAD SWISSCO receives notice of such regulatory request, inquiry or other action. Neither
Party shall respond to any Regulatory Authority request or inquiry relating to the safety of the Product without discussing the
issue with the other Party to the extent reasonably feasible in context of relevant timelines applicable to such responses and
to the extent reasonably likely that such responses would impact the Marketing Authorization or be materially relevant for the
Regulatory Authorities in the other Party’s Territory.

 

ARTICLE
10 – SUPPLY, FORECASTS AND ORDERING 

 

		10.1	As
                                         soon as practicable but no later than [***] after the Effective Date, the Parties shall,
                                         through a project team or subcommittee of the JSC, negotiate in good faith and agree
                                         on the terms of (i) a definitive agreement pursuant to which ARIAD US shall Manufacture
                                         and supply (or have Manufactured and supplied) Product as API or Unlabeled Bottles to
                                         ARIAD SWISSCO or its Affiliates for Final Manufacture as needed for Commercialization
                                         in the Territory (“Supply Agreement”) and (ii) a related Quality Agreement.
                                         Pending finalization of the Supply Agreement, the transitional supply of Product shall
                                         be made on the terms set out in Sections 10.2 to and including ARTICLE 14 and the terms
                                         of the Interim Quality Agreement in place (“Transitional Supply Arrangements”).
                                         The terms of the Transitional Supply Arrangements shall form the basis for the Supply
                                         Agreement and Quality Agreement.

 

		10.2	Product
                                         shall be supplied and may be ordered and Manufactured as follows:

 

		10.2.1	At
                                         any time during the Term until ARIAD SWISSCO commences [***], ARIAD US will supply [***]
                                         of Product ordered by ARIAD SWISSCO pursuant to the terms of this Agreement.

 

		10.2.2	At
                                         any time during the Term until ARIAD SWISSCO has [***], ARIAD US will supply [***] ordered
                                         by ARIAD SWISSCO pursuant to the terms of this Agreement, and ARIAD SWISSCO shall have
                                         the right to conduct Final Manufacturing of such [***] for purposes of Commercialization
                                         in the Territory.

 

		10.2.3	Beginning
                                         on a date notified to ARIAD US by ARIAD SWISSCO once ARIAD SWISSCO or its Subcontractor
                                         are ready to [***] ARIAD US shall supply [***] ordered by ARIAD SWISSCO pursuant to the
                                         terms of this Agreement and ARIAD SWISSCO shall have the right to conduct [***] for purposes
                                         of Commercialization in the Territory.

 

		10.3	Within
                                         [***] after the Effective Date and in the [***] of each [***] thereafter, ARIAD SWISSCO
                                         shall provide ARIAD US with a written [***] rolling Forecast
                                         of its anticipated quarterly requirements for the Product ([***]) in the Territory (each
                                         a “Forecast”). ARIAD US shall use Commercially Reasonable Efforts
                                         to ensure sufficient manufacturing capacity and Raw Materials to meet each Forecast.
                                         Each Forecast is a non-binding estimate for [***] and subject to Section 10.4 is binding
                                         on both Parties for [***]. ARIAD US shall not be obliged to Manufacture or supply ARIAD
                                         SWISSCO with quantities of the Product in excess of the binding portion of the most recent
                                         Forecast.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 37

     

    

 

		10.4	Within
                                         [***] of issuance of each Forecast the Parties will ensure that appropriate personnel
                                         of each of them responsible for manufacture and supply will discuss proposed batch runs
                                         and Delivery dates, which shall be within [***] in which the binding portion of the Forecast
                                         relates, and for the quantities of Product set out in the binding portion of that Forecast.
                                         ARIAD SWISSCO shall then promptly submit to ARIAD US and ARIAD US shall accept written
                                         purchase orders reflecting the binding portion of the Forecast, in such form as the Parties
                                         shall agree from time to time, specifying the quantities of Product ordered and, the
                                         agreed delivery date for the order. ARIAD SWISSCO shall submit each purchase order to
                                         ARIAD US in advance of the desired delivery date specified in such purchase order, with
                                         [***] lead time.  Any purchase orders for Product submitted by ARIAD SWISSCO to
                                         ARIAD US shall reference this Agreement and shall be governed exclusively by the terms
                                         contained herein. The Parties hereby agree that the terms and conditions of this Agreement
                                         shall supersede any term or condition in any order, confirmation or other document furnished
                                         by ARIAD SWISSCO or ARIAD US that is in any way inconsistent with, or supplementary to,
                                         the terms and conditions of this Agreement, unless expressly accepted in writing by the
                                         other Party.

 

		10.5	When
                                         ARIAD US [***] for ARIAD SWISSCO, ARIAD US shall carry a [***] sufficient to avoid [***]
                                         in the Territory in the event of [***]. In addition, whether ARIAD US is [***] for ARIAD
                                         SWISSCO, ARIAD US shall, with effect from the Effective Date, carry a safety stock of
                                         Product API allocated to the Territory, in accordance with past practice but in any event
                                         equal to not less than [***] projected requirement of [***] for ARIAD SWISSCO based on
                                         the most recent [***] and discussions between the Parties. Unless otherwise agreed by
                                         the Parties, such safety stock shall be [***] and identified as ARIAD SWISSCO [***].

 

		10.6	The
                                         price for the Manufacture of the Product shall be calculated as [***]. ARIAD US shall
                                         invoice ARIAD SWISSCO upon each Delivery of Product supplied under this Agreement and
                                         ARIAD SWISSCO shall pay the undisputed amounts of such invoice within [***] of receipt
                                         of such invoice. ARIAD US must include with each invoice a detailed calculation of the
                                         invoiced amount including details of the associated Direct Costs, Indirect Costs and
                                         any Third Party costs. ARIAD US shall keep complete and accurate books, records and accounts
                                         in accordance with all Applicable Laws and sound accounting practice covering all its
                                         Direct Costs, Indirect Costs and any Third Party costs and as otherwise may be necessary
                                         for the purpose of calculating all payments due to ARIAD US under this Section 10.6.
                                         ARIAD SWISSCO shall have the right, throughout any period during which payments are due
                                         under this under this Section 10.6 and for [***] thereafter, at reasonable times during
                                         business hours and upon reasonable notice to ARIAD US, to have ARIAD US’s books,
                                         records and accounts inspected and audited by one of the four major accounting firms
                                         to be appointed by ARIAD SWISSCO and reasonably acceptable to ARIAD US, to ensure the
                                         accuracy of all reports and payments made hereunder and in respect of all [***]. Such
                                         audit shall be covered by confidentiality obligations of the auditor. ARIAD US shall
                                         cooperate with the independent auditor and make available all work papers and other information
                                         related to the payments required under this Section 10.6 as reasonably requested in connection.

 

		10.7	In
                                         the event of any [***] in the available supply of Product, ARIAD US shall treat ARIAD
                                         SWISSCO’s demand [***] or [***] and, allocate manufacturing capacity to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 38

     

    

 

the respective
demand on a [***]; provided, that the foregoing supply on a [***] does not limit any other remedies ARIAD SWISSCO may have due
to a failure to supply under this Agreement or the Supply Agreement. ARIAD US shall promptly provide a written plan of action
stating in reasonable detail the root cause of any [***] and proposed measures to remedy the [***] and the date such [***] is
expected to end. ARIAD US shall use Commercially Reasonable Efforts to minimize the duration of any [***]; provided, that the
foregoing efforts of ARIAD US do not limit any remedies ARIAD SWISSCO may have due to a failure to supply under this Agreement
or the Supply Agreements.

 

ARTICLE
11 – SHIPMENT AND DELIVERY 

 

		11.1	Delivery
                                         Terms.

 

		11.1.1	ARIAD
                                         SWISSCO shall be the importer of record for all Product supplied under this Agreement.
                                         ARIAD SWISSCO shall be responsible for clearing the Product through customs in the Territory
                                         [***]. At all times, ARIAD SWISSCO shall maintain, [***], a valid import license for
                                         the Products, and shall be responsible, [***], for all required documentation and communications
                                         with the applicable customs office in connection therewith. ARIAD US shall provide assistance
                                         with such documentation and communications upon ARIAD SWISSCO’s reasonable request
                                         (e.g., by providing export documents or assisting with documentation as the exporter
                                         of the Product.) In this Section 11.1, any obligation on ARIAD SWISSCO may be performed
                                         by a Sub-licensee or Subcontractor.

 

		11.1.2	ARIAD
                                         US shall deliver the Product ordered by ARIAD SWISSCO in accordance with the quantities
                                         and delivery dates specified in the applicable purchase order. If ARIAD US fails to deliver
                                         at least [***] of the quantity ordered in a given purchase order within [***] of the
                                         specified delivery date, ARIAD SWISSCO shall only be required to pay for the quantity
                                         of Product Delivered and the price for such Product shall be reduced by [***].

 

		11.1.3	Deliveries
                                         shall be made Ex Works (Incoterms 2010) at the location specified in the Interim Quality
                                         Agreement or such other location as the Parties may agree in writing (“Delivery”).
                                         Title and risk to the Product shall pass to ARIAD SWISSCO upon Delivery.

 

		11.2	Acceptance
                                         and Rejection.

 

		11.2.1	Product
                                         Testing. No later than [***] prior to a scheduled Delivery ARIAD US
                                         shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review,
                                         unless within [***] of receipt of the Delivery Documents ARIAD SWISSCO gives written
                                         notice of rejection of the Product to be delivered, stating the reasons for such rejection,
                                         the Delivery shall proceed, and both Parties shall organize the same. Upon arrival
                                         at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the
                                         Product to identify any damage to the external packaging.  ARIAD SWISSCO may reject
                                         any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD
                                         US reasonable evidence of damage

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 39

     

    

 

within [***]
after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [***]
of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that
in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a
Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s
rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US
within [***] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

 

		11.2.2	Replacement
                                         of Product and Dispute Procedure. If ARIAD SWISSCO rejects, in accordance
                                         with Section 11.2.1 any proposed delivery or shipment (or portion thereof) of
                                         the Product as Non-Conforming and ARIAD US disagrees that the alleged Non-Conformance
                                         exists, ARIAD US shall so notify ARIAD SWISSCO in writing (an “Objection Notice”)
                                         within [***] of receipt of ARIAD SWISSCO’s notice of rejection and the following
                                         procedures shall apply: in the case of a Latent Defect ARIAD US shall inspect the returned
                                         representative sample of Product or other evidence of Non-Conformance and attempt to
                                         reach agreement with ARIAD SWISSCO as to whether or not the Product is Non-Conforming.
                                         If ARIAD SWISSCO and ARIAD US fail within [***] after delivery of the Objection Notice
                                         to agree as to whether the Product is Non-Conforming, in the case of a Latent Defect
                                         representative samples of the batch of the Product in question and their reference samples
                                         shall be submitted to a mutually-acceptable, independent, qualified Third Party laboratory
                                         or consultant for analysis or review to determine whether there is a Non-Conformance.
                                         For clarity, this may include a decision whether or not contamination is present. The
                                         results of such evaluation shall be binding upon the Parties. The Parties initially shall
                                         [***] the cost of such evaluation, except that the Party that is determined to have been
                                         incorrect in its determination of whether the Product was or was not Non-Conforming shall
                                         assume the responsibility for, and pay, the costs of any such evaluation and reimburse
                                         the other Party for any amounts previously paid to the independent laboratory or consultant
                                         in connection with that determination.

 

		11.2.3	Cost
                                         of Replacement of Rejected Product. If any delivery or shipment of the Product
                                         is rejected by ARIAD SWISSCO following review of the Delivery Documents or a visual inspection
                                         or any other alleged Non-Conformance, ARIAD SWISSCO’s duty to pay all amounts payable
                                         to ARIAD US in respect of the rejected Product shall be suspended. In the case of Latent
                                         Defect Non-Conformance if there is a determination by the independent laboratory or consultant
                                         in support of ARIAD US’s Objection Notice, or the Parties otherwise reach agreement
                                         that the Product was not Non-Conforming, payment shall then be made by ARIAD SWISSCO
                                         If only a portion of a shipment is rejected, ARIAD SWISSCO’s duty to pay

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 40

     

    

 

the amount
allocable to the Non-Conforming portion only shall be suspended.

 

		11.2.4	Return
                                         of Rejected Product. If a shipment or partial shipment is rejected by ARIAD
                                         SWISSCO pursuant to the provisions of Section 11.2.1 and (i) where relevant, ARIAD
                                         US does not provide an Objection Notice within the [***] period set forth in Section
                                         11.2.2, (ii) the Parties agree that the Product is Non-Conforming within the [***] period
                                         set forth in Section 11.2.2, or (iii) there is a determination by the independent laboratory
                                         or consultant in support of ARIAD SWISSCO’s allegation of Non-Conformance, ARIAD
                                         SWISSCO shall return to ARIAD US at ARIAD US’s request and expense (or, at the
                                         election of ARIAD US, destroy at ARIAD US’s cost and provide evidence of such destruction
                                         to ARIAD US) any such rejected Product (provided that if the Product has been packaged
                                         by or on behalf of ARIAD SWISSCO at the time of rejection, ARIAD SWISSCO shall not be
                                         obliged to remove any packaging prior to its return). ARIAD US shall (i) credit
                                         the original invoice in respect of the rejected Product and reimburse ARIAD SWISSCO for
                                         any duties, freight, insurance, handling or other charges incurred by ARIAD SWISSCO in
                                         respect of such rejected Product, and (ii) adjust the invoice to ARIAD SWISSCO for
                                         the Product that was not rejected, payment of which is due in accordance with the terms
                                         of the original invoice. Except as set forth in ARTICLES 14 and 22, such credit or adjustment
                                         shall be ARIAD US’s sole Liability, and ARIAD SWISSCO’s sole remedy, with
                                         respect to any rejected Product.

 

		11.2.5	Supply
                                         of Replacement Product. During any rejection discussions, upon ARIAD SWISSCO’s
                                         request, ARIAD US shall supply ARIAD SWISSCO with additional Product, using expedited
                                         shipping at ARIAD US’s expense, which ARIAD SWISSCO shall otherwise purchase on
                                         the same terms (adjusted for credit for Non-Conforming Product) as the Product that is
                                         the subject of the rejection discussions.

 

		11.2.6	Detection
                                         of Latent Defect by ARIAD US. If ARIAD US detects a Latent Defect in any Product
                                         supplied to ARIAD SWISSCO, ARIAD US shall notify ARIAD SWISSCO in writing, specifying
                                         the affected lots, and credit ARIAD SWISSCO for the Non-Conforming Product as provided
                                         in Section 11.2.4.

 

		11.2.7	No
                                         Product Returns Policy. Except as expressly provided elsewhere in this Section 11.2
                                         or in ARTICLE 14, no Products supplied by or on behalf of ARIAD US to ARIAD SWISSCO may
                                         be returned by ARIAD SWISSCO to ARIAD US after they have been Delivered to ARIAD SWISSCO
                                         at the location designated under Section 11.1.3.

 

ARTICLE
12 – MANUFACTURING OF THE PRODUCT 

 

		12.1	Manufacture
                                         of the Product. ARIAD US shall Manufacture or have Manufactured the Labeled Bottles,
                                         Unlabeled Bottles and API in accordance with the Specifications,

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 41

     

    

 

cGMP and
Applicable Laws in the country of Manufacture and, to the extent applicable, in the Territory.

 

		12.2	Packaging.
                                         ARIAD US shall package the Product in accordance with the Specifications and requirements
                                         notified to it with sufficient advance notice by ARIAD SWISSCO to comply with Applicable
                                         Laws.

 

		12.3	Changes
                                         to the Specifications or to the Manufacturing Process. If ARIAD US proposes
                                         (a) a change to the Specifications or the Raw Materials, equipment (other than changes
                                         for maintenance, repair, and like-for-like replacement) or process used to Manufacture
                                         the Product, or (b) a change to the procedures or facilities used to Manufacture
                                         the Product (collectively, the “Manufacturing Process”) that, in the
                                         case of (a) or (b) would require approval of any applicable Regulatory Authority in the
                                         Territory or would require an amendment of any Marketing Authorization application or
                                         Registration, the prior written approval of ARIAD SWISSCO is required before implementation
                                         of such change. If a change to the Specifications, Raw Materials, equipment or Manufacturing
                                         Process is required by one or more Regulatory Authorities or regulatory authorities outside
                                         the Territory or shall be applied globally, including for the manufacture of Products
                                         inside and outside the Territory, and if such change would require approval of any Regulatory
                                         Authority in the Territory or an amendment of any Marketing Authorization application
                                         or Registration, ARIAD US shall provide ARIAD SWISSCO with all information needed to
                                         amend the Marketing Authorization application or Registration and/or obtain the approval
                                         of the Regulatory Authority, as applicable, and the Parties shall cooperate with each
                                         other in obtaining any necessary modifications to any Registrations in the Territory
                                         to allow such change to be implemented. If the proposed change is required by a Regulatory
                                         Authority, then such notice shall include disclosure of the Regulatory Authority request
                                         and relevant correspondence. If any change to the Specifications, Raw Materials, equipment
                                         or Manufacturing Process is not required by any Regulatory Authority outside the Territory
                                         and shall not be applied globally and would require approval of any Regulatory Authority
                                         in the Territory or an amendment of any Marketing Authorization application or Registration,
                                         ARIAD US shall provide advanced written notice to ARIAD SWISSCO and shall consult with
                                         ARIAD SWISSCO regarding the implementation of such change. If the change is required
                                         by a Regulatory Authority inside the Territory but not in any other part of the world,
                                         [***] of implementing such change. If the change proposed by ARIAD US is required only
                                         by one or more regulatory authorities outside the Territory, or is not required by any
                                         Regulatory Authority, [***] of implementing such change. If the change is required by
                                         one or more Regulatory Authorities inside the Territory and by one or more regulatory
                                         authorities outside the Territory, [***]. For the avoidance of doubt, [***] of implementing
                                         a change to the Specifications, Raw Materials, equipment or Manufacturing Process if
                                         such change is mandated by a Regulatory Authority inside the Territory, and [***] of
                                         implementing such a change that is not mandated by any Regulatory Authority, including
                                         any such non-mandated change that ARIAD SWISSCO approves and that requires an amendment
                                         of a Marketing Authorization application or Registration or approval of a Regulatory
                                         Authority in the Territory. For clarity, ARIAD US shall have the right, [***], to change
                                         equipment for maintenance, repair, and like-for-like replacement, and to make other changes
                                         that ARIAD US reasonably determines shall not require approval of any Regulatory

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 42

     

    

 

Authority
or affect the Marketing Authorization application(s) or Registration(s) in the Territory, without notice to or consent of ARIAD
SWISSCO. Further for clarity, the Quality Agreements shall contain change control procedures, and any changes made to the Specifications,
Raw Materials, equipment or Manufacturing Process shall be made in accordance with the Quality Agreements and in compliance with
cGMP and Applicable Laws.

 

		12.4	Final
                                         Manufacturing. Subject to Section 10.2.1, with effect from the Effective Date, ARIAD
                                         SWISSCO shall be responsible for the Final Manufacturing of all Product, including performing
                                         secondary packaging, labeling and providing product inserts and final release and stability
                                         testing in accordance with the Marketing Authorization and Regulatory Requirements in
                                         the country in the Territory that is the intended market for such lot of Product, and
                                         in accordance with all Applicable Laws.

 

		12.5	Inspections.
                                         At ARIAD SWISSCO’s request, ARIAD US will authorize ARIAD SWISSCO or its representatives,
                                         during normal business hours (or at other times for cause), to review documents including
                                         but not limited to: completed manufacturing batch records, analytical results for product
                                         release and stability, associated manufacturing standard operating procedures and other
                                         standard operating procedures that are associated with maintenance of the process, facility
                                         and personnel in accordance with cGMPs, and observe the Manufacture of Product to confirm
                                         ARIAD US’s compliance with the terms of this Agreement and the Quality Agreement.
                                         ARIAD US will notify ARIAD SWISSCO within [***] of all contacts with Regulatory Authorities
                                         (written or verbal) related to each Product. ARIAD US shall inform ARIAD SWISSCO of the
                                         result of any regulatory inspection which directly affects the Manufacture of a Product,
                                         including any notice of inspection, notice of violation or other similar notice received
                                         by ARIAD US affecting Manufacturing, facility, testing, storage or handling of a Product.
                                         In the event of an FDA inspection which directly involves a Product, ARIAD SWISSCO shall
                                         be immediately informed of the issuance of the Notice of Inspection (FDA Form 482). In
                                         the event that there are inspectional observations (FDA Form 483), ARIAD SWISSCO shall
                                         be informed immediately and shall have the opportunity to review and provide ARIAD US
                                         with comments to ARIAD US’s response. ARIAD SWISSCO shall provide its comments
                                         to the response of these observations within [***]. The contents of ARIAD US’s
                                         response shall be determined by ARIAD US in its sole discretion. ARIAD US agrees to reasonably
                                         cooperate with applicable Regulatory Authorities and shall permit reasonable Product-specific
                                         inspections by such Regulatory Authorities.

 

ARTICLE
13 – QUALITY ASSURANCE

 

		13.1	Quality.
                                         The details of quality obligations and responsibilities of the Parties, including
                                         responsibility for submissions of reports to Regulatory Authorities, shall be set forth
                                         in one or more separate quality technical agreements (each, a “Quality Agreement”).
                                         As of the Effective Date the Parties will enter into an interim quality agreement in
                                         relation to the Transitional Supply Arrangements (“Interim Quality Agreement”).
                                         The Parties shall negotiate to agree a further Quality Agreement to be signed concurrently
                                         with the Supply Agreement and, once executed, that Quality Agreement shall supersede
                                         and replace the Interim Quality Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 43

     

    

 

ARTICLE
14 - RECALLS AND PRODUCT WITHDRAWAL 

 

		14.1	Notice.
                                         Each Party shall make every reasonable effort to notify the other Party promptly following
                                         the first Party’s determination that any event, incident, or circumstance has occurred
                                         that may result in the need for a Product Withdrawal anywhere in the world or a Recall
                                         anywhere in the world. Such Party shall include in such notice the reasoning behind such
                                         determination, and any supporting facts.

 

		14.2	Product
                                         Withdrawal. With respect to a Product Withdrawal within the Territory, immediately
                                         after receipt of such notification, the JSC (or its co-chairpersons) shall discuss and,
                                         unless the Product Withdrawal is mandated by a Regulatory Authority, shall attempt to
                                         agree on whether to voluntarily implement the Product Withdrawal within the Territory.
                                         If a Regulatory Authority mandates that the Product Withdrawal within the Territory be
                                         implemented then ARIAD SWISSCO, in consultation with ARIAD US, shall initiate the Product
                                         Withdrawal within the Territory as and to the extent mandated by the Regulatory Authority
                                         and in compliance with Applicable Laws. In the case of a Product Withdrawal that is not
                                         mandated by Regulatory Authority, if the JSC (or its co-chairpersons) fail(s) to agree
                                         within a reasonably appropriate time period (depending upon the circumstances) whether
                                         to voluntarily implement or undertake a Product Withdrawal within the Territory, then
                                         ARIAD SWISSCO and/or the MAH shall have the right to make the determination whether or
                                         not to voluntarily implement such Product Withdrawal within the Territory; provided that,
                                         to the extent practicable prior to deciding to initiate a Product Withdrawal within the
                                         Territory, ARIAD SWISSCO shall or shall procure that the relevant MAH shall consider
                                         ARIAD US’s reasonable comments in good faith. ARIAD SWISSCO or its Sublicensees
                                         shall carry out such Product Withdrawal activities in consultation with ARIAD US, in
                                         a manner which enables the Parties to meet their respective Regulatory Requirements as
                                         expeditiously as possible, and in compliance with all Applicable Laws. In the event of
                                         a mandated or voluntary Product Withdrawal in the Territory, the Parties will consider
                                         whether such action is necessary also in the Reserved Territory. If either Party or the
                                         relevant MAH does not choose to undertake a voluntary Product Withdrawal in its respective
                                         territory, despite the other Party’s written recommendation that such Product Withdrawal
                                         should be undertaken, then, notwithstanding anything to the contrary herein, such Party
                                         shall indemnify and hold harmless the other Party from and against any Losses that may
                                         arise or result thereafter from such Party’s failure to undertake such Product
                                         Withdrawal following such written recommendation from the other Party pursuant to the
                                         procedures set forth in Section 22.3.

 

		14.3	Recall.
                                         If a Regulatory Authority mandates that a Recall be implemented or undertaken by ARIAD
                                         SWISSCO in the Territory or by ARIAD US in the Reserved Territory, then ARIAD SWISSCO
                                         and/or the relevant Sublicensee, in consultation with ARIAD US (in the case of Recalls
                                         in the Territory) or ARIAD US and/or the relevant licensee, in consultation with ARIAD
                                         SWISSCO (in the case of Recalls in the Reserved Territory), shall initiate the Recall
                                         as and to the extent mandated by the Regulatory Authority and in compliance with Applicable
                                         Laws. With respect to a Recall in the Territory that is not mandated by a Regulatory
                                         Authority, (i) the Parties’ JSC co-chairs shall discuss and attempt to agree on
                                         whether to voluntarily implement the Recall and (ii) if the Parties’ JSC co-chairs
                                         fail to agree within a reasonably appropriate time period (depending upon the circumstances),
                                         then ARIAD SWISSCO

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 44

     

    

 

shall have
the right to make the determination whether or not to voluntarily implement a Recall in the Territory and ARIAD US shall have
the right to make the determination whether or not to voluntarily implement a Recall in the Reserved Territory.

 

		14.4	Expenses.
                                         [***], unless and to the extent the Recall or Product Withdrawal is based on the fault
                                         of [***], including in relation to Manufacture in which case such [***].

 

ARTICLE
15 – COMMERCIALIZATION OF THE PRODUCT 

 

		15.1	Commercialization
                                         Plan. The Parties shall annually update their part of the Commercialization Plan
                                         for the following Calendar Year before a mutually agreeable date prior to December 31
                                         in the preceding year. The JCC shall consider and discuss the revised plans, and ARIAD
                                         SWISSCO shall consider in good faith the input of ARIAD US on the ARIAD SWISSCO part
                                         of the Commercialization Plan for the Territory. ARIAD SWISSCO shall use Commercially
                                         Reasonable Efforts to implement its part of the then current Commercialization Plan.

 

		15.2	Commercialization
                                         Efforts. ARIAD SWISSCO shall either itself or through its Affiliates, Sublicensees
                                         or Subcontractors, have the sole right to Commercialize the Product [***] and in accordance
                                         with applicable cGMP and any other Applicable Laws and Industry Guidelines in each country
                                         of the Territory. ARIAD SWISSCO will conduct, as it deems appropriate, marketing and
                                         medical affairs activities to support the Commercialization of the Product in the Territory.
                                         ARIAD SWISSCO and its Affiliates will devote the following [***] to cover all [***] of
                                         their [***] business as a whole for the Product, [***] (it being understood that (a)
                                         such commercial costs will include a [***] of the Product [***] based on the number of
                                         products they carry, (b) such medical affairs costs will include costs only for [***]
                                         who support Product or work in CML or other approved indications of Product, and (c)
                                         both [***] will exclude Third Party costs that are not meaningfully related to the Product):
                                         [***] for calendar year [***] and for each year thereafter until the earlier of (a) the
                                         expiration of the Full Royalty Term in the last to expire country of the countries listed
                                         in Appendix 1.167 Part B or (b) the launch of a Generic Product in any of [***], the
                                         [***] will remain at [***] of Net Sales unless the Net Sales of Product by ARIAD SWISSCO
                                         in the Territory in calendar year [***] or in any calendar year thereafter is less than
                                         the Net Sales of Product by ARIAD SWISSCO in the Territory in calendar year [***], in
                                         which case the percentage of Net Sales applicable for such calendar shall be [***]. Notwithstanding
                                         the foregoing, the [***] for each calendar year from calendar year [***] through the
                                         earlier of (i) expiration of the Full Royalty Term in the last to expire country of the
                                         countries listed in Appendix 1.167 Part B or (ii) the launch of a Generic Product in
                                         any of [***] for each such calendar year. ARIAD SWISSCO will provide ARIAD US within
                                         [***] of calendar year end, an annual report of its commercial and medical expenses in
                                         support of Product, such report to contain the total [***], and other such details that
                                         the Parties mutually agree.

 

		15.3	Promotion.
                                         The Parties shall meet on a periodic basis, through the JCC, to (i) review and discuss
                                         the global Product communication strategy/brand positioning (“Global Product
                                         Positioning”) for the Product (as proposed by ARIAD US with input from

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 45

     

    

 

ARIAD SWISSCO
as well as other Product partners globally) (ii) discuss marketing strategies in their respective territories, (iii) discuss planned
marketing/promotional activities at international medical/scientific meetings/conferences in either Party’s territories.
ARIAD SWISSCO shall be entitled to use all existing print marketing, advertising and promotional materials, brand plan and strategy
used in respect of the Product in the Territory, and all training manuals currently used for ARIAD SWISSCO’s medical science
liaisons and sales representatives as at the Effective Date. Any new materials shall be developed and prepared by ARIAD SWISSCO
in its sole discretion, provided that ARIAD SWISSCO shall consider Global Product Positioning when preparing such materials and,
upon written request by ARIAD US, provide a courtesy copy of such materials to ARIAD US. ARIAD US shall provide a courtesy
copy of any new print marketing, advertising and promotional materials that it may develop to ARIAD SWISSCO. Each Party shall
have the right to purchase stock of the other Party's print marketing, advertising and promotional materials on mutually agreeable
terms.

 

		15.4	Independent
                                         Contractor. ARIAD SWISSCO shall make clear in all dealings with its actual and prospective
                                         Customers that it is selling the Product in its own name and for its own account as an
                                         independent contractor and not as agent of ARIAD US.

 

		15.5	Use
                                         of Internet.

 

		15.5.1	All
                                         of ARIAD SWISSCO’s internet marketing, advertising and promotional materials concerning
                                         the Product, the ARIAD US Trademarks and/or ARIAD US shall be developed and prepared
                                         by ARIAD SWISSCO in its sole discretion, provided that ARIAD SWISSCO will consider Global
                                         Product Positioning when performing such development.

 

		15.5.2	ARIAD
                                         US may grant to ARIAD SWISSCO the right to operate a website under a domain name registered
                                         in the name of ARIAD US and relevant to or which contains information about ARIAD US,
                                         the Product, and the Trademarks, subject to terms and conditions of this Agreement.

 

		15.5.3	In
                                         the event that any Applicable Law or regulation in the Territory requires the domain
                                         name of any website relevant to the Product, the Trademarks and/or ARIAD US to be registered
                                         in the name of ARIAD SWISSCO or an Affiliate, then any such domain name shall be registered
                                         in the name of ARIAD SWISSCO or Affiliate as legally required. All such content shall
                                         be or shall become the exclusive property of ARIAD US. Upon expiration or termination
                                         of the Agreement ARIAD SWISSCO and its Affiliates agree to execute any and all further
                                         documentation required to ensure that all such content and all copyright in such content
                                         is owned by ARIAD US. To the extent permitted by Applicable Law, ARIAD SWISSCO shall
                                         be required to assign to ARIAD US or its designee all domain name registrations containing
                                         the name of the Compound, the Product, the ARIAD US Trademarks or the name ARIAD US,
                                         or variants thereof, upon the expiration or termination of this Agreement. Neither ARIAD
                                         SWISSCO nor its Affiliate may assign or license any such domain name to any other Third
                                         Party.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 46

     

    

 

ARTICLE
16 – BUY-BACK OPTION

 

		16.1	If
                                         ARIAD US undergoes a Change of Control prior to six (6) years from the Effective Date,
                                         ARIAD US’s successor (“ARIAD US Successor”) shall have the right,
                                         within [***] of the effective date of the Change of Control to elect to terminate this
                                         Agreement and all ancillary arrangements relating thereto earlier than the expiry of
                                         the Term (the “Buy-Back Option”). ARIAD US Successor shall exercise
                                         such Buy-Back Option by giving notice in writing (“Termination Notice”)
                                         to ARIAD SWISSCO, specifying (i) the proposed date of early termination, which (A) in
                                         the case of a Termination Notice prior to the second anniversary of the Effective Date,
                                         shall be the third anniversary of the Effective Date, and (B) in all other cases shall
                                         be the one-year anniversary of Termination Notice, in each case such termination not
                                         to be effectuated later than seven (7) years after Effective Date and (ii) whether payment
                                         option (A) or (B) set forth in Section 16.2 is elected. On the sixth (6th) anniversary
                                         of the Effective Date, the right to give a Termination Notice in order to exercise the
                                         Buy-Back Option shall expire and ARIAD US Successor shall have no right to terminate
                                         this License Agreement and all ancillary arrangements relating thereto pursuant to this
                                         ARTICLE 16.

 

		16.2	Upon
                                         exercise of the Buy-Back Option, ARIAD US Successor shall [***], pay to ARIAD SWISSCO
                                         (i) an amount equal to the Purchase Price (as defined in the Share Purchase Agreement)
                                         plus all milestone and Development Costs previously paid by ARIAD SWISSCO to ARIAD US
                                         or ARIAD US Successor pursuant to this Agreement; and (ii) at [***], either (A) an amount
                                         equal to [***] Net Sales of the Product of ARIAD SWISSCO for the twelve (12) month period
                                         ending upon termination of this Agreement and a payment of twenty-five percent (25%)
                                         of Net Sales of the Product sold by ARIAD US Successor, its affiliates and sublicensees
                                         in the Territory with effect from the date of termination of this Agreement; or (B) an
                                         amount equal to [***] the Net Sales of the Product [***] in accordance with applicable
                                         accounting standards for the twelve (12) month period ending upon termination of this
                                         Agreement plus a payment of twenty percent (20%) of Net Sales of the Product sold by
                                         ARIAD US Successor, its affiliates and sublicensees in the Territory with effect from
                                         the date of termination of this Agreement. The payments being a percent Net Sales shall
                                         be made during the Full Royalty Term, and shall reduce to [***] of Net Sales thereafter
                                         for the Reduced Royalty Term. Sections 19.2.3, 19.3, 19.5, 19.6, 19.7, 19.9, and 19.10
                                         shall apply mutatis mutandi to payments on Net Sales made pursuant to this Section
                                         16.2 and to ARIAD US Successor in connection therewith. Following exercise of the Buy-Back
                                         Option, the payment obligations under this Section 16.2 shall survive any termination
                                         of this Agreement and shall be binding upon ARIAD US and ARIAD US Successor.

 

		16.3	Following
                                         exercise of the Buy-Back Option the Transition Back Arrangements will apply, and both
                                         Parties shall implement the same.

 

		16.4	If,
                                         within [***] after the exercise of the Buy-Back Option, ARIAD US Successor determines
                                         to [***], ARIAD US Successor shall (and ARIAD US shall ensure that ARIAD US Successor
                                         shall) so notify ARIAD SWISSCO in writing, and if ARIAD SWISSCO desires to enter into
                                         negotiations with ARIAD US Successor with respect to such [***], ARIAD SWISSCO shall
                                         so notify ARIAD US Successor in writing within [***] of receipt of ARIAD US Successor’s
                                         written notice, and in such case the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 47

     

    

 

Parties
shall enter into exclusive good faith negotiations with respect to such [***]. If, notwithstanding such negotiations, the Parties
are unable to reach a definitive agreement within [***] after ARIAD US Successor’s receipt of ARIAD SWISSCO’s written
notice, then ARIAD US Successor shall be free to negotiate and [***]. Notwithstanding anything to the contrary contained herein,
in no event shall the entering into [***] by ARIAD SWISSCO with ARIAD US Successor with respect to such rights [***] affect in
any manner any of the payments due to ARIAD SWISSCO under this ARTICLE 16, unless mutually agreed by ARIAD SWISSCO and ARIAD US
Successor.

 

ARTICLE
17  – MEDICAL AFFAIRS ACTIVITIES 

 

		17.1	ARIAD
                                         SWISSCO shall be solely responsible, [***], for medical affairs activities in the Territory,
                                         including providing medical liaisons, medical information and medical education programs
                                         and medical publications in the Territory, and attending relevant medical or scientific
                                         meetings and congresses, and shall allocate sufficient, appropriately qualified personnel
                                         and resources to conduct such activities, as set forth herein. Each Party shall have
                                         the right to purchase stock of the other Party’s medical education program materials
                                         and medical publications on mutually agreeable terms.

 

		17.2	ARIAD
                                         SWISSCO will use Commercially Reasonable Efforts to ensure that its Medical Affairs activities
                                         and communications are consistent with the Global Product Positioning, and will consider
                                         in good faith comments and input from ARIAD US to that effect. ARIAD SWISSCO shall appropriately
                                         disseminate medical information relating to the Compound and the Product in accordance
                                         with Applicable Laws and in a manner consistent with any medical affairs materials provided
                                         by ARIAD US to ARIAD SWISSCO in writing, if any (provided such materials provided by
                                         ARIAD US are compliant with Applicable Laws and Industry Guidelines).

 

		17.3	ISTs
                                         - General: Subject to the exceptions below, each Party is responsible for, at its
                                         expense, ISTs in its respective territory. The Parties shall review and discuss, through
                                         a joint medical affairs team or other mutually agreed process, each new proposal for
                                         an IST that a Party would like to support, and consider in good faith inputs or comments
                                         from the other Party. Each Party may then proceed with the IST subject to the other Party’s
                                         veto right in Sections 5.6 and 5.7.2.

 

Existing
Contractual ISTs: Notwithstanding the generality of the foregoing but subject to the remaining provisions of this Section,
where ARIAD US has entered into binding contractual arrangements prior to the Effective Date in respect of the ISTs in the Territory
listed in Part A of Appendix 17.3 (“Existing Contractual ISTs”), ARIAD US shall [***]. If ARIAD US proposes
to [***], the Parties shall discuss in good faith whether they would [***] as may be agreed between the Parties or whether [***],
provided that, subject to the following, ARIAD US shall [***] without the [***] of the Parties. Notwithstanding the foregoing,
ARIAD US shall be entitled to [***], by providing [***] to ARIAD SWISSCO, on the grounds that, in ARIAD US's [***].

 

ISTs Under Discussion:
In respect of ISTs in the Territory which ARIAD US has considered but has not entered into binding contractual arrangements prior
to the Effective Date, a list of which is set out at Part B of

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 48

     

    

 

Appendix 17.3 (“Existing
Non-Contractual ISTs”), the Parties shall discuss in good faith whether they [***] as may be agreed between the Parties.
In the event that ARIAD SWISSCO does not wish to participate in a particular Existing Non-Contractual IST [***], ARIAD US shall,
[***]. Notwithstanding the foregoing, ARIAD SWISSCO shall [***].

 

		17.4	ARIAD
                                         SWISSCO shall ensure that requests for information by Healthcare Professionals are answered
                                         in an appropriate, accurate and lawful manner by appropriately qualified personnel. Requests
                                         for information that are inconsistent with the Marketing Authorization for the relevant
                                         country shall be handled by the medical affairs personnel only.

 

		17.5	ARIAD
                                         SWISSCO’s medical personnel shall conduct periodic visits to clinical trial sites
                                         and investigators participating in any Product clinical trials in the Territory (including
                                         Global Studies, Proposed Studies and Ongoing Studies) to support initiation and enrollment
                                         through the provision of appropriate information and documentation and through issue
                                         escalation and coordination with clinical research organizations involved in the conduct
                                         of such studies.

 

ARTICLE
18 – TRADEMARKS 

 

		18.1	ARIAD
                                         SWISSCO shall use the ARIAD US Trademarks in relation to the Development and Commercialization
                                         of the Products in the Territory. If in any country of the Territory it is not legally
                                         possible or it is not commercially practicable to use the ARIAD US Trademarks, ARIAD
                                         SWISSCO shall be allowed to select and use ARIAD SWISSCO Trademarks. All details of the
                                         reasons for the need to use ARIAD SWISSCO Trademarks and the ARIAD SWISSCO Trademarks
                                         proposed to be used shall be disclosed to ARIAD US at JCC meetings, and ARIAD SWISSCO
                                         shall make good faith efforts to take account of ARIAD US comments.

 

		18.2	ARIAD
                                         SWISSCO shall continue to have the right to sell inventory of Product containing reference
                                         to ARIAD US corporate names and logos as follows. ARIAD SWISSCO shall be permitted to
                                         sell any stock or inventory existing as of the Effective Date without limitation. ARIAD
                                         SWISSCO shall: (i) as soon as practicable after the Effective Date, and in any event
                                         by no later than the date falling [***] following the Effective Date re-design the packaging
                                         and/or labelling information on the Product which includes any ARIAD US corporate names
                                         and logos, so that the design and/or labelling information for such stock or packaging
                                         no longer includes any ARIAD US corporate names and logos; and (ii) as soon as practicable
                                         following receipt of any necessary approval from the applicable Regulatory Authorities
                                         cease the production and sale of any stock or packaging bearing any ARIAD US corporate
                                         names and logos; except in each case if the use of the ARIAD US corporate names and logos
                                         is required by a Regulatory Authority or under Applicable Law.

 

		18.3	ARIAD
                                         SWISSCO shall use the ARIAD US Trademarks only and exclusively in connection with and
                                         for the purpose of the Commercialization of the Product in the Field in the Territory.
                                         ARIAD SWISSCO acknowledges that it shall not be entitled to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 49

     

    

 

any rights
whatsoever in the ARIAD US Trademarks or ARIAD US’s corporate name or logo except as required by a Regulatory Authority
or under Applicable Law or as is specifically granted pursuant to this Agreement.

 

		18.4	The
                                         ARIAD US Trademarks shall always be used together with the sign “R” or the
                                         sign “TM” or such other customary symbol or legend that correctly identifies
                                         the status of the ARIAD US Trademark (i.e., registered or unregistered) in the Territory.

 

		18.5	Nothing
                                         contained in this Agreement shall be construed as giving ARIAD SWISSCO the right to use
                                         any of the ARIAD US Trademarks or the name or logo of ARIAD US outside the Territory
                                         or for any other product than the Product and solely in the Field. ARIAD SWISSCO recognizes
                                         the exclusive ownership rights of ARIAD US in and to the ARIAD US Trademarks and the
                                         name and logo of ARIAD US and acknowledges that it shall not acquire any ownership or
                                         other rights in respect of the ARIAD US Trademarks or the name or logo of ARIAD US and/or
                                         of the goodwill associated therewith and that all such rights and goodwill are, and shall
                                         at all times remain, vested in ARIAD US. ARIAD SWISSCO acknowledges and agrees that all
                                         use of the ARIAD US Trademarks and the name and logo of ARIAD US inures to and is for
                                         the benefit of ARIAD US. ARIAD SWISSCO shall, if requested by ARIAD US, execute an assignment
                                         to ARIAD US of any and all rights that ARIAD SWISSCO may acquire in respect of any of
                                         the ARIAD US Trademarks or the name or logo of ARIAD US and/or of the goodwill associated
                                         therewith.

 

		18.6	ARIAD
                                         US shall use Commercially Reasonable Efforts to maintain the validity of the ARIAD US
                                         Trademarks in the Territory throughout the Term, [***]. For ARIAD US Trademarks currently
                                         used by ARIAD SWISSCO under this Agreement, ARIAD SWISSCO agrees to provide any reasonable
                                         assistance in this effort [***], provided, however, that [***] in connection with such
                                         assistance.

 

		18.7	ARIAD
                                         SWISSCO shall promptly notify ARIAD US with respect to any threatened, potential or presumed
                                         counterfeits, copies, imitations, simulations of, or infringements upon, the ARIAD US
                                         Trademarks or the name “ARIAD US” which comes to its attention during any
                                         period where such marks or names are actively used by ARIAD SWISSCO. ARIAD US shall decide
                                         on the steps to be taken after having discussed such threatened, potential or presumed
                                         counterfeits, copies, imitations, simulation and/or infringements with ARIAD SWISSCO.
                                         ARIAD SWISSCO shall provide all reasonable assistance (with ARIAD SWISSCO bearing [***]
                                         solely for the purpose of engaging any Third Party to assist in the performance of any
                                         action contemplated by this Section 18.7) to ARIAD US in taking legal action,
                                         if deemed necessary by ARIAD US, in its sole and absolute discretion, with respect to
                                         such matters.

 

		18.8	ARIAD
                                         SWISSCO acknowledges that ARIAD US would have no adequate remedy under this Agreement
                                         or at law in the event that ARIAD SWISSCO were to use the ARIAD US Trademarks in a manner
                                         not authorized by this Agreement and that ARIAD US would, in such circumstances, be entitled
                                         to specific performance, injunctive or other equitable relief.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 50

     

    

 

ARTICLE
19 – CONSIDERATION AND PAYMENTS

 

		19.1	Milestone
                                         Payments.

 

		19.1.1	ARIAD
                                         SWISSCO shall pay ARIAD US the following non-refundable, non-creditable milestone payments
                                         after the first achievement or occurrence of the following by ARIAD SWISSCO, its Affiliates
                                         or Sublicensees:  

 

	Milestone Event	 	Payment Amount
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

 

		19.1.2	With
                                         the exception of the [***] milestones, each of the milestone payments set out in Section
                                         19.1.1 shall be payable only upon the first occurrence of the applicable event, whenever
                                         it occurs. ARIAD SWISSCO shall report the occurrence of each milestone event to ARIAD
                                         US within [***] of its occurrence. Upon notification, ARIAD US shall invoice ARIAD SWISSCO
                                         for the amount of the milestone. ARIAD SWISSCO shall pay the milestone invoice within
                                         [***] of receipt of the invoice. Milestone payment to ARIAD US shall be made by wire
                                         transfer to an account designated in writing by ARIAD US.

 

		19.2	Royalties.

 

		19.2.1	Full
                                         Royalty Term. Subject to the adjustments provided in this Section 19.2, Section 19.11
                                         and ARIAD SWISSCO’s offset rights, ARIAD SWISSCO will pay to ARIAD US during the
                                         Full Royalty Term as set forth below:

 

royalty = A+B+C+D+E, where:

 

A equals thirty-two
percent (32%) of that portion of Net Sales of Product in the Territory which, during the calendar year in question, is less than
or equal to [***];

 

B equals [***] of that
portion of Net Sales of Product in the Territory which, during the calendar year in question, is greater than [***] and less than
or equal to [***];

 

C equals [***] of that
portion of Net Sales of Product in the Territory which, during the calendar year in question, is greater than [***] and less than
or equal to [***];

 

D equals [***] of that
portion of Net Sales of Product in the Territory which, during the calendar year in question, is greater than [***] and less than
or equal to [***];

 

E equals fifty percent
(50%) of that portion of Net Sales of Product in the Territory which, during the calendar year in question, is greater than [***].

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 51

     

    

 

		19.2.2	Reduced
                                         Royalty Term. Subject to Section 19.11 and ARIAD SWISSCO’s offset rights, ARIAD
                                         SWISSCO shall pay to ARIAD US a royalty of [***] of Net Sales in each country in the
                                         Territory as to which the Full Royalty Term has expired. Such royalty obligation shall
                                         begin in each country in the Territory on the day after the Full Royalty Term has expired
                                         and continue until the [***] of such expiration (the “Reduced Royalty Term”).
                                         Further for clarity, after the expiration of the Reduced Royalty Term in each country
                                         in the Territory, no further royalties shall be due with respect to Net Sales in such
                                         country and the licenses granted to ARIAD SWISSCO hereunder shall become fully paid-up
                                         and royalty-free with respect to such country for the remainder of the Term.

 

		19.2.3	Net
                                         Sales Reports and Royalty Payments

 

		(a)	[***]
                                         before the end of each calendar quarter (other than during the first [***] after the
                                         Effective Date, when no such estimate shall be required), ARIAD SWISSCO shall deliver
                                         to ARIAD US a report with estimated Net Sales made in such quarter, including:

 

		(i)	Net
                                         Sales of Product in local currency, by country by Presentation, during the quarter; and

 

		(ii)	all
                                         exchange rate conversions in accordance with Section 19.5..

 

The Parties,
through a Transition Services Agreement as defined in the Share Purchase Agreement, will agree upon an approach through which
the foregoing reports can be provided by ARIAD SWISSCO, whether through successful migration to ARIAD SWISSCO or ARIAD US providing
continued access to its reporting systems.

 

		(b)	Within
                                         [***] after the end of each calendar quarter, ARIAD SWISSCO shall deliver to ARIAD US
                                         a report setting out the details described in (a) and (b) above with respect to actual
                                         Net Sales made in such calendar quarter.

 

		(c)	Promptly
                                         following receipt of the royalty report ARIAD US shall issue an invoice for the royalties
                                         due and , ARIAD SWISSCO shall pay the invoiced royalty within [***]
                                         of receipt of the invoice. Royalty payment to ARIAD US shall be made by wire transfer
                                         to an account designated in writing by ARIAD US.

 

		19.3	ARIAD
                                         SWISSCO shall provide (a) such monthly sales reports as ARIAD US may reasonably request
                                         in relation to the sales data and information reasonably necessary to understand, the
                                         level of gross sales invoiced in the Territory and (b) such quarterly sales reports as
                                         ARIAD US may reasonably request in relation to the sales data and information reasonably
                                         necessary to understand, gross sales invoiced and deductions taken in Sections 1.112(a)
                                         through 1.112(g) to arrive at Net Sales in the Territory.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 52

     

    

 

		19.4	Distribution
                                         Agreement Milestone Payments. ARIAD SWISSCO shall, promptly, upon receipt (and in
                                         any event within [***] of receipt) pay to ARIAD US [***] of the Distribution Agreement
                                         Milestone Payments in [***]. ARIAD SWISSCO hereby agrees to (i) use all Commercially
                                         Reasonable Efforts to enforce the provisions of the relevant Distribution Agreement pursuant
                                         to which the Distribution Agreement Milestone Payments are payable and collect payment
                                         thereof from the relevant counterparty; and (ii) not [***] the relevant Distribution
                                         Agreement pursuant to which the [***] or take any other steps that would [***] under
                                         this Section 19.4 without ARIAD US’ prior written consent or without providing
                                         compensation for such impact.

 

		19.5	Payment
                                         Currency and Exchange Rate. All amounts due under this Agreement shall be paid in
                                         US dollars. The amount of Net Sales under Section 19.2 shall be determined in Local Currency.
                                         The Net Sales amount shall be converted from Local Currency into US dollars using the
                                         average interbank exchange rate for conversion of one unit of Local Currency to one US
                                         dollar during the calendar quarter prior to the payment due date. Exchange rates shall
                                         be as published by OANDA.com “The Currency Site” under the heading “FxHistory:
                                         historical currency exchange rates” at www.OANDA.com/convert/fxhistory. All payments
                                         under this Agreement shall be made by bank wire transfer in immediately available funds
                                         to a bank account designated in writing by the payee Party or by other means as directed
                                         by the payee Party in writing.

 

		19.6	Interest.
                                         Payments made under this Agreement shall be considered to be made as of the day on which
                                         there were sent. In the event that any payment due under this Agreement is not made when
                                         due, the payment shall accrue simple interest from the date due at a rate per annum equal
                                         to [***] above the [***] published in the [***], (or, if the [***], ceases to publish
                                         such rates, such other reputable financial news source as ARIAD US may select) in
                                         effect on the date of the scheduled date of payment; provided that, in no event shall
                                         such rate exceed the applicable maximum legal annual interest rate then in effect. The
                                         payment of such interest shall not limit the payee Party from exercising any other rights
                                         it may have as a consequence of the lateness of any payment. [***]. The payer Party shall
                                         pay the interest together with the overdue amount.

 

		19.7	Tax
                                         Matters. Unless otherwise agreed in writing by the Parties or required by Applicable
                                         Laws, all amounts payable by one Party to the other Party pursuant to this Agreement
                                         (each a “Payment”) excludes all withholding, sales, use, consumption,
                                         value-added, customs, excise and other taxes, duties or governmental assessments (collectively,
                                         “Taxes”). The Parties shall use commercially reasonable efforts to
                                         structure all Payments to minimize the applicability of withholding taxes to the maximum
                                         extent consistent with Applicable Laws. If any Payment is subject to a deduction or withholding
                                         of Tax pursuant to Applicable Laws, the Parties shall use commercially reasonable efforts
                                         to perform all acts (including by executing all appropriate documents) so as to enable
                                         the payee Party to take advantage of any applicable double taxation agreement or treaty
                                         or to otherwise secure any applicable exemption from or reduction in withholding Taxes.
                                         In the event there is no applicable double taxation (or other exemption) agreement or
                                         treaty, or if an applicable double taxation (or other) agreement or treaty reduces but
                                         does not eliminate such withholding Tax, the payer Party shall pay the applicable Tax
                                         to the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 53

     

    

 

appropriate
governmental authority, shall provide to the payee Party evidence of such payment, and shall deduct the amount paid from the Payment
due the payee Party. If the payer Party has to pay applicable withholding tax because of a failure by the payer Party to complete
any procedural formalities necessary for it to obtain authorization to make payments pursuant to this Agreement without the obligation
to make deduction or withholding, then the amount due from the payer Party to ARIAD US shall be increased to an amount which (after
making any deduction for withholding in respect of taxes) leaves an amount equal to the payment which payee Party would have received
if no such deduction or withholding had been required. Any withholding tax imposed on a payment from an ARIAD SWISSCO Affiliate,
Sublicensee or distributor in the Territory to ARIAD SWISSCO is the responsibility of ARIAD SWISSCO.

 

		19.8	Payments
                                         and Adjustments.

 

		19.8.1	ARIAD
                                         SWISSCO shall be entitled to offset or otherwise withhold or adjust any Payment due to
                                         ARIAD US under this Agreement and any actual tax payment made to a tax authority under
                                         Section 9.7 (Tax Matters) of the Share Purchase Agreement in view of claims that ARIAD
                                         SWISSCO may have.

 

		19.8.2	Within
                                         [***] after the end of each calendar year (except for the final payment, which shall
                                         be made within [***] of the [***] of the Effective Date), ARIAD US shall pay to ARIAD
                                         SWISSCO an amount equal to the Year-End Compensating Payment as set forth on Appendix
                                         19.8.2.

 

		19.8.3	Each
                                         Party shall make all payments due by it to the other Party under this Agreement in accordance
                                         with the time periods set forth in this Agreement for the applicable payment in full
                                         amount of such payment except (in the case of payments under this Agreement other than
                                         those under Sections 19.1, 19.2 and 19.4) as may be disputed in good faith by such paying
                                         Party. Notice of the basis for, and reasonable detail of, any such dispute shall be provided
                                         in writing together with such payment, together with the identity of the designated finance
                                         representative of such paying Party. The finance representatives of each Party shall
                                         promptly, but no later than [***] after the receipt of such notice, in order to attempt
                                         in good faith to resolve such dispute; provided, that, after [***], such dispute shall
                                         be escalated to the Senior Officers under Section 29.2. If the Senior Officers are not
                                         able to resolve such dispute in accordance with Section 29.2, upon the request of one
                                         of the Parties, such dispute shall be submitted to an independent accounting firm in
                                         accordance with the general procedures set forth in Section 19.9, or, absent such submission,
                                         either Party may invoke the provisions of Section 29.3 with respect to such dispute.

 

		19.9	Books,
                                         records and accounts. Throughout the Royalty Term and for a period of at least [***]
                                         thereafter, ARIAD SWISSCO shall keep complete and accurate books, records and accounts
                                         in accordance with all Regulatory Laws and Regulatory Requirements and sound accounting
                                         practice covering all its operations hereunder and as may be necessary for the purpose
                                         of calculating all payments due to ARIAD US under this ARTICLE 19 and the required expenditures
                                         under Section 15.2.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 54

     

    

 

ARIAD US
shall have the right, throughout the Term and for a period of [***] thereafter, at reasonable times during business hours and
upon reasonable notice to ARIAD SWISSCO, to have ARIAD SWISSCO’s books, records and accounts inspected and audited by a
reputable independent auditor employed by one of the four major accounting firms to be appointed by ARIAD US and reasonably acceptable
to ARIAD SWISSCO, to ensure the accuracy of all reports and payments made hereunder and in respect of all Development Costs and
the expenditures made by ARIAD SWISSCO and its Affiliates as required in Section 15.2. Such audit shall be covered by confidentiality
obligations of the auditor. Such inspection and audit may not be (i) conducted for any calendar year more than [***] after the
end of such year, (ii) conducted more than once in any [***] period, or (iii) repeated for any [***]. ARIAD SWISSCO shall cooperate
with the independent auditor and make available all work papers and other information related to this Agreement reasonably requested
in connection herewith (subject to written obligations of confidentiality to ARIAD SWISSCO). For purposes of (a) payments under
this Agreement including Sections 5.3.1, 5.3.2, 5.7.3, 5.7.4, and 5.9 and calculation of any Development Costs that one Party
must pay to the other under this Agreement, (b) the determination of the Cost of Manufacture, (c) calculation of the Year-End
Compensating Payment pursuant to Appendix 19.8.2, and (d) calculation of manufacturing technology transfer costs, this Section
19.9 shall apply mutatis mutandi to the applicable Party’s books, records and accounts and for the applicable party to audit
such books, records and accounts.

 

		19.10	Currency
                                         embargoes. If at any time currency embargoes or similar legal restrictions in any
                                         country in the Territory prevent the prompt remittance of any payments hereunder, ARIAD
                                         SWISSCO shall make such payments by depositing the amount thereof in local currency to
                                         the account of ARIAD US in a bank or depository in such country designated by ARIAD US.

 

		19.11	Generic
                                         Competition. In countries in the Territory where (i) a Generic Product enters the
                                         market, the royalty rates set out in Section 19.2 above shall be reduced by [***] during
                                         the Full Royalty Term and by [***] thereafter in such country, (ii) the Generic Product(s)
                                         comprises more than [***] of the unit sales of Product and Generic Products in such country,
                                         the royalty rates set out in Section 19.2 above shall be reduced by [***] during the
                                         Full Royalty Term and by [***] thereafter, and (iii) the Generic Product(s) comprises
                                         more than [***] of the unit sales of Product and Generic Products in such country, the
                                         royalty rates set out in Section 19.2 above shall be reduced to [***] during the Full
                                         Royalty Term and by [***] thereafter. If such a Generic Product enters the market prior
                                         to the expiration of the Composition Patent in such country and if ARIAD US institutes
                                         an action or proceeding in accordance with Section 23.4 and prevails in such action the
                                         applicable royalty rates set out in Section 19.2 would be reinstated until such other
                                         time as the foregoing provision applies.

 

		19.12	No
                                         amounts will be due and payable by ARIAD SWISSCO under Section 19.1 upon the Buy-Back
                                         Option having been exercised pursuant to ARTICLE 16.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 55

     

    

 

ARTICLE
20 – REPRESENTATIONS AND WARRANTIES

 

		20.1	ARIAD
                                         US hereby represents and warrants to ARIAD SWISSCO as of the Effective Date, and with
                                         respect to Sections 20.1.4, 20.1.5, 20.1.6, 20.1.7 and 20.1.17 only, throughout the Term,
                                         as follows:

 

		20.1.1	Organization.
                                         ARIAD US has been duly organized and is validly existing as a corporation in good standing
                                         under the laws of the State of Delaware, USA. ARIAD US has the corporate power and authority
                                         to enter into this Agreement and to consummate the transactions contemplated by this
                                         Agreement.

 

		20.1.2	Authorization.
                                         The execution, delivery and performance of this Agreement, and the consummation of the
                                         transactions contemplated by this Agreement, by ARIAD US have been duly and validly authorized
                                         by all requisite corporate actions. This Agreement constitutes a legal, valid and binding
                                         agreement of ARIAD US, enforceable against ARIAD US in accordance with its terms.

 

		20.1.3	Execution.
                                         The persons executing this Agreement on behalf of ARIAD US are duly authorized to do
                                         so and by so doing have bound ARIAD US to the terms and conditions of this Agreement.

 

		20.1.4	No
                                         Inconsistent Obligations. Except as disclosed in the Disclosure Schedules, the execution,
                                         delivery and performance by ARIAD US of this Agreement, and the consummation of the transactions
                                         contemplated by this Agreement, do not and shall not (i) contravene or conflict with
                                         the charter or bylaws of ARIAD US or its Affiliates, as applicable, or (ii) conflict
                                         with, constitute a default in any material respect under or give rise to any right of
                                         termination or cancellation of, any agreement or instrument to which ARIAD US or its
                                         Affiliates is a party that would have a material adverse effect on the ability of ARIAD
                                         US or its Affiliates to perform its obligations hereunder. As of the Effective Date,
                                         there is no action, suit, investigation or proceeding pending against, or to the Knowledge
                                         of ARIAD US, threatened against or affecting, ARIAD US or its Affiliates before any court,
                                         arbitrator or any governmental authority, including Regulatory Authorities, which, if
                                         decided against ARIAD US or its Affiliates, would have a material adverse effect on the
                                         ability of ARIAD US or its Affiliates to perform their obligations hereunder.

 

		20.1.5	Product.
                                         Product Delivered hereunder shall:

 

		(a)	be
                                         Manufactured in all material respects in accordance with the Marketing Authorization,
                                         the applicable Quality Agreements, all Applicable Laws and cGMPs;

 

		(b)	have
                                         the requisite shelf life on the date of Delivery as set forth in the Specifications;

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 56

     

    

 

		(c)	conform
                                         to the Specifications at the time of Delivery until the expiry date set forth on the
                                         label for the given lot of the Product; and

 

		(d)	at
                                         the time of Delivery, be free and clear of any lien or encumbrance.

 

		20.1.6	Right
                                         to Grant License. ARIAD US and its Affiliates are the sole and exclusive owners of
                                         the Patents listed in Appendix 1.128 and the Know How, and ARIAD US is entitled to grant
                                         the licenses to ARIAD SWISSCO specified in ARTICLE 2.

 

		20.1.7	Patent
                                         Validity and No Patent Challenge. To the Knowledge of ARIAD US, the claims of the
                                         issued patents included in the Patents listed in Appendix 1.128 are not invalid and the
                                         issued patents included in the Patents listed in Appendix 1.128 are not unenforceable
                                         in the Territory. No Third Party has challenged in writing, or, to the Knowledge of ARIAD
                                         US, has threatened to challenge, the enforceability or validity of any issued
                                         patents included in the Patents listed in Appendix 1.128 or any claims therein, respectively
                                         in the Territory through the institution of legal proceedings in a court or through opposition,
                                         interference, reexamination, nullity or similar invalidity proceedings before a patent
                                         office or any equivalent government agency in the Territory. Appendix 1.128 represents
                                         all Patents that cover or disclose the Compounds and Products as of the Effective Date.

 

		20.1.8	No
                                         ARIAD US Trademark Challenge. No Third Party has challenged in writing, or, to the
                                         Knowledge of ARIAD US, has threatened to challenge, ARIAD US’s right to use and
                                         license the ARIAD US Trademarks in the Territory.

 

		20.1.9	No
                                         Infringement by Third Parties. To the Knowledge of ARIAD US, no Third Party is infringing
                                         the Patents in the Territory.

 

		20.1.10	No
                                         Claim that Development or Commercialization Infringes Third Party IP. There are no
                                         claims asserted in writing, judgments, or settlements in effect against, or amounts with
                                         respect thereto owed by, ARIAD US or any of its Affiliates relating to the Patents in
                                         the Territory. No claim or litigation is pending or, to the Knowledge of ARIAD US, threatened
                                         alleging that the manufacture, use or sale of the Product in the Territory infringes
                                         or would infringe any issued patent in the Territory. To ARIAD US’s Knowledge,
                                         the Development, Manufacture, and Commercialization of Compounds or Products in the Field
                                         in the Territory will not infringe or misappropriate the intellectual property or proprietary
                                         rights of any Third Party in the Territory.

 

		20.1.11	Regulatory
                                         Documentation. The status of Marketing Authorizations in each country or other
                                         jurisdiction in the Territory as of the Effective Date is accurately reflected on Appendix
                                         1.167 and each of them is in full force and effect. To the Knowledge of ARIAD US, ARIAD
                                         US and its Affiliates have generated, prepared, maintained, and retained all material
                                         records that are required to be maintained or retained pursuant to and in accordance
                                         with

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 57

     

    

 

good laboratory
practice and cGMP and Applicable Law, and all such information is true, complete and correct. Neither ARIAD US nor its Affiliates
have received any written notice that any Regulatory Authority with jurisdiction in the Territory over the Products has commenced
or will commence any action: (i) to suspend, revoke, not renew or materially amend any Marketing Authorization held by ARIAD US
or its Affiliates; or (ii) prohibit production, development, marketing or sale of the Product in the Territory.

 

		20.1.12	Patent
                                         Prosecution. The Patents listed in Appendix 1.128 have been filed and maintained,
                                         and are being diligently prosecuted, in the respective patent offices where filed in
                                         the Territory in accordance with Applicable Laws. All applicable and material fees due
                                         prior to the Effective Date in connection with the prosecution and maintenance of the
                                         Patents listed in Appendix 1.128 in the Territory have been paid.

 

		20.1.13	Compliance
                                         with Law. Except as disclosed in the Disclosure Schedules, ARIAD US and its Affiliates
                                         and, to the Knowledge of ARIAD US, their respective contractors and consultants, have
                                         complied in all material respects with Applicable Laws in the Development, manufacture
                                         and Commercialization of the Compound and Product in the Territory prior to the Effective
                                         Date.

 

		20.1.14	No
                                         Encumbrances. ARIAD US or its Affiliates Control the entire right, title and interest
                                         in the Patents and the Know-How, free of any encumbrance, lien, or claim of ownership
                                         by any Third Party, except its obligations to PDL BioPharma, Inc. under the PDL Agreements.

 

		20.1.15	Employee
                                         Assignments. All current and former officers or employees of ARIAD US or any of its
                                         Affiliates who are inventors of or have otherwise contributed in a material manner to
                                         the creation or development of any Patents or Know-How have (i) executed and delivered
                                         to ARIAD US or any such Affiliate an assignment or other agreement regarding the protection
                                         of proprietary information and the assignment to ARIAD US or any such Affiliate of any
                                         such Patents or Know How; and (ii) to ARIAD US’s Knowledge, no current officer
                                         or employee of ARIAD US or any of its Affiliates is in violation of any term of any assignment
                                         or other agreement regarding the protection of Patents or Know-How or of any employment
                                         contract or any other contractual obligation relating to the relationship of any such
                                         Person with ARIAD US or any such Affiliate. ARIAD SWISSCO has no obligation to contribute
                                         to any remuneration of any inventor employed or previously employed by ARIAD US or any
                                         of its Affiliates in respect of any such Patents and Know-How and discoveries and intellectual
                                         property rights therein that are so assigned to ARIAD US or its Affiliate(s).

 

		20.1.16	No
                                         Debarment. Neither ARIAD US nor any of its Affiliates has been debarred by the FDA,
                                         is not subject to any similar sanction of other Regulatory Authorities in the Territory,
                                         and neither ARIAD US nor any of its Affiliates has used, in any capacity, in connection
                                         with this Agreement or any ancillary agreements (if any), any Person who either has been

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 58

     

    

 

debarred
by such a Regulatory Authority, or is the subject of a conviction described in Section 306 of the US Federal Food, Drug, and Cosmetic
Act or similar sanction of other Regulatory Authorities.

 

		20.1.17	Post-Marketing
                                         Requirements. Appendix 20.1.17 contains a true and complete list of all post-marking
                                         requirements of all Regulatory Authorities related to the Products. ARIAD US shall promptly
                                         notify ARIAD SWISSCO of any changes in post-marketing requirements, ARIAD US and its
                                         Affiliates have and during the Term, will comply with all such requirements.

 

For the purposes of this ARTICLE 20, Disclosure
Schedules shall mean the Disclosure Schedules set out in Appendix 20 to this Agreement.

 

ARTICLE
21 – COMPLIANCE WITH LAW; DATA PRIVACY; ANTI-BRIBERY AND ANTI-CORRUPTION 

 

		21.1	Each
                                         Party shall obtain and keep current all licenses, certificates, approvals and permits
                                         of whatever nature required under the Regulatory Laws and the Regulatory Requirements
                                         for the fulfilment of such Party’s obligations under this Agreement.

 

		21.2	In
                                         the performance of its obligations hereunder, each Party shall comply and shall cause
                                         its Affiliates, employees and contractors involved in the performance of this Agreement,
                                         and its Sublicensees and Subcontractors to comply with all Applicable Laws, including
                                         Anti-Corruption Laws, and Industry Guidelines, and, without limiting the foregoing, each
                                         Party shall comply, and shall cause its Affiliates, Sublicensees, employees and Subcontractors
                                         involved in Named Patient Program to comply with all Industry Guidelines and Applicable
                                         Laws with respect to Named Patient Programs.

 

		21.3	Each
                                         Party shall certify to the other Party on an annual basis the following:

 

		(a)	it
                                         has in effect and implements an appropriate Anti-Corruption policy;

 

		(b)	that
                                         training and training materials on such Anti-Corruption Policy (including Anti-Corruption
                                         Laws) have been provided to all persons employed by such Party who perform work under
                                         this Agreement and interact with Government Officials or Healthcare Professionals in
                                         the normal course of their responsibilities; and

 

		(c)	It
                                         has maintained true and accurate records necessary to demonstrate compliance with the
                                         requirements of this Section 21.3.

 

		21.4	At
                                         times, either Party may provide the other Party with personal information that falls
                                         under the protection of certain data security and privacy laws (“Protected Personal
                                         Information”). Without limiting the generality of Section 21.1, each Party
                                         agrees to comply with all Applicable Laws relating to the use, storage, collection or
                                         other processing of such Protected Personal Information (“Data Protection Laws”).
                                         The Parties agree to use good-faith efforts to agree upon and implement any security
                                         protocols and information handling guidelines that their respective legal advisors

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 59

     

    

 

recommend
in connection with the Parties’ compliance with such data security and privacy laws.

 

		21.5	Notice
                                         of Compliance Events. Each Party agrees that if it learns of any violation of Anti-Corruption
                                         Laws or any material violation of any Data Protection Laws, Regulatory Laws or Export
                                         Control Laws by an employee or Subcontractor (in the case of ARIAD SWISSCO) or contractor
                                         (in the case of ARIAD US) that performs work under this Agreement (a “Compliance
                                         Event”), such Party (the “Notifying Party”) shall promptly
                                         notify the other Party (the “Notified Party”) in writing of such Compliance
                                         Event and the measures Notifying Party has taken and intends to take to remedy such Compliance
                                         Event and to prevent its recurrence. The Notified Party reserves the right to require
                                         the Notifying Party to prohibit the employee, Subcontractor or contractor (as the case
                                         may be) from performing any work related to this Agreement after due consultation with
                                         Notifying Party.

 

ARTICLE
22 – INDEMNIFICATION, LIMITATIONS OF LIABILITY AND INSURANCE 

 

		22.1	Upon
                                         the terms and conditions of this ARTICLE 22, ARIAD SWISSCO shall defend, indemnify and
                                         hold ARIAD US and its Affiliates, and their respective officers, directors and employees
                                         and agents, wholly free and harmless from and against any and all liabilities, damages,
                                         losses, costs, taxes, expenses (including reasonable attorneys’ fees and other
                                         expenses of litigation and arbitration), claims, demands, suits, penalties, judgments
                                         or administrative and judicial orders (collectively, “Losses”) relating
                                         to any Proceeding or Proceeding threatened in writing to the extent arising out of or
                                         resulting from (a) any failure by ARIAD SWISSCO to comply with any Applicable Laws; (b)
                                         the performance (or failure to perform) by ARIAD SWISSCO, its Affiliates, Sublicensees,
                                         Subcontractors, or its service providers or any of their respective officers, directors,
                                         employees or agents of any of ARIAD SWISSCO’s obligations under this Agreement
                                         (including the Manufacture of Product by ARIAD SWISSCO, its Affiliates or its or their
                                         Third Party contract manufacturers); (c) any negligent act or omission or willful misconduct
                                         of ARIAD SWISSCO, its Affiliates, Sublicensees, Subcontractors, or its service providers,
                                         or any of their respective officers, directors, employees or agents; (d) any breach by
                                         ARIAD SWISSCO, its Affiliates, Sublicensees, Subcontractors, or service providers, or
                                         any of their respective officers, directors, employees or agents, of any of ARIAD SWISSCO’s
                                         representations, warranties, covenants or material obligations contained in this Agreement;
                                         (e) the storage, sampling, record-keeping or transfer of the Product by ARIAD SWISSCO,
                                         its Affiliates, Sublicensees, Subcontractors, or its service providers, or any of their
                                         respective officers, directors, employees or agents; and (f) failure of ARIAD SWISSCO
                                         to undertake a voluntary Product Withdrawal in its respective territory, despite the
                                         ARIAD US’s written recommendation that such Product Withdrawal should be undertaken,
                                         except, in each of the foregoing cases, to the extent ARIAD US has the obligation to
                                         indemnify for such Losses pursuant to Section 22.2.

 

		22.2	Upon
                                         the terms and conditions of this ARTICLE 22, ARIAD US shall defend, indemnify and hold
                                         ARIAD SWISSCO and its Affiliates, and their respective officers, directors and employees
                                         and agents, wholly free and harmless from and

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 60

     

    

 

against
any and all Losses relating to any Proceeding or Proceeding threatened in writing to the extent arising out or resulting from
(a) any failure by ARIAD US to comply with any Applicable Laws; (b) the performance (or failure to perform) by ARIAD US, its Affiliates,
subcontractors or its service providers, or any of their respective officers, directors, employees or agents of any of ARIAD US’s
obligations under this Agreement (including the Manufacture of Product by ARIAD US, its Affiliates or its or their Third Party
contract manufacturers); (c) any negligent act or omission or willful misconduct of ARIAD US, its Affiliates, subcontractors or
its service providers, or any of their respective officers, directors, employees or agents; (d) any breach by ARIAD US, its Affiliates,
subcontractors or its service providers, or any of their respective officers, directors, employees or agents of any of ARIAD US’s
representations, warranties, covenants or obligations contained in this Agreement; (e) the storage, sampling, record-keeping or
transfer of the Product by ARIAD US, its Affiliates, subcontractors, or its service providers, or any of their respective officers,
directors, employees or agents; (f) the Development, commercialization, Manufacture, final manufacture or other exploitation of
the Products or the Compounds anywhere in the world prior to the Effective Date or after the Effective Date for the Reserved Territory;
and (g) failure of ARIAD US to undertake a voluntary Product Withdrawal in its respective territory, despite the ARIAD SWISSCO’s
written recommendation that such Product Withdrawal should be undertaken, except for such activities conducted by or on behalf
of ARIAD SWISSCO or its Affiliates.

 

		22.3	Procedure.
                                         The following shall apply to all Proceedings subject to the obligations set forth in
                                         Sections 22.1 and 22.2 above:

 

		22.3.1	A
                                         Party or its indemnified entity seeking indemnification pursuant to Section 22.1
                                         or Section 22.2 (an “Indemnified Party”) shall give to the
                                         Party from whom such indemnification is sought (the “Indemnifying Party”)
                                         prompt written notice (a “Claim Notice”) of the assertion of any claim,
                                         or the commencement of any Proceeding for which the Indemnified Party believes the Indemnifying
                                         Party may be liable under Section 22.1 or Section 22.2 of this Agreement,
                                         as the case may be. The failure by any Indemnified Party so to notify the Indemnifying
                                         Party shall not relieve the Indemnifying Party from Liability under Section 22.1
                                         or Section 22.2 of this Agreement, as the case may be, except to the extent that
                                         the Indemnifying Party shall have been prejudiced in any material respect as a result
                                         of such failure. A Claim Notice shall describe the nature of the claim or Proceeding
                                         and shall indicate the amount of Losses (estimated to the extent that the Losses in respect
                                         of any claim or Proceeding are reasonably capable of being estimated); provided, however,
                                         that the failure to estimate Losses (or the inaccuracy thereof) shall not affect the
                                         validity of a Claim Notice or the amount of Losses to which the Indemnified Party may
                                         be entitled.

 

		22.3.2	The
                                         Indemnifying Party shall have the right at its discretion to control the defense of any
                                         claim or Proceeding and the right to settle or compromise any such claim or Proceeding;
                                         provided that the prior written consent of the Indemnified Party shall be required
                                         in connection with any settlement or compromise unless such settlement, compromise, discharge
                                         or consent to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 61

     

    

 

judgment
(i) includes the delivery of a written release from all Liability in respect of such claim or Proceeding, (ii) does not contain
any admission or statement suggesting any wrongdoing or Liability on behalf of the Indemnified Party, and (iii) does not contain
any equitable order, judgment or term which in any manner affects, restrains or interferes with the business of the Indemnified
Party or any of its Affiliates. The Indemnifying Party shall exercise such right by delivering written notice of its intent to
undertake the defense of such claim or Proceeding to the Indemnified Party within [***] after the receipt of a Claim Notice. If
the Indemnifying Party elects to control the defense of the claim or Proceeding, then all expenses and legal fees of such defense
shall be borne by the Indemnifying Party. If the Indemnifying Party elects to control the defense of the claim or Proceeding,
then the Indemnified Party may participate therein through counsel of its choice, but the cost of such counsel shall be borne
solely by the Indemnified Party. Only in the event that the Indemnifying Party does not assume such defense within [***] after
its receipt of a Claim Notice or the Indemnifying Party notifies the Indemnified Party that it will not assume such defense, the
Indemnified Party may control the defense of such claim or Proceeding at the Indemnifying Party’s cost and the Indemnified
Party may settle the claim or Proceeding on behalf of and for the account and risk of the Indemnifying Party, who shall be bound
by the result.

 

		22.3.3	The
                                         Indemnifying Party or the Indemnified Party, as the case may be, shall at all times use
                                         commercially reasonable efforts to keep the Indemnifying Party or the Indemnified Party,
                                         as the case may be, reasonably appraised of the status of the defense of any matter the
                                         defense of which it is maintaining and to cooperate in good faith with the Indemnifying
                                         Party or the Indemnified Party, as the case may be, with respect to the defense of any
                                         such matter.

 

		22.4	EXCEPT
                                         AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE SUPPLY AGREEMENT OR THE QUALITY AGREEMENT,
                                         NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, EITHER
                                         IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY
                                         DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING
                                         ANY WARRANTY OF QUALITY, MERCHANTABILITY, NON-INFRINGEMENT, COMMERCIAL POTENTIAL, CAPACITY
                                         OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE KNOW-HOW, THE PATENTS AND/OR
                                         THE PRODUCT. NEITHER PARTY NOR ANY OF ITS RESPECTIVE EMPLOYEES OR REPRESENTATIVES IS
                                         AUTHORIZED TO GIVE ANY WARRANTIES OR MAKE ANY REPRESENTATION ON BEHALF OF THE OTHER PARTY.

 

		22.5	SUBJECT
                                         TO SECTION 22.6 AND EXCEPT AS EXPRESSLY SET FORTH IN SECTION 10.7, TO THE MAXIMUM EXTENT
                                         PERMITTED BY APPLICABLE LAW, NEITHER OF THE PARTIES SHALL BE LIABLE TO THE OTHER PARTY
                                         FOR INDIRECT, SPECIAL, PUNITIVE, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOSSES
                                         ARISING OUT OF THIS

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 62

     

    

 

AGREEMENT,
INCLUDING LOSS OF PROFITS OR REVENUES, REGARDLESS OF WHETHER SUCH DAMAGES WERE FORESEEABLE OR NOT AND REGARDLESS OF ANY NOTICE
OF SUCH DAMAGES OR LOSSES.

 

		22.6	THE
                                         LIMITATIONS AND EXCLUSIONS OF LIABILITY SET FORTH IN SECTIONS 22.4 AND 22.5 SHALL NOT
                                         LIMIT OR RESTRICT: (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY WITH
                                         RESPECT TO LOSSES AWARDED TO THIRD PARTY CLAIMANTS IN THIRD PARTY PROCEEDINGS THAT ARE
                                         SUBJECT TO THE OBLIGATIONS IN SECTION 22.1 OR SECTION 22.2; OR (B) ANY
                                         LIABILITY THAT CANNOT BE LIMITED OR EXCLUDED UNDER APPLICABLE LAW.

 

		22.7	Each
                                         Party agrees to procure and maintain in full force and effect during the Term valid and
                                         collectible insurance policies in connection with its activities as contemplated herein
                                         in amounts that are normal and customary in the pharmaceutical industry generally for
                                         prudent companies similarly situated. In particular, ARIAD SWISSCO’s coverage shall
                                         have limits of Liability which are commercially reasonable in the Territory but shall
                                         be [***] per loss occurrence. [***]. Each Party shall provide to the other Party upon
                                         such other Party’s request a certificate evidencing the coverage required hereby
                                         and the amount thereof. Each Party’s coverage shall be with a reputable insurance
                                         company and shall have to be maintained for not less than [***] following expiration
                                         or termination of this Agreement for any reason.

 

ARTICLE
23 – THE PATENTS 

 

		23.1	Patent
                                         Marking. ARIAD SWISSCO acknowledges and agrees that any of the Product Commercialized
                                         by it shall be marked with a notice of patent rights as necessary or desirable, and legally
                                         possible, under Applicable Law to enable the Patents to be enforced to the maximum extent
                                         permissible under Applicable Laws.

 

		23.2	Claims
                                         Relating to Patent Validity. ARIAD SWISSCO shall reasonably cooperate with ARIAD
                                         US in connection with any claim, action, lawsuit, hearing, patent office review or other
                                         Proceeding relating to the validity of the Patents in the Territory, including by being
                                         joined as a necessary party to any such Proceeding [***]. For clarity, any Proceeding
                                         attacking the validity of a Patent in connection with an action under Section 23.4 (for
                                         example, an alleged infringer’s attack on the validity of a Patent as a defense
                                         to an allegation of infringement of such Patent) shall be dealt with pursuant to Section
                                         23.4.

 

		23.3	Patent
                                         Prosecution and Maintenance. 

 

		23.3.1	ARIAD
                                         US shall have the first right to prepare, file, prosecute (including any reissues, re-examinations,
                                         post-grant proceedings, requests for patent term extensions, supplementary protection
                                         certificates, interferences, and defense of invalidation or opposition proceedings or
                                         of other challenges to validity or enforceability) and maintain the Patents in the Territory,
                                         and shall keep ARIAD SWISSCO informed regarding any such matters. ARIAD US shall consider
                                         in good faith all comments, recommendations, analysis, and strategies provided by ARIAD
                                         SWISSCO for patent

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 63

     

    

 

protection
in the Territory. ARIAD SWISSCO shall provide reasonable assistance in connection with any such prosecution and maintenance, including
reasonably cooperating with ARIAD US, as may be reasonably requested by ARIAD US from time to time for the purpose of filing for
and obtaining patent extensions and supplementary or complementary protection certificates, if available, of the Patents under
the relevant Applicable Laws of the Territory. [***] shall be responsible for any Patent prosecution and maintenance costs for
the Territory and shall reimburse [***] of [***]’s costs related to such Patent prosecution and maintenance for the Territory
within [***] of receipt of an invoice therefor incurred in relation to its obligations under this Section 23.3.1.

 

		23.3.2	In
                                         the event that ARIAD US intends to cease to prosecute, or maintain a Patent in a country
                                         in the Territory, ARIAD US shall provide reasonable prior written notice to ARIAD SWISSCO
                                         of such intention (which notice shall, in any event, be given no later than [***] prior
                                         to the next deadline for any action that may be taken with respect to prosecution or
                                         maintenance of such ARIAD US Patent in such country), and ARIAD SWISSCO shall thereupon
                                         have the option, in its sole discretion, to assume the control and direction of the,
                                         prosecution and maintenance of such Patent in such country. Upon ARIAD SWISSCO’s
                                         written exercise of such option, ARIAD SWISSCO shall assume responsibility and full control
                                         for the prosecution and maintenance of such patent in such country at its own expense.

 

		23.4	Patent
                                         Enforcement.

 

		23.4.1	Each
                                         Party shall, within [***], inform the other Party in writing upon its becoming aware
                                         of any potential infringement or misappropriation of any of the Patents in the Territory.
                                         ARIAD SWISSCO shall provide reasonable assistance in connection with any Proceedings
                                         to stop such infringement and/or recover damages for such infringement in the Territory
                                         (including joining any action if necessary), as may be reasonably requested by ARIAD
                                         US. ARIAD US shall have the first right to control any such Proceedings and ARIAD SWISSCO
                                         shall reimburse ARIAD US [***] of ARIAD US’s costs related to such Proceedings
                                         within [***] of receipt of an invoice therefor incurred in relation to its obligations
                                         under this Section. ARIAD SWISSCO shall also have the option to be represented by counsel
                                         of its own choice to participate in the Proceedings in the Territory [***]. For clarity,
                                         the foregoing option shall not relieve ARIAD SWISSCO’s obligation to reimburse
                                         ARIAD US [***] of ARIAD US’s costs related to such Proceedings.

 

		23.4.2	If
                                         ARIAD US does not institute an action or proceeding or take other action to prevent or
                                         terminate such possible infringement in the Territory prior to the earlier of (i) [***]
                                         following receipt of notice of such possible infringement or (ii) in the case an injunction
                                         may be required, as soon as such injunction is reasonably necessary, then ARIAD SWISSCO
                                         shall have the right to institute an action or proceeding or take other appropriate action
                                         that it believes is reasonably required to prevent or terminate such possible

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 64

     

    

 

infringement
in the Territory, including possible infringement of the Patents in the Territory if (and only if) such possible infringement
involves the development or commercialization of a product that contains the Compound, with the reasonable assistance and cooperation
of ARIAD US. In the event that ARIAD SWISSCO institutes an action or proceeding or takes other appropriate action that it believes
is reasonably required to prevent or terminate such possible infringement in the Territory, ARIAD SWISSCO reserves the right to
have sole control over such proceedings, subject to Section 23.4.4.

 

		23.4.3	In
                                         the event that ARIAD SWISSCO becomes aware of any challenge to the validity of any Patent
                                         in a country in the Territory, ARIAD SWISSCO shall provide reasonable prior written notice
                                         to ARIAD US of such challenge (which notice shall, in any event, be given within [***]
                                         of ARIAD SWISSCO becoming aware of such challenge), and ARIAD US shall thereupon have
                                         the option, in its sole discretion, to assume the control and direction of any Proceedings
                                         in relation to such Patent in such country.

 

		23.4.4	ARIAD
                                         SWISSCO shall not settle any action or Proceedings in a manner that would have a material
                                         adverse effect on the rights or interests of ARIAD US or its Affiliates without the prior
                                         written consent of the ARIAD US.

 

		23.4.5	Any
                                         recoveries from such Proceedings or amounts received by ARIAD US or ARIAD SWISSCO from
                                         the settlement of the same shall be allocated as follows: First, each Party shall be
                                         reimbursed for its direct, out-of-pocket expenses for conducting, or cooperating with,
                                         such Proceeding, and second, the balance shall be [***], provided that any recovery or
                                         settlement amount that includes countries outside of the Territory shall be [***], acting
                                         reasonably and in good faith, prior to such allocation between the Parties.

 

		23.4.6	ARIAD
                                         SWISSCO shall have no right to sue or institute an action or proceeding or take other
                                         action to prevent infringement of any Patent other than as set out in this Section 23.4.

 

		23.5	Infringement
                                         Claims by Third Parties.

 

		23.5.1	Each
                                         Party shall promptly notify the other Party in writing of any allegation by a Third Party
                                         in the Territory that any Compound and/or Product development, Commercialization (including
                                         import or export) or manufacturing activities conducted by the Parties pursuant to this
                                         Agreement infringe or misappropriate or may infringe or misappropriate the Intellectual
                                         Property Rights in the Territory of such Third Party (a “Third Party Infringement
                                         Claim”). The Parties shall discuss which Party shall defend the Third Party
                                         Infringement Claim, and absent mutual agreement otherwise, each Party shall have the
                                         right to control the defense of any such Third Party Infringement Claim brought against
                                         it, by counsel of its own choice. If a Third Party Infringement Claim is brought against
                                         one Party (the “Defending Party”) but not the other Party, the non-Defending
                                         Party

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 65

     

    

 

shall have
the right, at its own expense, to be represented in such Third Party Infringement Claim by counsel of its own choice.

 

		23.5.2	Each
                                         Defending Party shall keep the other Party reasonably informed of all material developments
                                         in connection with any Third Party Infringement Claim. Each Defending Party agrees to
                                         provide the other Party with copies of all pleadings filed in any suit or proceeding
                                         relating to such Third Party Infringement Claim. The Defending Party may enter into a
                                         settlement or compromise of any Third Party Infringement Claim, provided that, if such
                                         settlement or compromise would admit Liability on the part of the non-Defending Party
                                         or any of its Affiliates or would otherwise have a material adverse effect on the rights
                                         or interests of the non-Defending Party or its Affiliates, the Defending Party shall
                                         not enter into such settlement or compromise without the prior written consent of the
                                         non-Defending Party.

 

		23.5.3	If
                                         a Third Party Infringement Claim is brought against both Parties, or initially against
                                         one Party and the other Party is subsequently joined to the Proceedings, all out-of-pocket
                                         expenses incurred by each Defending Party in defending such Third Party Infringement
                                         Claim in the Territory (including outside counsel fees), and all amounts payable by either
                                         Defending Party as a judgment based on such Third Party Infringement Claim or in settlement
                                         of such Third Party Infringement Claim (excluding payments pursuant to any Third Party
                                         License, which is governed by Section 23.6), shall be paid for by the Parties as follows:
                                         [***] by ARIAD SWISSCO and [***] by ARIAD US.

 

		23.5.4	If
                                         a Third Party Infringement Claim is brought against only one Defending Party and the
                                         other Party is not subsequently joined to the Proceedings, all out-of-pocket expenses
                                         incurred by such Defending Party in defending such Third Party Infringement Claim in
                                         the Territory (including outside counsel fees), and all amounts payable by such Defending
                                         Party as a judgment based on such Third Party Infringement Claim or in settlement of
                                         such Third Party Infringement Claim (excluding payments pursuant to any Third Party License,
                                         which is governed by Section 23.6), shall be [***].

 

		23.5.5	Any
                                         recovery by a Party of any sanctions or other amounts awarded to such Party against a
                                         Third Party asserting a Third Party Infringement Claim shall be applied in the same manner
                                         as recoveries in an action as set forth in Section 23.4.5.

 

		23.5.6	If
                                         a Defending Party elects to enter into an agreement with a Third Party to obtain a license
                                         under such Third Party’s Intellectual Property Rights (“Third Party License”)
                                         in settlement of a Third Party Infringement Claim asserted by such Third Party, the provisions
                                         of Section 23.6 shall apply.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 66

     

    

 

		23.6	Third
                                         Party Licenses.

 

		23.6.1	Territory-Only
                                         Third Party License.

 

		(a)	With
                                         respect to any Third Party License under which ARIAD SWISSCO is granted rights relating
                                         to its exercise of its license grant under this Agreement and which does not relate to
                                         the retained rights of ARIAD US with respect to the Reserved Territory (“Territory-Only
                                         Third Party License”), the Parties (through the JSC) shall discuss (1) whether
                                         such license is necessary or (2) or whether such license is useful (but not necessary)
                                         and, in the case of this clause (2), whether to obtain such Territory-Only Third Party
                                         License. A Territory-Only Third Party License shall be considered necessary (and the
                                         JSC shall have no discretion with regarding to such determination) if the intellectual
                                         property included in such Third Party license covers the Compound or Product or the Manufacture
                                         thereof in accordance with Section 6.4.

 

		(b)	If
                                         a Territory-Only Third Party License is necessary for ARIAD SWISSCO to exercise its license
                                         grant under this Agreement, ARIAD SWISSCO shall have the responsibility for negotiating
                                         such license and shall have the final decision-making authority regarding the terms of
                                         such license, subject to Section 23.6.3.

 

		(c)	If
                                         a Territory-Only Third Party License is useful (but not necessary) for ARIAD SWISSCO
                                         to exercise its license grant under this Agreement, the JSC shall determine (with neither
                                         Party having final decision-making authority) whether to obtain such Territory-Only Third
                                         Party License and, if such a determination is made to obtain such license, ARIAD SWISSCO
                                         shall have responsibility for negotiating such license in accordance with terms agreed
                                         upon by the Parties. If the Parties are unable to agree upon terms for a useful Territory-Only
                                         Third Party License that the JSC has determined to obtain, ARIAD SWISSCO shall have the
                                         final decision-making authority regarding the terms of such license, subject to Section
                                         23.6.3.

 

		(d)	In
                                         the event ARIAD SWISSCO enters into a Territory-Only Third Party License (i) in accordance
                                         with Section 23.6.1(b) or (ii) in accordance with Section 23.6.1(c) in the event of a
                                         determination by the JSC to obtain such license, ARIAD SWISSCO shall have the right to
                                         deduct [***] of all payments paid pursuant to such Territory-Only Third Party License
                                         from the royalties payable to ARIAD US pursuant to Section 19.2; provided, that in no
                                         event shall the royalty rate otherwise payable to ARIAD US pursuant to Section 19.2.1
                                         and Section 19.2.2 be reduced by more than [***] in the aggregate; and provided further
                                         that, if, but for the preceding proviso, the deduction under this Section 23.6.1(d) would
                                         have reduced a royalty payment made by ARIAD SWISSCO to ARIAD US by more than [***],
                                         then the amount of such deduction that exceeds [***] will be carried over

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 67

     

    

 

to subsequent
royalty payments until the full amount that ARIAD SWISSCO would have been entitled to deduct (absent the preceding proviso) is
deducted.

 

		(e)	In
                                         the event ARIAD SWISSCO enters into a Territory-Only Third Party License in accordance
                                         with Section 23.6.1(c) with absence of a determination by the JSC to obtain such license,
                                         ARIAD SWISSCO shall have the sole responsibility for making any payments due thereunder.

 

		23.6.2	Global
                                         Third Party License.

 

		(a)	With
                                         respect to any Third Party License to (i) Develop or Manufacture Product in the Territory
                                         and the Reserved Territory, or (ii) Commercialize Product in the Field in the Territory
                                         and the Reserved Territory (“Global Third Party License”), the Parties
                                         (through the JSC) shall determine whether to obtain such Global Third Party License and
                                         which Party will be responsible for negotiating such license (it being agreed that if
                                         such Global Third Party License relates to the US then ARIAD US shall be the Party responsible).
                                         If the Parties (through the JSC) do not agree to obtain such Global Third Party License,
                                         cannot agree upon the negotiating Party or cannot agree on the final form of such Global
                                         Third Party License, ARIAD SWISSCO may enter into a Territory-Only Third Party License
                                         pursuant to the terms of 23.6.1.

 

		(b)	If
                                         the Parties proceed with a Global Third Party License, ARIAD SWISSCO shall be responsible
                                         for [***] of payments owed under such Global Third Party License that are attributable
                                         to the Territory (and may deduct such amounts from the royalties payable to ARIAD US
                                         pursuant to Section 19.2) and ARIAD US shall be responsible for [***] of the payments
                                         attributable to the Territory and [***] of the payments attributable to the Reserved
                                         Territory.

 

		23.6.3	For
                                         Territory-Only Third Party Licenses other than those for which ARIAD SWISSCO has sole
                                         responsibility for payments, ARIAD SWISSCO shall keep ARIAD US reasonably informed with
                                         respect to the negotiations and deal terms relating to such license (including scope
                                         of the license and financial terms) and the ARIAD SWISSCO shall consider in good faith
                                         any comments, recommendations or analysis provided by ARIAD US. With respect to any Global
                                         Third Party License, the negotiating Party shall keep the other Party reasonably informed
                                         with respect to the negotiations and deal terms relating to such license (including scope
                                         of the license and financial terms), provide the other Party a reasonable opportunity
                                         to comment and consider in good faith all comments provided by the other Party and shall
                                         secure the written consent of the other Party prior to executing such Global Third Party
                                         License.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 68

     

    

 

ARTICLE
24 – CONFIDENTIALITY

 

		24.1	Each
                                         Party shall treat as strictly confidential any information, data and/or document provided
                                         orally, visually, in writing or other form by or on behalf of the other Party or its
                                         Affiliates hereunder and not generally known to the trade and non-public information
                                         relating to the business of the disclosing Party or its Affiliates (all hereinafter referred
                                         to as the “Confidential Information”), and each receiving Party shall
                                         use the Confidential Information of the disclosing Party solely for the purpose of and
                                         in accordance with this Agreement. Each Party may disclose Confidential Information of
                                         the other Party to its employees and agents and to the employees and agents of its Affiliates,
                                         Sublicensees (in the case of ARIAD SWISSCO), Subcontractors (in the case of ARIAD SWISSCO)
                                         and other Third Party contractors solely for purposes, and only to the extent reasonably
                                         required, to facilitate the performance of such Party’s rights or obligations under
                                         this Agreement, provided that each such employee and agent and such Sublicensee, Subcontractor
                                         or other Third Party contractor, as applicable, has confidentiality obligations with
                                         such receiving Party containing provisions that protect the Confidential Information
                                         of the disclosing Party that are materially equivalent to, or more protective than, the
                                         provisions of this ARTICLE 24. In addition, ARIAD US and ARIAD SWISSCO each agrees that
                                         the other Party may disclose its Confidential Information (a) to such other Party’s
                                         legal and financial advisors, (b) as reasonably necessary in connection with an actual
                                         or potential (i) debt or equity financing of such other Party, (ii) merger, acquisition,
                                         consolidation, share exchange or other similar transaction involving such Party and any
                                         Third Party, or (iii) prosecution, defense or enforcement of any patent pursuant to ARTICLE
                                         23 or of any litigation, (c) as reasonably required in preparing Regulatory Documentation
                                         and obtaining Registrations, (d) to comply with Applicable Law or any obligation in this
                                         Agreement, (e) in communications with existing or bona fide prospective acquirers, merger
                                         partners, lenders (including PDL BioPharma Inc. under the PDL Agreements) or investors,
                                         and consultants and advisors in connection with transactions or bona fide prospective
                                         transactions with the foregoing, in each case on a “need-to-know” basis and
                                         under appropriate confidentiality provisions substantially equivalent to those of this
                                         Agreement; provided, however, that the receiving Party shall remain responsible for any
                                         violation of such confidentiality provisions by any Third Party receiving such Confidential
                                         Information; (f) to its Affiliates, Sublicensees or prospective Sublicensees, Subcontractors
                                         or prospective Subcontractors (including Third Party manufacturers), consultants, agents
                                         and advisors on a “need-to-know” basis in order for the receiving Party to
                                         exercise its rights or fulfill its obligations under this Agreement, each of whom prior
                                         to disclosure must be bound by obligations of confidentiality and restrictions on use
                                         of such Confidential Information that are no less restrictive than those set forth in
                                         this ARTICLE 24; provided, however, that, in each of the above situations, the receiving
                                         Party shall remain responsible for any failure by any Person who receives Confidential
                                         Information pursuant to this Section 24.1(f) to treat such Confidential Information as
                                         required under this ARTICLE 24 and (g) for any other purpose with the other Party’s
                                         written consent, not to be unreasonably withheld, conditioned or delayed. Except as set
                                         forth in the two preceding sentences, neither Party shall make Confidential Information
                                         of the other Party available to any Third Party, or any of its Affiliates, except in
                                         accordance with Section 24.3 or to applicable government agencies as required by Applicable
                                         Laws, and in this case (1) solely to the extent required by such Applicable Laws (based
                                         on

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 69

     

    

 

advice of
legal counsel) and (2) only upon exercise of its reasonable efforts to cause said agencies to maintain confidentiality thereof.

 

		24.2	Subject
                                         to any different arrangements agreed in writing by the Parties pursuant to this Agreement,
                                         prior to the publication or presentation of any information or data arising from any
                                         Development activity performed by a Party or its Affiliates pursuant to ARTICLE 5, or
                                         other Development activities
                                         performed hereunder, the Developing Party shall submit to the other Party a summary of
                                         the proposed publication or presentation at least [***] prior
                                         to the submission thereof for publication or presentation. The purposes for such prior
                                         submission are: (i) to provide the non-Developing Party with the opportunity to review
                                         and comment on the contents of the proposed publication or presentation; and (ii) to
                                         identify any Confidential Information to be deleted from the proposed publication or
                                         presentation. Any Confidential Information identified by the non-Developing Party shall
                                         be deleted prior to publication or presentation. 

 

		24.3	Notwithstanding
                                         expiration or termination of this Agreement for any reason, the foregoing confidentiality
                                         and non-use obligations shall continue for a period of [***] after expiration or termination
                                         of this Agreement. Notwithstanding the foregoing, nothing contained in this ARTICLE 24
                                         shall in any way restrict or impair the right of either Party to use, disclose or otherwise
                                         deal with Confidential Information of the disclosing Party, which the receiving Party
                                         can demonstrate by competent written evidence:

 

		24.3.1	is
                                         or hereafter becomes part of the public domain through no act or omission of the receiving
                                         Party, its employees, Affiliates, sublicensees and/or subcontractors; or

 

		24.3.2	was
                                         in the lawful possession of the receiving Party prior to receipt of the Confidential
                                         Information from the disclosing Party; or

 

		24.3.3	previously
                                         was, or at any time hereafter is, provided to the receiving Party by a Third Party having
                                         the right to do so and which did not originate directly or indirectly from the disclosing
                                         Party; or

 

		24.3.4	at
                                         the time of disclosure, was known by the receiving Party or an Affiliate, sublicensee
                                         or subcontractor other than as a result of disclosure to such party by the disclosing
                                         Party;

 

		24.3.5	or
                                         after disclosure was independently developed by the receiving Party, an Affiliate, sublicensee
                                         or subcontractor without use of the Confidential Information of the disclosing Party.

 

		24.4	The
                                         content of this Agreement shall constitute Confidential Information of each Party and
                                         shall be treated by both Parties in accordance with the provisions of this ARTICLE 24
                                         and Section 30.9 (Public Statements).

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 70

     

    

 

ARTICLE
25 – TERM 

 

		25.1	This
                                         Agreement comes into force at the Effective Date hereof and shall remain in effect country
                                         by country of the Territory until the expiration of the Royalty Term in such country,
                                         unless earlier terminated in accordance with the terms of this Agreement.

 

ARTICLE
26 – TERMINATION

 

		26.1	Uncured
                                         Material Breach. If either Party (the “Non-Breaching Party”) believes
                                         that the other Party (the “Breaching Party”) is in material breach
                                         of any of its obligations under this Agreement, then the Non-Breaching Party may deliver
                                         written notice of such material breach to the Breaching Party specifying the nature of
                                         the breach (a “Default Notice”). The Breaching Party shall have [***]
                                         (or [***] in the event of a payment breach) from the receipt of the Default Notice to
                                         cure such breach or to dispute the allegation of breach; provided that,
                                         if such breach (other than a payment breach) is capable of being cured, but cannot be
                                         cured within such [***] period, and the Breaching Party initiates actions to cure such
                                         breach within such period and thereafter diligently pursues such actions, the Breaching
                                         Party shall have such additional period as is reasonable to cure such breach, but in
                                         no event will such additional period exceed [***]. If the Breaching Party fails to cure,
                                         and fails to dispute, such breach within the applicable cure period, then the Non-Breaching
                                         Party may pursue any or all available remedies at law or equity but may not terminate
                                         this Agreement; provided, that, if such material breach materially diminishes,
                                         or materially frustrates, the value of this Agreement taken as a whole to the Non-Breaching
                                         Party, then the Non-Breaching Party shall have the right to terminate this Agreement
                                         (1) if such material breach and failure to cure is solely with respect to a particular
                                         country or countries, such right to terminate this Agreement shall be solely with respect
                                         to such country or countries, as applicable, or (2) if such material breach and failure
                                         to cure is not solely with respect to a particular country or countries, such right to
                                         terminate this Agreement shall be with respect to this Agreement in its entirety. The
                                         Non-Breaching Party may effectuate such termination by giving the Breaching Party written
                                         notice of termination, which termination shall be effective immediately upon the Breaching
                                         Party’s receipt of such notice of termination. If the Breaching Party disputes
                                         in good faith the existence or materiality of a breach specified in a Default Notice
                                         or disputes any allegation that the Breaching Party failed to cure or remedy such breach,
                                         and the Breaching Party provides written notice of such dispute to the Non-Breaching
                                         Party within the above applicable cure period, the matter shall be addressed under the
                                         dispute resolution procedures in ARTICLE 29 (and during the pendency of such dispute
                                         resolution, the Non-Breaching Party may not terminate this Agreement). If, as a result
                                         of the application of such dispute resolution procedures, the Breaching Party is determined
                                         to be in material breach of any provision of this Agreement (an “Adverse Ruling”),
                                         and if the Breaching Party fails to complete the actions specified by the Adverse Ruling
                                         to cure such material breach within [***] after its receipt of such Adverse Ruling (or
                                         within [***] in the case of an Adverse Ruling resulting from a payment breach), then,
                                         if such Adverse Ruling specifies that such material breach materially diminishes, or
                                         materially frustrates, the value of this Agreement taken as a whole to the Non-Breaching
                                         Party, the Non-Breaching Party may terminate this Agreement with respect to such

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 71

     

    

 

particular
country or countries, or with respect to this Agreement in its entirety, as applicable in accordance with clauses (1) and (2)
above, by giving the Breaching Party written notice of termination, which termination shall be effective immediately upon the
Breaching Party’s receipt of such notice of termination.

 

		26.2	Bankruptcy
                                         or Insolvency.

 

		26.2.1	Either
                                         Party shall have the right to terminate this Agreement immediately upon written notice
                                         to the other Party, if such other Party or any of its Affiliates (i) files a petition
                                         under any bankruptcy act or has any such petition filed against it that is not discharged
                                         within [***] of the filing thereof, (ii) makes an assignment for the benefit of creditors,
                                         or (iii) appoints or suffers appointment of a receiver or trustee over substantially
                                         all of its property that is not discharged within [***] after such filing.

 

		26.2.2	All
                                         licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed
                                         to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions
                                         in any other country or jurisdiction, licenses of rights to “intellectual property”
                                         as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that ARIAD
                                         SWISSCO, as licensee of such rights under this Agreement, shall retain and may fully
                                         exercise all of its rights and elections under the U.S. Bankruptcy Code or any analogous
                                         provisions in any other country or jurisdiction. The Parties further agree that, in the
                                         event of the commencement of a bankruptcy proceeding by or against ARIAD US under the
                                         U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction
                                         which proceeding is not terminated or withdrawn within [***] after such commencement,
                                         ARIAD SWISSCO shall be entitled (unless ARIAD US elects to continue to perform all of
                                         its obligations under this Agreement) to a complete duplicate of (or complete access
                                         to, as appropriate) any such intellectual property and all embodiments of such intellectual
                                         property necessary to exercise its license rights granted hereunder, which, if not already
                                         in the ARIAD SWISSCO’s possession, shall be promptly delivered to it (i) after
                                         [***] following any such commencement of a bankruptcy proceeding, upon ARIAD SWISSCO’s
                                         written request therefor (unless ARIAD US elects to continue to perform all of its obligations
                                         under this Agreement), or (ii) if not delivered under subsection (i) above, following
                                         the rejection of this Agreement by or on behalf of ARIAD US, upon written request therefor
                                         by ARIAD SWISSCO.

 

		26.3	Termination
                                         for Force Majeure. For the avoidance of doubt, this Agreement also may be terminated
                                         as set forth in ARTICLE 27 (Force Majeure).

 

		26.4	Termination
                                         by ARIAD SWISSCO for Convenience. At any time after the three (3) year anniversary
                                         of the Effective Date, ARIAD SWISSCO may terminate this Agreement in its entirety, or
                                         on a country-by-country basis, for any or no reason, upon twelve (12) months’ prior
                                         written notice to ARIAD US.

 

		26.5	Termination
                                         by ARIAD US. If ARIAD SWISSCO and its Affiliates fail to meet at least [***] of the
                                         minimum expenditure obligations set forth in Section 15.2 in each

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 72

     

    

 

of [***],
and if ARIAD SWISSCO fails to exceed by at least [***] the minimum expenditure obligations in each of the succeeding [***], then
ARIAD US may terminate this Agreement in its entirety upon [***] prior written notice to ARIAD SWISSCO. Notwithstanding anything
to the contrary in this Agreement, the provisions of this Section 26.5 shall be the sole and exclusive remedy of ARIAD US in this
event.

 

		26.6	Effects
                                         of Termination and Expiration.

 

		26.6.1	Termination
                                         or expiration of this Agreement for any reason shall not extinguish any existing claims
                                         either of the Parties may have for indemnification pursuant to the terms and conditions
                                         of this Agreement, and shall not preclude either of the Parties from pursuing any claim
                                         for indemnification such Party otherwise may have pursuant to the terms and conditions
                                         of this Agreement to the extent that the circumstances giving rise to such claim arose
                                         prior to, on or after the date of termination or expiration of this Agreement. Furthermore,
                                         the termination or expiration this Agreement shall have no effect on a Party’s
                                         obligation to make any payment accruing prior to the date of termination or expiration.

 

		26.6.2	Following
                                         expiration of the Royalty Term, the grants in Section 2.1 shall become exclusive, fully-paid,
                                         royalty-free, perpetual and irrevocable.

 

		26.6.3	Upon
                                         termination of this entire Agreement by ARIAD US under Sections 26.1, 26.2, or 26.5 or
                                         by ARIAD SWISSCO under Section 26.4, or under ARTICLE 27 for Force Majeure, the Transition
                                         Back Arrangements shall apply and shall be implemented by the Parties.

 

		26.6.4	In
                                         the event of termination of this Agreement by ARIAD US under Section 26.1 in relation
                                         to a particular country or countries all rights granted to ARIAD SWISSCO in relation
                                         to such country or countries shall terminate and ARIAD SWISSCO shall cease any use and/or
                                         exploitation of the Registration with respect to the Product in the terminated country
                                         or countries and shall promptly and unconditionally transfer such Registration to ARIAD
                                         US or to ARIAD US’s nominee or if not so assignable, permit ARIAD US or such nominee
                                         to cross-refer to such Registration when applying for a new registration in their own
                                         name. ARIAD SWISSCO shall cease Commercializing the Product in the terminated country
                                         or countries, subject to a [***] sell off period.

 

		26.6.5	Upon
                                         the termination of this Agreement for any reason, ARIAD SWISSCO shall have the right
                                         but not the obligation to sell all or a part of ARIAD SWISSCO’s remaining stocks
                                         of the Product.

 

ARTICLE
27 – FORCE MAJEURE

 

		27.1	If
                                         the performance of this Agreement is prevented or restricted by government action, war,
                                         fire, explosion, flood, strike, lockout, embargo, epidemics, pandemics, quarantines,
                                         acts of terrorism, lockouts or other labor disturbances, act of God, failures of common
                                         carriers, or any other similar cause beyond the control of the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 73

     

    

 

defaulting
Party, or supply failures due to the foregoing or similar causes beyond the control of the defaulting Party’s suppliers
or contractors, the Party so affected shall be released for the duration of the force majeure, or such other period agreed between
the Parties as being reasonable in all circumstances, from its contractual obligations directly affected by the force majeure,
provided that the Party concerned shall:

 

		(a)	give
                                         prompt notice in writing to the other Party of the cause of force majeure;

 

		(b)	use
                                         Commercially Reasonable Efforts to avoid or remove such cause of non-performance; and

 

		(c)	continue
                                         the full performance of this Agreement as soon as such cause is removed.

 

		27.2	The
                                         Parties shall take all reasonable steps to minimize the effects of force majeure on the
                                         performance of this Agreement and shall, if necessary, agree upon appropriate measures
                                         to be taken. Should the force majeure continue for more than [***], then the Party not
                                         affected by such force majeure shall have the right to terminate this Agreement immediately
                                         upon written notice to the affected Party.

 

		27.3	Notwithstanding
                                         anything contained in this ARTICLE 27, obligations to pay money are never excused by
                                         force majeure.

 

ARTICLE
28 – LAW TO GOVERN

 

		28.1	This
                                         Agreement shall be governed by and construed in accordance with the law of the State
                                         of New York, United States of America, excluding any conflicts or choice of law rule
                                         or principle that might otherwise make this Agreement subject to the substantive law
                                         of another jurisdiction.  

 

ARTICLE
29  – DISPUTE RESOLUTION

 

		29.1	Generally.
                                         The Parties recognize that disputes as to matters arising under or relating to this Agreement
                                         or either Party’s rights and/or obligations hereunder may arise from time to time.
                                         It is the objective of the Parties to establish procedures to facilitate the resolution
                                         of such disputes in an expedient manner by mutual cooperation and without resort to litigation.
                                         To accomplish this objective, the Parties agree to follow the procedures set forth in
                                         this ARTICLE 29 to resolve any such dispute if and when it arises. 

 

		29.2	Escalation
                                         to Senior Officers. If an unresolved dispute as to matters arising under or relating
                                         to this Agreement or either Party’s rights and/or obligations hereunder arises
                                         (other than any dispute at the JSC which is subject to the dispute resolution procedures
                                         set forth in Section 4.7, or any other matter that is expressly subject to either Party’s
                                         final decision-making authority or final approval as set forth elsewhere herein), either
                                         Party may refer such dispute to the Senior Officers or their respective designees, who
                                         shall meet in person or by telephone within [***] after such referral to attempt in good
                                         faith to resolve such dispute and each Senior Officer may include a relevant subject
                                         matter expert relevant to the dispute. If such matter cannot be

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 74

     

    

 

resolved
by discussion of such officers within such [***] period (as may be extended by mutual written agreement), such dispute shall be
resolved in accordance with Section 29.3. The Parties acknowledge that these discussions between the Parties to resolve
disputes are settlement discussions under applicable rules of evidence and without prejudice to either Party’s legal position.

 

		29.3	Jurisdiction.
                                         Any unresolved dispute that was the subject of Section 29.2 (and for which a Party does
                                         not have final decision making authority) shall be brought exclusively in the federal
                                         courts of the United States of America located in New York City, New York (and each party
                                         hereby consents to personal jurisdiction and venue in, and agrees to service of process
                                         issued or authorized by, such court); provided that either Party may seek injunctive
                                         relief from any court of competent jurisdiction with respect to any claim for specific
                                         performance or injunctive or other equitable relief as a remedy for a breach or threatened
                                         breach of this Agreement and either Party may seek the enforcement of any award of damages,
                                         in any court of competent jurisdiction.

 

ARTICLE
30 – MISCELLANEOUS

 

		30.1	Entire
                                         Agreement. Each schedule, exhibit or appendix hereto is integral to this Agreement
                                         and is hereby incorporated herein. This Agreement supersedes all prior agreements and
                                         understandings, including the CDA, the Buy-In License Agreement, CSA Agreement, whether
                                         oral or written, made by either Party or between the Parties and constitutes the entire
                                         Agreement of the Parties with regard to the subject matter hereof. It shall not be considered
                                         extended, cancelled or amended in any respect unless done so in writing and signed on
                                         behalf of the Parties hereto. Information disclosed by either Party or its Affiliates
                                         under the CDA shall be governed by the CDA until the Effective Date of this Agreement,
                                         and shall be deemed to be Confidential Information of the applicable Party disclosed
                                         hereunder and subject to the confidentiality provisions of this Agreement from and including
                                         the Effective Date for the duration set forth herein. If there is any conflict between
                                         any provision of the main body of this Agreement and any provision set forth in a schedule,
                                         exhibit or appendix hereto (each of which is hereby incorporated herein), the provision
                                         set forth in the main body of this Agreement shall govern.

 

		30.2	Severability.
                                         The Parties hereby expressly state that neither Party intends to violate any rule, law
                                         or regulation. If any provision of this Agreement is in violation of any rule, law or
                                         regulation it shall be invalid and unenforceable, without affecting the validity or enforceability
                                         of other provisions of this Agreement. The Parties agree to renegotiate such provision
                                         in good faith and, to the extent possible, to replace it with valid and enforceable provisions
                                         in such a way as to reflect as nearly as possible the intent and purpose of the original
                                         provision.

 

		30.3	Independent
                                         contractor status. The status of ARIAD US and ARIAD SWISSCO under the business arrangement
                                         established by this Agreement is that of independent contractors. When ARIAD SWISSCO
                                         acquires Products from ARIAD US or ARIAD US’s nominee it shall Commercialize them
                                         to its Customers in its own name, and for its own account. Neither Party has authority
                                         whatsoever to act as an agent or representative of the other Party except as expressly
                                         set forth in this Agreement, nor

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 75

     

    

 

any authority
or power to contract in the name of or create any Liability against or otherwise bind the other Party or its Affiliate in any
way for any purpose, nor shall ARIAD US or its Affiliate have such authority or power to so bind ARIAD SWISSCO.

 

		30.4	Notices.
                                         Other than routine communications made through the JSC, its subcommittees or project
                                         teams, or the Alliance Managers within the remit of such committees or persons, as contemplated
                                         elsewhere herein, all reports, notices, approvals and communications required or permitted
                                         to be made pursuant to this Agreement by one Party to the other shall be validly given
                                         or made for all purposes, in the absence of acknowledgement of receipt, on the date of
                                         mailing if mailed by registered airmail or by international courier to the addressee
                                         Party at the following addresses, respectively:

 

Notices to ARIAD US:

 

ARIAD
US Pharmaceuticals, Inc.

26
Landsdowne Street

Cambridge,
Massachusetts 02139-4234

USA

Attention:
General Counsel

Tel:
[***]

 

With
copies (which shall be required but shall not itself constitute notice) to:

 

Baker
& McKenzie LLP

100
New Bridge Street

London,
EC4V 6JA

United
Kingdom

Attention:
J. Hobson

Tel:
[***]

 

Notices to ARIAD SWISSCO:

 

ARIAD
Pharmaceuticals (Europe) Sárl

Route
de La Corniche 1

1066
Epalinges

Switzerland

Attention:
Laurent Chardonne

Tel:
[***]

 

With
copies (which shall be required but shall not itself constitute notice) to:

 

Incyte
Corporation

1801
Augustine Cut-Off

Wilmington,
DE 19803

United
States of America

Attention:
General Counsel

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 76

     

    

 

Tel:
[***]

 

and

 

Morgan,
Lewis & Bockius LLP

502
Carnegie Center

Princeton,
NJ 08540-6241

United
States

Attention:
Randall B. Sunberg

Tel:
[***]

 

		30.5	Binding
                                         Effect. This Agreement shall inure to the benefit of, and be binding upon, the respective
                                         successors of the Parties. For the avoidance of doubt, subject to ARTICLE 16, the continued
                                         existence of this Agreement shall not be affected in case of change of control of either
                                         Party.

 

		30.6	Waiver.
                                         The delay or failure of a Party to insist upon strict performance of any of the terms
                                         and conditions of this Agreement by the other Party shall not constitute a waiver of
                                         any of the provisions hereof and no waiver by a Party of any of said terms and conditions
                                         shall be deemed to have been made unless expressed in writing and signed by such waiving
                                         Party.

 

		30.7	Interpretation.

 

		30.7.1	The
                                         language of this Agreement is English. No translation into any other language shall be
                                         taken into account in the interpretation of the Agreement itself.

 

		30.7.2	The
                                         headings in this Agreement are inserted for convenience only and shall not affect its
                                         construction.

 

		30.7.3	Where
                                         appropriate, the terms defined in this Agreement and denoting a singular number only
                                         shall include the plural and vice versa. Unless otherwise stated, references to days
                                         means calendar days, references to quarters means calendar quarters beginning on the
                                         first of January, April, July and October and references to years means calendar years
                                         beginning on January 1.

 

		30.7.4	The
                                         word “including” and similar words and phrases mean including without limitation,
                                         whether or not expressly stated. The words “herein,” “hereof”
                                         and “hereunder” and other words of similar import refer to this Agreement
                                         as a whole and not to any particular Articles or other subdivision. References to the
                                         singular include the plural. References to one gender include all genders.

 

		30.7.5	References
                                         to any law, regulation, statute or statutory provision includes a reference to the law,
                                         regulation, statute or statutory provision as from time to time amended, extended or
                                         re-enacted.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 77

     

    

 

		30.8	Assignment.

 

		30.8.1	This
                                         Agreement and the rights conferred upon a Party under this Agreement cannot be transferred
                                         or assigned by a Party without the prior, written authorization of the other Party, which
                                         authorization shall not be unreasonably withheld, conditioned or delayed. Notwithstanding
                                         the foregoing, each Party may make such transfer or assignment without the other Party’s
                                         consent to (i) its Affiliates or (ii) to a successor of all or substantially all of the
                                         business to which this Agreement relates, whether in a merger, sale of stock, sale of
                                         assets or any other transaction, provided that written notice of the transfer or assignment
                                         is provided to the other Party. With respect to an assignment to an Affiliate, the assigning
                                         Party shall remain responsible for the performance by such Affiliate of all of such Party’s
                                         rights and obligations hereunder.

 

		30.8.2	This
                                         Agreement shall be binding upon and inure to the benefit of the Parties’ respective
                                         successors and permitted assigns.

 

		30.9	Public
                                         Statements.

 

		30.9.1	Subject
                                         to Section 30.9.2, neither Party shall make any public announcement concerning this Agreement
                                         or the subject matter hereof without the prior written consent of the other Party or
                                         as provided in the Share Purchase Agreement. Once initial consent to a particular disclosure
                                         or public announcement has been given and the disclosure or statement has been made concerning
                                         particular subject matter, each Party may make any further public statement concerning
                                         such subject matter so long as any such public statement is accurate and not inconsistent
                                         with the prior public disclosures or public statements approved by the other Party pursuant
                                         to this Section 30.9.1 and does not reveal non-public information about the other
                                         Party, the Compound or the Product.

 

		30.9.2	In
                                         the event that a Party is, based on the advice of the disclosing Party’s counsel,
                                         required by Applicable Laws or the rules of a stock exchange on which its securities
                                         are listed (or to which an application for listing has been submitted) to make a public
                                         disclosure regarding this Agreement or its subject matter (including the terms of this
                                         Agreement), such Party shall submit the proposed disclosure (or proposed redacted copy
                                         of the Agreement, as applicable) in writing to the other Party as far in advance as reasonably
                                         practicable (and in no event less than [***] prior to the anticipated date of disclosure)
                                         so as to provide a reasonable opportunity for the other Party to comment thereon. Neither
                                         Party shall be obligated to obtain approval from the other Party with respect to any
                                         filings made with the applicable securities exchange commission. Neither Party shall
                                         be required to seek the permission of the other Party to repeat any information regarding
                                         the terms of this Agreement or any amendment thereto that has already been publicly disclosed
                                         by such Party, or by the other Party, in accordance with the terms of this Agreement,
                                         provided such information remains accurate as of such time and provided the frequency
                                         and form of such disclosure are reasonable.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 78

     

    

 

		30.9.3	Except
                                         as expressly permitted in this Agreement or as required by Applicable Law (or the regulations
                                         of applicable stock exchanges), neither Party may use the other Party’s trademarks,
                                         service marks or trade names, or otherwise refer to or identify that other Party in marketing
                                         or promotional materials, press releases, statements to news media or other public announcements,
                                         without the other Party’s prior written consent, which that other Party may grant
                                         or withhold in its sole discretion.

 

		30.10	Expenses.
                                         Unless specifically and expressly provided for to the contrary in this Agreement, a Party
                                         who has an obligation or right to take an action under this Agreement shall be solely
                                         responsible for any and all expenses associated with such action.

 

		30.11	Survival.
                                         The following Articles and Sections shall survive expiration or termination of this Agreement
                                         for any reason: ARTICLE 1 (to the extent necessary to give force to, or otherwise understand,
                                         surviving provisions), ARTICLE 16, Sections 19.8, 19.9, 22.1, 22.2, 22.3, 22.4, 22.5,
                                         and 22.6, ARTICLE 24, Section 26.6, ARTICLE 28, ARTICLE 29 (with respect to any matters
                                         commenced prior to expiration or termination), and Sections 30.1, 30.2, 30.4, 30.7, 30.11,
                                         30.12, 30.13, 30.14, and 30.18. 

 

		30.12	Waiver
                                         of Contra Proferentem Rule of Construction. Each Party has had the
                                         opportunity to consult with counsel in connection with the review, drafting and negotiation
                                         of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement
                                         shall be construed against the drafting Party shall not apply.

 

		30.13	Remedies
                                         to be cumulative. Each Party’s remedies under this Agreement and under the
                                         law are intended to be cumulative, and not mutually exclusive.

 

		30.14	Counterparts.
                                         The Parties may execute this Agreement in multiple counterparts, each of which constitutes
                                         an original as against the Party that signed it, and all of which together constitute
                                         one agreement. This Agreement is effective upon delivery of one executed counterpart
                                         from each Party to the other Parties. The signatures of all Parties need not appear on
                                         the same counterpart. The delivery of signed counterparts by facsimile or email transmission
                                         that includes a copy of the sending Party’s signature(s) is as effective as signing
                                         and delivering the counterpart in person.

 

		30.15	Further
                                         Assurance. Each Party shall duly execute and deliver, or cause to be duly executed
                                         and delivered, such further instruments and do and cause to be done such further acts
                                         and things, including the filing of such assignments, agreements, documents, and instruments,
                                         as may be necessary or as the other Party may reasonably request in connection with this
                                         Agreement or to carry out more effectively the provisions and purposes hereof, or to
                                         better assure and confirm unto such other Party its rights and remedies under this Agreement.

 

		30.16	No
                                         Joint Venture. Nothing in this Agreement creates a joint venture or partnership between
                                         the Parties. This Agreement does not authorize any Party (a) to bind or commit, or to
                                         act as an agent, employee or legal representative of, another Party, except as may be
                                         specifically set forth in other provisions of this Agreement, or (b) to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 79

     

    

 

have the
power to control the activities and operations of another Party. The Parties are independent contractors with respect to each
other under this Agreement. Each Party agrees not to hold itself out as having any authority or relationship contrary to this
Section 30.16.

 

		30.17	No
                                         Third Party Rights. Nothing expressed or referred to in this Agreement will be construed
                                         to give any Third Party, other than the Parties to this Agreement, any legal or equitable
                                         right, remedy or claim under or with respect to this Agreement or any provision of this
                                         Agreement except such rights as may inure to a successor or permitted assignee.

 

		30.18	Waiver
                                         of Jury Trial. EACH OF THE PARTIES KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVES,
                                         TO THE FULLEST EXTENT PERMITTED BY LAW, ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
                                         OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING
                                         TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR THE ACTIONS OF
                                         ANY PARTY TO THIS AGREEMENT IN NEGOTIATION, EXECUTION AND DELIVERY, PERFORMANCE OR ENFORCEMENT
                                         OF THIS AGREEMENT.

 

		30.19	Guaranty.
                                         Incyte Corporation hereby unconditionally and irrevocably guarantees to ARIAD US
                                         the full and timely payment and discharge of all ARIAD SWISSCO'S payment obligations
                                         under this Agreement, including pursuant to Sections 5.3.1, 5.7.3, 5.9, 19.1, 19.2 and
                                         19.4. This is a guarantee of payment, and not of collection, and Incyte Corporation acknowledges
                                         and agrees that this guarantee is absolute, full, unconditional and irrevocable, and
                                         no release or extinguishment of the obligations or liabilities of ARIAD SWISSCO, whether
                                         by decree in any bankruptcy proceeding or otherwise, shall affect the continuing validity
                                         and enforceability of this guarantee, as well as any provision requiring or contemplating
                                         payment by Incyte Corporation. Incyte Corporation's guarantee under this Section 30.19
                                         shall continue irrespective of (i) any lack of validity or enforceability of this Agreement
                                         against ARIAD SWISSCO as a result of any bankruptcy, insolvency, reorganization, moratorium
                                         or other similar Laws affecting or relating to creditors’ rights generally, (ii)
                                         any modification, amendment, consent, extension, waiver of or consent under this Agreement
                                         that may be agreed to by ARIAD SWISSCO, (unless also agreed to by ARIAD US and Incyte
                                         Corporation) or (iii) any change in the ownership of ARIAD SWISSCO or any other Person,
                                         any merger or consolidation of ARIAD SWISSCO or any other Person into or with any other
                                         Person, or any sale, lease or other transfer of the assets of ARIAD SWISSCO or any other
                                         Person to any other Person. Incyte Corporation hereby waives, for the benefit of ARIAD
                                         US and its successors, (A) any right to require ARIAD US, as a condition of payment by
                                         Incyte Corporation, to proceed against ARIAD SWISSCO or pursue any other remedy whatsoever
                                         (provided, that, in the case of payments due by ARIAD SWISSCO under this Agreement, ARIAD
                                         US shall have, where applicable, issued an invoice in accordance with the terms of this
                                         Agreement and taken such other actions as are specifically required by the terms of this
                                         Agreement to obtain payment and, where applicable, waited the applicable payment period)
                                         and (B) to the fullest extent permitted by Applicable Law, any defenses or benefits that
                                         may be derived from or afforded by Applicable Law which limit the liability of or exonerate
                                         guarantors or sureties, except to the extent that any

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 80

     

    

 

such defense
would excuse the performance by ARIAD SWISSCO under the terms of this Agreement. Subject to the foregoing, ARIAD US hereby agrees
that Incyte Corporation shall have all defenses to its obligations hereunder that would be available to ARIAD SWISSCO under this
Agreement.

 

[Remainder of page intentionally blank;
signature page follows]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 81

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in duplicate by their duly authorized officers as
of the Effective Date.

 

	For and on behalf of	 	For and on behalf of
	 	 	 
	ARIAD Pharmaceuticals, Inc.	 	ARIAD Pharmaceuticals (Europe) Sarl 
	 	 	 
	/s/ Manmeet S. Soni	 	/s/ Jonathan Dickinson
	 	 	 
	Name: Manmeet S. Soni	 	Name:  Jonathan Dickinson
	 	 	 
	Title: Executive Vice President, Chief	 	Title:   Manager
	          Financial Officer
    and Treasurer	 	 
	 	 	 
	Solely in its capacity as guarantor under Section 30.19, for and on behalf
    of	 	 
	 	 	 
	Incyte Corporation	 	 
	 	 	 
	/s/ Hervé Hoppenot	 	 
	 	 	 
	Name: Hervé Hoppenot	 	 
	 	 	 
	Title: President and CEO	 	 

 

Signature Page to
Amended and Restated Buy-In License Agreement

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX 1.18

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.21

 

[***]
 

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX 1.35

 

COMMERCIALIZATION
PLAN

 

(see attached)

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.40

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.62

 

Distribution
Agreements

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX 1.128

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.134

 

PRIMARY
EFFICACY ENDPOINT

 

The “Primary
Efficacy Endpoint” means achieving the [***] by [***]
defined according to standard criteria as ≤[***]%
of [***] to [***] on
the [***], measured by [***]. 
The primary analysis of the primary endpoint will be performed using [***].
The study will be stratified by [***] at baseline (≥[***]
 versus <[***])
and [***]) to compare the MMR rate by [***] between
patients receiving either dose level of ponatinib (initial dose: [***] or
[***]) and patients receiving nilotinib (initial dose: [***])
and will follow a testing procedure to ensure an [***]. An efficacy
interim analysis is planned after the first [***] have at least
[***] of [***]. 
To maintain an overall [***] of [***] (2-sided),
an [***] will be used which requires a [***].
Thus, with 2 treatment comparisons significance will be declared for [***].
For each dose comparison, if this boundary is not crossed at the time of the interim analysis, then the primary analysis will
be conducted [***] following the [***].
A [***] will be used to adjust for comparisons of Cohorts A and
B to Cohort C, with a dose considered significant if the [***] is
<[***].

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.138

 

Proposed
Studies

 

(see
attached)

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.161

 

SUPERIORITY

 

“Superiority”
means ponatinib has demonstrated [***] to nilotinib where, for any ponatinib
arm the [***] is [***] at the interim or if both [***]. For each
dose comparison, if this boundary is not crossed at the time of the interim analysis, then the primary analysis will be conducted
[***] following the [***].
A [***] will be used to adjust for comparisons of Cohorts A and
B to Cohort C, with a dose considered significant if the [***].
Additionally, both dose comparisons will be considered significant if [***] are
[***] for the tests of the primary endpoint.  The primary
analysis will be based on the [***]. A sensitivity analysis of
the primary endpoint will be performed on the [***], with patients
not [***] treated as [***].

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
1.167

 

Territory

 

Part
A

 

	European Union Countries	 	[***]
	 	 	 
	1.    Austria[***]	 	[***]
	2.    Belgium[***]	 	33. Turkey
	3.    Bulgaria	 	[***]
	4.    Croatia	 	41. Israel[***]
	5.    Cyprus	 	[***]
	6.    Czech
    Republic[***]	 	45. Norway[***]
	7.    Denmark[***]	 	46. Russia
	8.    Estonia	 	[***]
	9.    Finland[***]	 	48. Switzerland
	10.  France[***]	 	[***]
	11.  Germany[***]	 	 
	12.  Greece	 	 
	13.  Hungary[***]	 	 
	14.  Ireland[***]	 	 
	15.  Italy[***]	 	 
	16.  Latvia	 	 
	17.  Lithuania	 	 
	18.  Luxembourg[***]	 	 
	19.  Malta	 	 
	20.  Netherlands[***]	 	 
	21.  Poland[***]	 	 
	22.  Portugal[***]	 	 
	23.  Romania[***]	 	 
	24.  Slovakia[***]	 	 
	25.  Slovenia[***]	 	 
	26.  Spain[***]	 	 
	27.  Sweden[***]	 	 
	28.  United Kingdom
    (Scotland[***], Wales[***], England[***] and Northern Ireland)	 	 

 

[***]

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

[***]

 

Part
B EU 16

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX 1.175

 

TRANSITION BACK
ARRANGEMENTS

 

		1.	Reversion

 

		1.1	All
                                         rights granted by ARIAD US to ARIAD SWISSCO hereunder including but not limited to the
                                         license granted in Section 2.1 shall [***].
                                         

 

		1.2	Subject
                                         to and in accordance with the Transition Plan referred to in para 2 below, ARIAD SWISSCO
                                         shall [***] of
                                         (A) the ARIAD US [***],
                                         (B) the [***],
                                         (C) [***],
                                         (D) the [***] (E)
                                         all [***],
                                         (F) all [***],
                                         (ii) where applicable, [***] all
                                         [***].

 

		1.3	ARIAD
                                         SWISSCO and its Affiliates shall, subject to the Transition Plan, [***].
                                         

 

		1.4	ARIAD
                                         SWISSCO shall [***] (i)
                                         the [***];
                                         and (ii) [***] in
                                         accordance with the Transition Plan. [***] will
                                         notify [***] of
                                         the [***] of
                                         [***] within
                                         [***].

 

		1.5	The
                                         [***] shall
                                         continue. 

 

		2.	Transition Plan

 

2.1  The Parties shall use Commercially
Reasonable Efforts to agree, in good faith, a transition plan to transition (the "Transition"), from ARIAD SWISSCO
to ARIAD US and/or its designee, responsibility for Development, Commercialization and Manufacturing activities (the "Transition
Plan"). Such Transition Plan shall include [***], including [***].

 

2.
2  The Transition Plan shall be for a period not exceeding [***] from
the date of termination of all or part of this Agreement, or any other shorter period as the Parties may agree in writing.

 

		3.	Registrations and Documentation

 

		3.1	In
                                         accordance with Applicable Laws, ARIAD US and ARIAD SWISSCO shall, as soon as is practicably
                                         possible after termination and in any event within [***] of
                                         termination, take such reasonable actions as are necessary to [***].

 

		3.2	ARIAD US and ARIAD SWISSCO shall
                                         execute all necessary and appropriate letters and applications to Regulatory Authorities
                                         (if any) to ensure that ownership of the Registrations are transferred to ARIAD US as
                                         soon as practicable.

 

		3.3	The date upon which Registration
                                         is registered in ARIAD US's name shall be known as the “Transfer Date”
                                         in respect of a particular Registration.

 

		3.4	In
                                         the event that such a transfer is not possible under Applicable Laws, ARIAD SWISSCO and
                                         ARIAD US shall each use Commercially Reasonable Efforts to [***].
                                         

 

		3.5	From
                                         (i) [***],
                                         until (ii) [***],
                                         ARIAD SWISSCO shall [***] 
                                         required to [***].

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

		4.	Employees

 

		4.1	If, in the event of the termination
                                         of this Agreement by ARIAD SWISSCO pursuant to Section 26.4 or 26.5, the Transition Back
                                         Arrangements are implemented pursuant to this Agreement, it is [***] after the date of
                                         such implementation of the Transition Plan:

 

1.   the
Parties shall [***] to procure that any such [***]; and

 

2.   if
the Parties are not able to procure that the [***] the [***] may [***] including [***]; provided that the [***]. The [***] of
this subparagraph (2) shall only apply in the event that [***].

 

For the
purposes of this Paragraph 4, "Transfer Regulations" means the Transfer of Undertakings (Protection of Employment) Regulations
2006 and any other law implementing in any jurisdiction the European Council Directive 2001/23/EC on the approximation of laws
of European member states relating to the safeguarding of employees' rights in the event of transfers of undertakings, businesses
or parts of undertakings or businesses as amended or replaced from time to time or any equivalent or analogous legislation or
regulations in any other country within the Territory.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
17.3

 

ISTs

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
19.8.2

 

YEAR-END
COMPENSATING PAYMENT

 

1.     [***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX 20

 

DISCLOSURE
SCHEDULES

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

APPENDIX
20.1.17

 

[***]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
 treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.2

EXECUTION VERSION

 

SHARE PURCHASE
AGREEMENT

 

by
and among

 

INCYTE
EUROPE S.à r.l.,

 

ARIAD
PHARMACEUTICALS (CAYMAN) L.P.,

 

ARIAD
PHARMACEUTICALS, INC. (AS GUARANTOR), 

 

and

 

INCYTE CORPORATION
(AS GUARANTOR)

 

 

 

May 9, 2016

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	Article 1 DEFINITIONS AND CONSTRUCTION	1
	 	 	 
	Section 1.1	Definitions	1
	 	 	 
	Section 1.2	Additional Defined Terms	9
	 	 	 
	Section 1.3	Construction	10
	 	 	 
	Article 2 THE TRANSACTION	10
	 	 	 
	Section 2.1	Sale and Purchase of Shares	10
	 	 	 
	Section 2.2	Purchase Price	11
	 	 	 
	Section 2.3	Closing Date Adjustment	11
	 	 	 
	Section 2.4	Post-Closing Adjustment	11
	 	 	 
	Section 2.5	Closing	14
	 	 	 
	Section 2.6	Closing Deliveries	14
	 	 	 
	Article 3 REPRESENTATIONS AND WARRANTIES OF THE SELLER	15
	 	 	 
	Section 3.1	Organization and Good Standing	15
	 	 	 
	Section 3.2	Authority and Enforceability	15
	 	 	 
	Section 3.3	No Conflict	16
	 	 	 
	Section 3.4	Capitalization and Ownership	16
	 	 	 
	Section 3.5	Brokers Fees	17
	 	 	 
	Section 3.6	Financial Statements	17
	 	 	 
	Section 3.7	No Undisclosed Liabilities	17
	 	 	 
	Section 3.8	Absence of Certain Changes and Events	18
	 	 	 
	Section 3.9	Tangible Personal Property	18
	 	 	 
	Section 3.10	Leased Real Property	19
	 	 	 
	Section 3.11	Intellectual Property	19
	 	 	 
	Section 3.12	Contracts	20
	 	 	 
	Section 3.13	Tax Matters	21
	 	 	 
	Section 3.14	Employee Benefit Matters	22
	 	 	 
	Section 3.15	Employment and Labor Matters	22
	 	 	 
	Section 3.16	Environmental, Health and Safety Matters	23
	 	 	 
	Section 3.17	Governmental Authorizations	23
	 	 	 
	Section 3.18	Compliance with Laws	24
	 	 	 
	Section 3.19	Product Liability	24
	 	 	 
	Section 3.20	Legal Proceedings	24

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 -i-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 3.21	Insurance	24
	 	 	 
	Section 3.22	Customers.	25
	 	 	 
	Section 3.23	Interested Party Transactions	25
	 	 	 
	Section 3.24	Bank Accounts	25
	 	 	 
	Section 3.25	No Other Representations or Warranties	25
	 	 	 
	Article 4 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER	26
	 	 	 
	Section 4.1	Organization and Good Standing	26
	 	 	 
	Section 4.2	Authority and Enforceability	26
	 	 	 
	Section 4.3	No Conflict	26
	 	 	 
	Section 4.4	Legal Proceedings	26
	 	 	 
	Section 4.5	Investment Intent	27
	 	 	 
	Section 4.6	Brokers Fees	27
	 	 	 
	Section 4.7	Financial Capacity	27
	 	 	 
	Section 4.8	Independent Investigation	27
	 	 	 
	Article 5 PRE-CLOSING COVENANTS	27
	 	 	 
	Section 5.1	Access and Investigation; Notice	27
	 	 	 
	Section 5.2	Operation of the Businesses of the Acquired Companies	28
	 	 	 
	Section 5.3	Consents and Filings; Commercially Reasonable Efforts	29
	 	 	 
	Section 5.4	Financing	30
	 	 	 
	Section 5.5	Public Announcements	30
	 	 	 
	Section 5.6	Intragroup Agreements	30
	 	 	 
	Section 5.7	Carve Out Restructuring	30
	 	 	 
	Section 5.8	Financial Statements	30
	 	 	 
	Section 5.9	CSC Guarantee	31
	 	 	 
	Article 6 CONDITIONS PRECEDENT TO OBLIGATION TO CLOSE	31
	 	 	 
	Section 6.1	Joint Condition	31
	 	 	 
	Section 6.2	Conditions to the Obligation of the Purchaser	31
	 	 	 
	Section 6.3	Conditions to the Obligation of the Seller	32
	 	 	 
	Article 7 TERMINATION	32
	 	 	 
	Section 7.1	Termination Events	32
	 	 	 
	Section 7.2	Effect of Termination	32

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 -ii-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 7.3	Certain Effects of Termination	33
	 	 	 
	Article 8 INDEMNIFICATION	33
	 	 	 
	Section 8.1	Indemnification by the Seller	33
	 	 	 
	Section 8.2	Indemnification by the Purchaser	33
	 	 	 
	Section 8.3	Claim Procedure	33
	 	 	 
	Section 8.4	Survival	34
	 	 	 
	Section 8.5	Limitations on Liability	35
	 	 	 
	Section 8.6	Tax Refunds, Insurance Proceeds and Other Payments	35
	 	 	 
	Section 8.7	Subrogation	36
	 	 	 
	Section 8.8	Exclusive Remed	36
	 	 	 
	Article 9 TAX MATTERS	36
	 	 	 
	Section 9.1	Swiss Tax Rulings	36
	 	 	 
	Section 9.2	Liability and Indemnification for Taxes	37
	 	 	 
	Section 9.3	Tax Return Filing; Audit Responsibilities	37
	 	 	 
	Section 9.4	Cooperation	38
	 	 	 
	Section 9.5	No Code Section 338 Election	38
	 	 	 
	Section 9.6	Tax Treatment of Indemnity Payments.	38
	 	 	 
	Article 10 EMPLOYEE MATTERS	39
	 	 	 
	Section 10.1	Employees	39
	 	 	 
	Section 10.2	Indemnity	39
	 	 	 
	Article 11 POST-CLOSING COVENANTS	40
	 	 	 
	Section 11.1	Confidentiality	40
	 	 	 
	Section 11.2	Indemnification	40
	 	 	 
	Section 11.3	Seller’s Group Marks	40
	 	 	 
	Section 11.4	Standstill	41
	 	 	 
	Section 11.5	Further Actions	42
	 	 	 
	Section 11.6	Books and Records and Cooperation with Litigation	42
	 	 	 
	Article 12 GENERAL PROVISIONS	42
	 	 	 
	Section 12.1	Notices	42
	 	 	 
	Section 12.2	Amendment	44
	 	 	 
	Section 12.3	Waiver and Remedies	44

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 -iii-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 12.4	Entire Agreement	44
	 	 	 
	Section 12.5	Assignment, Successors and No Third Party Rights	44
	 	 	 
	Section 12.6	Severability	44
	 	 	 
	Section 12.7	Exhibits and Schedules	44
	 	 	 
	Section 12.8	Interpretation	45
	 	 	 
	Section 12.9	Expenses	45
	 	 	 
	Section 12.10	Governing Law	45
	 	 	 
	Section 12.11	Limitation on Liability	45
	 	 	 
	Section 12.12	Specific Performance	45
	 	 	 
	Section 12.13	Jurisdiction and Service of Process	45
	 	 	 
	Section 12.14	Waiver of Jury Trial	46
	 	 	 
	Section 12.15	No Joint Venture	46
	 	 	 
	Section 12.16	Non Recourse	46
	 	 	 
	Section 12.17	Guaranty	46
	 	 	 
	Section 12.18	Counterparts	46

 

Exhibits

 

Exhibit A       Amended and Restated Buy-In
License Agreement Territory

Exhibit B       Territory

Exhibit C       Joint Press Release

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 -iv-

     

    

 

SHARE PURCHASE
AGREEMENT

 

This Share Purchase
Agreement (the “Agreement”) is made as of May 9, 2016, by and among Incyte Europe S.à r.l., an entity
formed under the laws of Switzerland (the “Purchaser”), ARIAD Pharmaceuticals (Cayman) L.P., an Exempted Limited
Partnership registered in the Cayman Islands, acting by its general partner, ARIAD Pharmaceuticals (Cayman) Inc., an Exempted Company
incorporated in the Cayman Islands with limited liability (the “Seller”), ARIAD Pharmaceuticals, Inc., a Delaware
corporation (“ARIAD US”), solely in its capacity as guarantor under Section 13.17(a) hereof, and Incyte Corporation,
a Delaware corporation (“Incyte US”), for the purposes of Section 11.4 and in its capacity as guarantor under
Section 13.17(b).

 

WITNESSETH:

 

WHEREAS, the Seller
owns all of the shares in the share capital of ARIAD Pharmaceuticals (Luxembourg)
S.à r.l., a private limited liability company (société à responsabilité limitée)
organized and existing under the laws of the Grand Duchy of Luxembourg, with a share capital of USD 20,000, having its registered
office at 6, rue Eugène Ruppert, L-2453 Luxembourg and registered with the Luxembourg Trade and Companies Register under
number B 169.951 (the “Company”);

 

WHEREAS, this Agreement
contemplates the sale by the Seller to the Purchaser of all of the share capital of the Company; and

 

WHEREAS, this Agreement
is being executed in the presence of the Company.

 

NOW, THEREFORE, intending
to be legally bound and in consideration of the mutual provisions set forth in this Agreement and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

Article
1

DEFINITIONS AND CONSTRUCTION

 

Section 1.1           Definitions.
 For the purposes of this Agreement and the Ancillary Agreements:

 

“Acquired
Companies” means, collectively, the Company and its Subsidiaries.

 

“Affiliate”
means, with respect to a specified Person, any other Person that controls, is controlled by or is under common control with that
Person. For the purposes of this definition, the terms “controls”, “controlled by” and “under common
control with” as used with respect to any Person, means (i) to possess (directly or indirectly) the power to direct the management
or affairs of such Person, whether through ownership of voting securities or other equity rights or by contract relating to voting
rights or corporate governance or otherwise, or (ii) to own, directly or indirectly, more than fifty percent (50%) of the outstanding
voting securities or other ownership interest of such Person.

 

“Affiliated
Group” means a group of corporations with which any Acquired Company has filed consolidated, combined, unitary or similar
Tax Returns.

 

“Amended and
Restated Buy-In License Agreement” means the Amended and Restated Buy-In License Agreement in the form attached as Exhibit
A.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	1

     

    

 

“Ancillary
Agreements” means, collectively, the Amended and Restated Buy-In License, the Interim Quality Agreement, the Marketing
Authorization Services Agreement, the Transition Services Agreement and the Reverse Transition Services Agreement.

 

“Antitrust
Approvals” means all authorizations, orders, grants, consents, clearances, permissions and approvals and all expirations,
lapses and terminations of any required waiting periods (including extensions thereof), in each case under any Antitrust Law, required
to consummate the transactions contemplated by this Agreement.

 

“ARIAD SWISSCO”
means ARIAD Pharmaceuticals (Europe) S.a.r.l.

 

“ARIAD SWISSCO
Intragroup Indebtedness” means any Indebtedness outstanding under (i) the credit facility entered into between the Seller
and ARIAD SWISSCO on October 12, 2012; and (ii) the loan agreement entered into between ARIAD US and ARIAD SWISSCO on August 7,
2012, in the case of each of (i) and (ii) as from time to time supplemented, modified or amended.

 

“Australian
Business” means the business carried on by ARIAD Pharmaceuticals (Australia) Pty Ltd.

 

“Books and
Records” means minutes books, stock books, stock ledgers, books of account, manuals, general, financial, warranty and
shipping records, invoices, customer and supplier lists, correspondence, engineering, maintenance and operating records and other
documents, records and files, in each case exclusively related to the business of the Acquired Companies.

 

“Business
Day” means any day other than Saturday, Sunday or any day on which banking institutions in the US or Switzerland are
closed either under applicable Law or action of any Governmental Authority. For the avoidance of doubt, any other reference to
days shall mean calendar days.

 

“Cash”
means, with respect to a Person, the amount of cash, cash equivalents and liquid investments on hand or credited to any account
open in the name of such Person with a financial institution (plus all uncollected bank deposits and less all outstanding checks).

 

“Change”
means a change, circumstance, condition, event, effect, development or state of facts.

 

“Claims”
means any charges, mortgages, pledges, security interests, escrows, options, rights of first refusal, indentures, security agreements
or other encumbrances, claims, agreements, arrangements or commitments of any kind or character and whether or not relating in
any way to credit or the borrowing of money.

 

“Closing
Cash” means the Cash of the Acquired Companies on a consolidated basis calculated as of 11:59 p.m., New York City
time, on the date immediately preceding the Closing Date in accordance with GAAP in a manner consistent with the methods and
practices used to prepare the Company Interim Balance Sheet (with any amounts denominated in Foreign Currency converted to US
Dollars using the Exchange Rate).

 

“Closing Indebtedness”
means the sum of (a) Indebtedness of the Acquired Companies on a consolidated basis calculated as of 11:59 p.m., New York City
time, on the date immediately preceding the Closing Date, after giving effect to the settlement of the ARIAD SWISSCO Intragroup
Indebtedness, in accordance with GAAP in a manner consistent with the methods and practices used to prepare the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	2

     

    

 

Company Interim Balance
Sheet plus (b) an amount equal to the aggregate Retention Payments (with any amounts denominated in Foreign Currency converted
to US Dollars using the Exchange Rate). 

 

“Closing Net
Cash” means the difference between (a) the Closing Cash and (b) the Closing Indebtedness. For purposes of this definition,
if the Closing Indebtedness exceeds the Closing Cash, then the Closing Net Cash amount will be represented by a negative number.

 

“Closing Net
Working Capital” means (a) all current assets of the Acquired Companies (excluding Closing Cash and any assets relating
to Taxes, including assets that relate to the right to use Tax Attributes and any assets that relate to a right to a tax refund
or that otherwise results from the overpayment of Taxes in any period) on a consolidated basis minus (b) all current liabilities
of the Acquired Companies (excluding the Deferred Revenue, Deferred Refund Obligations and any Closing Indebtedness, to
the extent made up of current liabilities, and Liabilities relating to Taxes and as adjusted pursuant to Section 5.8), in each
case calculated as of 11:59 p.m., New York City time, on the date immediately preceding the Closing Date in accordance with GAAP
in a manner consistent with the methods and practices used to prepare the Company Interim Balance Sheet (with any amounts denominated
in Foreign Currency converted to US Dollars using the Exchange Rate). For purposes of this definition, if the current Liabilities
of the Acquired Companies on a consolidated basis exceed the current assets of the Acquired Companies on a consolidated basis,
then the Closing Net Working Capital amount will be represented by a negative number.

 

“Code”
means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

 

“Commercialize”
means all activities directed to importing (into, or within, the Territory), exporting (within the Territory), storing, marketing,
promoting, selling, offering for sale and distributing the Product in the Territory. “Commercializes,” “Commercialized,”
“Commercialization” and other forms of the word “Commercialize” shall have the correlative meaning. For
clarity, “Commercialize” excludes manufacture.

 

“Company Plan”
means any “employee benefit plan” (as defined in Section 3(3) of ERISA), any Pension Arrangement and any other material
plan, Contract or arrangement involving direct or indirect compensation, including insurance coverage, severance benefits, ill
health, disability, deferred compensation, bonuses, stock options, stock purchase, phantom stock, stock appreciation or other forms
of incentive compensation or post-retirement compensation sponsored or maintained by any Acquired Company or the Seller for the
benefit of any current or former director, officer or Transferred Employee of any Acquired Company.

 

“Compound”
has the meaning given to that term in the Amended and Restated Buy-In License Agreement.

 

“Contract”
means any written contract, agreement, lease, license, commitment, understanding, franchise, warranty, guaranty, mortgage, note,
bond or other instrument or consensual obligation that is legally binding.

 

“Controlled
Person” means Incyte US, its direct and indirect Subsidiaries [***].

 

“CSC Guarantee”
means that certain guarantee provided by ARIAD US for the benefit of CSC Pharmaceuticals Handels GmbH (“CSC”)
to guarantee the performance of the obligations of ARIAD

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	3

     

    

 

SWISSCO under the Market
Access Services and Distribution and Supply Agreement between ARIAD SWISSCO and CSC.

 

“Deferred
Revenue” means the amounts recorded in other current liabilities in the Financial Statements attributable to the matter
described in Section 3.7 of the Seller Disclosure Schedule.

 

“Deferred
Refund Obligations” means the aggregate amount of the refunds payable to the applicable Governmental Authority relating
to the Deferred Revenue and described in Section 3.7 of the Seller Disclosure Schedule.

 

“Encumbrance”
means any charge, mortgage, encumbrance, pledge, security interest, or other lien other than (a) carrier’s, warehousemen’s,
mechanic’s, materialmen’s and other similar liens with respect to amounts that are not yet due and payable or that
are being contested in good faith, (b) liens for Taxes that are not yet due and payable or that are being contested in good faith,
(c) liens securing rental payments under capital lease arrangements, (d) restrictions arising under applicable zoning and other
land use Laws that do not, individually or in the aggregate, have a material adverse effect on the present use or occupancy of
the property subject thereto.

 

“Environmental
Law” means any Law concerning (a) the treatment, disposal, emission, discharge, Release or threatened Release of Hazardous
Material or (b) the protection of the environment (including natural resources, air and surface or subsurface land or waters).

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Exchange
Rate” means the exchange rate between the applicable Foreign Currency and US Dollars observed by Bloomberg at 9:00 a.m.,
New York City time, three Business Days prior to the Closing Date.

 

“Foreign Currency”
means any currency other than US Dollars.

 

“GAAP”,
unless otherwise stated, means United States generally accepted accounting principles.

 

“Governmental
Authority” means any (a) nation, region, state, county, city, town, village, district or other jurisdiction, (b) federal,
state, local, municipal, foreign or other government, (c) governmental or quasi-governmental authority of any nature (including
any governmental agency, branch, department or other entity and any court or other tribunal), (d) multinational organization exercising
judicial, legislative or regulatory power or (e) body exercising, or entitled to exercise, any administrative, executive, judicial,
legislative, police, regulatory or taxing authority or power of any nature of any federal, state, local, municipal, foreign or
other government.

 

“Governmental
Authorization” means any approval, consent, ratification, waiver, license, permit, registration or other authorization
issued or granted by any Governmental Authority.

 

“Hazardous
Material” means any waste or other substance that is listed, defined, designated or classified as hazardous, radioactive
or toxic or a pollutant or a contaminant under any Environmental Law, including any admixture or solution thereof, and including
petroleum and all derivatives thereof or synthetic substitutes therefor, asbestos or asbestos-containing materials in any form
or condition and polychlorinated biphenyls.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	4

     

    

 

“Indebtedness”
means, with respect to any Person (a) all indebtedness of such Person, whether or not contingent, for borrowed money, (b) all obligations
of such Person evidenced by notes, bonds, debentures or other similar instruments or debt securities and warrants or other rights
to acquire any such instruments or securities and (c) all indebtedness of others referred to in clauses (a) and (b) hereof guaranteed,
directly or indirectly, in any manner by such Person, or in effect guaranteed directly or indirectly by such Person through an
agreement (i) to pay or purchase such Indebtedness or to advance or supply funds for the payment or purchase of such Indebtedness,
(ii) to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling
the debtor to make payment of such Indebtedness or to assure the holder of such Indebtedness against Loss, (iii) to supply funds
to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether
such property is received or such services are rendered), (iv) to grant an Encumbrance on property owned or acquired by such Person,
whether or not the obligation secured thereby has been assumed or (v) otherwise to assure a creditor against Loss, except in the
case of any of items (a), (b) or (c) to the extent solely between or among the Acquired Companies.

 

“Intellectual
Property” means all (a) patents (including utility and design patents), patent applications, Patent Cooperation
Treaty filings, patent disclosures and all related extensions, continuations, continuations-in-part, divisions, reissues, and reexaminations,
utility models, certificates of invention and design patents, and all extensions thereto, (b) trademarks, service marks, trade
dress, brand names, certification marks, logos, slogans, rights in designs, industrial designs, corporate names, trade names, business
names, together with the goodwill associated with any of the foregoing, in each case whether registered or unregistered, and all
applications and registrations therefor (“Trademarks”), (c) domain names, URLs and any other addresses
for use on the Internet, (d) copyrights and registrations and applications therefor, together with all renewals, extensions,
translations, adaptations, derivations and combinations therefor, works of authorship, publications, documentation, website content,
rights in fonts and typefaces, and database rights, (e) rights of publicity, rights of privacy, royal warrants and moral rights,
(f) know-how, trade secrets, confidential and proprietary information, rights in research and development, financial, marketing
and business data, pricing and cost information, plans (including business and marketing plans), formulae, inventions, processes,
techniques, technical data, designs, drawings (including engineering and auto-cad drawings), specifications, databases, blue prints,
and customer and supplier lists and information, in each case whether patentable or not and whether or not reduced to practice,
(g) other intellectual property or similar corresponding or equivalent right to any of the foregoing or other proprietary
or Contract right relating to any of the foregoing (including remedies against infringements thereof and rights of protection of
interest therein under the laws of all jurisdictions) and (h) copies and tangible embodiments thereof, in each case whether
or not the same are in existence as of the date of this Agreement or developed after such date and in any jurisdiction throughout
the world.

 

“Interim Quality
Agreement” means a quality agreement in the form reasonably acceptable to the parties to this Agreement.

 

“Intragroup
Agreement” means a Contract between or among any member of the Seller’s Group, on the one hand, and any Acquired
Company, on the other hand, but excluding any Ancillary Agreement.

 

“Judgment”
means any order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Authority or arbitrator
or other court or tribunal.

 

“Knowledge”
means the actual knowledge of any of each Person listed in Section 1.1(a) of the Seller Disclosure Schedule, after such inquiry
as such Persons normally would conduct in the ordinary course of their duties to Seller and its Affiliates.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	5

     

    

 

“Law”
means any federal, state, local, municipal, foreign, international, multinational, or other constitution, law, statute, treaty,
rule, regulation, ordinance or code.

 

“Liability”
means any liability or obligation, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated,
due or to become due.

 

“Loss”
means any direct and actual Liabilities, losses, damages, penalties, fines, costs or expenses (including reasonable attorney’s
or other professional fees and expenses), but excluding any special, incidental indirect, exemplary, punitive or consequential
damages, lost profits, loss of revenue, lost sales, or amounts calculated as a multiple of earnings, profits, revenue, sales or
other measures; provided, that the foregoing exclusions shall not limit the rights any party to indemnity for such
damages to the extent actually paid to Persons other than the parties hereto, any Indemnified Party or their respective Affiliates.

 

“Marketing
Authorization Services Agreement” means a marketing authorization services agreement in the form reasonably acceptable
to the parties to this Agreement.

 

“Material
Adverse Effect” means any Change that has a material adverse effect on (a) the business, assets (whether tangible or
intangible), liabilities, financial condition, operations or results of operations of the Acquired Companies, taken as a whole,
or (b) the ability of the Seller to consummate timely the transactions contemplated by this Agreement; provided that none
of the following shall be deemed, either alone or in combination, to constitute, and none of the following shall be taken into
account in determining whether there has been, a Material Adverse Effect: (i) any Change generally affecting economic, regulatory
or political conditions, (ii) any Change generally affecting the financial, credit, securities or other capital markets in the
United States or any foreign jurisdiction, (iii) any Change generally affecting the industry in which the Acquired Companies operate,
(iv) any hurricane, tornado, flood, earthquake, tsunami, volcanic eruption or other natural disaster, (v) any Change occurring
in national or international political conditions, including acts of war, sabotage or terrorism, or any escalation or worsening
of any such acts of war, sabotage or terrorism, (vi) any Change occurring after the date of this Agreement in applicable Law or
generally accepted accounting principles, (vii) the public announcement of the execution of this Agreement and (viii) any failure
to meet any internal or published projections, forecasts or revenue or earnings predictions for any period ending on or after the
date of this Agreement (but not the facts or circumstances underlying or giving rise to such failure), except, with respect to
the foregoing clauses (i) through (vi), to the extent that the effects of any such matter are, or would reasonably be expected
to be, disproportionately adverse to the business, financial condition, operations or results of operations of the Acquired Companies,
taken as a whole, as compared to other companies operating in the industries and markets in which the Acquired Companies operate.

 

“Marketing
Authorization” means a marketing authorization (or equivalent product approval in any country within the Territory) issued
by a Governmental Authority with respect to the Product to enable the Product to be placed on the market in a country in the Territory.

 

“Organizational
Documents” means, with respect to any entity, the certificate of incorporation or formation, the articles of incorporation,
by-laws, articles of organization, partnership agreement, limited liability company agreement, formation agreement, joint venture
agreement or other similar organizational documents of such entity (in each case, as amended).

 

“Pension Arrangement”
means any pension plan disclosed at Section 3.14(a) of the Seller Disclosure Schedule.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	6

     

    

 

“Person”
means an individual or an entity, including a (for profit or not for profit) corporation, limited liability company, general or
limited partnership, trust, association or other business or investment entity, academic institution, research institution, or
any Governmental Authority.

 

“Post-Closing
Period” means any taxable period or portion of a period that begins after the Closing Date.

 

“Pre-Closing
Period” means any taxable period or portion of a period that begins on or before the Closing Date and ends on or before
the Closing Date.

 

“Pre-Sale
Restructuring” means: (i) the financial restructuring of ARIAD SWISSCO for the purposes of settling the ARIAD SWISSCO
Intragroup Indebtedness; (ii) ARIAD SWISSCO entering into the Amended and Restated Buy-In License Agreement; and (iii) any transaction
or arrangement required for the implementation of the transactions in (i) and (ii).

 

“Proceeding”
means any action, arbitration, audit, examination, investigation, hearing, litigation or suit (whether civil, criminal, administrative,
judicial or investigative, whether formal or informal, and whether public or private) commenced, brought, conducted or heard by
or before, or otherwise involving, any Governmental Authority or arbitrator.

 

“Product”
means any pharmaceutical product containing Compound as an active chemical entity, alone or in combination with one or more other
active ingredients, in any and all forms, presentations, dosages, and formulations.

 

“Registrations”
means (a) Marketing Authorizations, (b) receipt of any license issued by a Governmental Authority required to import Product(s)
into each country in the Territory, and (c) any other license issued by a Governmental Authority or approval which is legally required
to Commercialize the Product in each country of the Territory (e.g., wholesale licenses).

 

“Regulatory
Authority” means the European Medicines Agency or any other Governmental Authority that is a competent authority for
the issuance of any of the Registrations, or any part of them, in any country of the Territory.

 

“Release”
means the release, spill, emission, leaking, pumping, pouring, emptying, escaping, dumping, injection, deposit, disposal, discharge,
dispersal, leaching or migrating of any Hazardous Material into the environment.

 

“Representatives”
means, with respect to a Person, the directors, managers, officers, employees, agents or advisors (including attorneys, accountants,
consultants, bankers and financial advisors) of such Person.

 

“Required
Contracts” means the Contracts listed at Section 1.1(b) of the Seller Disclosure Schedule.

 

“Retention
Payments” means the payments listed at Section 1.1(c) of the Seller Disclosure Schedule.

 

“Reverse Transition
Services Agreement” means a reverse transition services agreement in the form reasonably acceptable to the parties to
this Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	7

     

    

 

“Schedule”
means the Seller Disclosure Schedule or the Purchaser Disclosure Schedule, as the context requires.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“Seller Fundamental
Representations” means those representations and warranties of the Seller set out in Section 3.1(a), Section 3.1(b),
Section 3.2, Section 3.4(a), Section 3.4(b) and Section 3.5.

 

“Seller’s
Group” means the Seller and its Affiliates, but excluding the Acquired Companies.

 

“Seller’s
Group Marks” means any marks or logos that contain Seller’s name “ARIAD,” including but not limited
to, ARIAD, ARIAD PASS, and ARIAD PHARMACEUTICALS and ARIAD with Spiral Design.

 

“Shares”
means all of the issued and outstanding share capital of the Company.

 

“Straddle
Period” means any taxable period that begins before and ends after the Closing Date.

 

“Subsidiary”
means, with respect to a specified Person, any corporation or other Person of which securities or other interests having the power
to elect a majority of that corporation’s or other Person’s board of directors or similar governing body, or otherwise
having the power to direct the business and policies of that corporation or other Person (other than securities or other interests
having such power only upon the happening of a contingency that has not occurred) are held by the specified Person or one or more
of its Subsidiaries. When used in this Agreement without reference to a particular Person, “Subsidiary” means a Subsidiary
of the Company.

 

“Swiss Tax
Authorities” means any taxing or other authority competent to impose any liability in respect of Tax or responsible for
the administration and/or collection of Tax or enforcement of any law in relation to Tax in Switzerland.

 

“Tax”
means (a) any federal, state, local, foreign or other tax, charge, fee, duty (including customs duty), levy or assessment, including
any income, gross receipts, net proceeds, alternative or add-on minimum, corporation, ad valorem, turnover, real property, personal
property (tangible or intangible), sales, use, franchise, excise, value added, stamp, leasing, lease, user, transfer, fuel, excess
profits, profits, occupational, premium, interest equalization, windfall profits, severance, license, registration, payroll, environmental,
capital stock, capital duty, disability, estimated, gains, wealth, welfare, employee’s income withholding, other withholding,
unemployment or social security or other tax of whatever kind (including any fee, assessment or other charges in the nature of
or in lieu of any tax) that is imposed by any Governmental Authority, (b) any interest, fines, penalties or additions resulting
from, attributable to, or incurred in connection with any items described in this paragraph or any related contest or dispute and
(c) any Liability for the Taxes of another Person.

 

“Tax Attributes”
means any net operating loss, net capital loss, investment tax credit, foreign credit, charitable deduction or any other credit
or tax attribute that could be carried forward or back to reduce Taxes (including deductions and credits relating to alternative
minimum Taxes), and any additional items described in Section 381 of the Code without reference to the conditions and limitations
described therein.

 

“Tax Contest”
means an audit, claim, dispute or controversy relating to Taxes.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	8

     

    

 

“Tax Return”
means any report, return, declaration, claim for refund, notice, or information return or statement related to Taxes, including
any schedule or attachment thereto, and including any amendment thereof.

 

“Territory”
means the area within the geographic boundaries as set forth in Exhibit B.

 

“Third Party”
means any Person other than Seller and Purchaser and their respective Affiliates.

 

“Transition
Services Agreement” means a transition services agreement in the form reasonably acceptable to the parties to this Agreement.

 

“US Dollars”
means the lawful currency of the United States as at the date of this Agreement.

 

Section 1.2           Additional
Defined Terms.  For purposes of this Agreement, the following terms have the meanings
specified in the indicated Section of this Agreement:

 

	Defined Term	 	Section
	Adjustment Calculation	 	Section 2.4(a)
	Adjustment Notice	 	Section 2.4(a)
	Affiliate Indemnified Party	 	Section 12.2
	Agreement	 	Preamble
	Antitrust Laws	 	Section 5.3(b)
	ARIAD SWISSCO Balance Sheet	 	Section 3.6(a)(i)
	ARIAD US	 	Preamble
	Audited Consolidated Balance Sheets	 	Section 5.8
	Audited Consolidated Financial Statements	 	Section 5.8
	Carve Out Restructuring	 	Section 5.7
	Claim Notice	 	Section 8.3(a)
	Closing	 	Section 2.5
	Closing Balance Sheet	 	Section 2.4(a)
	Closing Date	 	Section 2.5
	Closing Date Payment	 	Section 2.2
	Closing Net Cash Statement	 	Section 2.4(a)
	Closing Net Working Capital Statement	 	Section 2.4(a)
	Company	 	Preamble
	Company Balance Sheet	 	Section 3.6(a)(ii)
	Company Information	 	Section 12.1(b)
	Company Intellectual Property	 	Section 3.11(a)
	Company Interim Balance Sheet	 	Section 3.6(a)(iii)
	Confidentiality Agreement	 	Section 12.1(a)
	Continuation Period	 	Section 10.1(a)
	Controlling Party	 	Section 8.3(d)
	Dispute Notice	 	Section 2.4(c)(ii)
	Estimated Closing Net Cash	 	Section 2.3(a)
	Estimated Closing Net Working Capital	 	Section 2.3(b)
	FCPA	 	Section 3.18
	Final Closing Net Cash	 	Section 2.4(f)
	Final Closing Net Working Capital	 	Section 2.4(f)
	Financial Statements	 	Section 3.6(a)
	Indemnified Party	 	Section 8.3(a)

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	9

     

    

 

	Indemnifying Party	 	Section 8.3(a)
	Independent Accounting Firm	 	Section 2.4(e)
	Initial Purchase Price	 	Section 2.2
	Leased Real Property	 	Section 3.10(a)
	Material Contracts	 	Section 3.12(a)
	Material Customers	 	Section 3.22(a)
	Non-controlling Party	 	Section 8.3(d)
	Other Consolidated Financial Statements	 	Section 5.8
	Purchase Price	 	Section 2.2
	Purchaser	 	Preamble
	Purchaser Indemnified Parties	 	Section 8.1
	Real Property Leases	 	Section 3.10(a)
	Resolution Period	 	Section 2.4(e)
	Seller	 	Preamble
	Seller Disclosure Schedule	 	Article 3
	Seller Indemnified Parties	 	Section 8.2
	Subsidiary Shares	 	Section 3.4(b)
	Swiss Tax Rulings	 	Section 9.1(a)
	Third Party Claim	 	Section 8.3(b)
	Transferred Employees	 	Section 10.1(a)
	Transferred Former Employees	 	Section 10.1(a)
	Warranted Leased Real Property	 	Section 3.10(b)

 

Section 1.3           Construction.
The language in all parts of this Agreement will be construed, in all cases, according to its fair meaning. Any reference in this
Agreement to an “Article,” “Section,” “Exhibit” or “Schedule” refers to the corresponding
Article, Section, Exhibit or Schedule of or to this Agreement, unless the context indicates otherwise. The table of contents and
the headings of Articles and Sections are provided for convenience only and are not intended to affect the construction or interpretation
of this Agreement. All words used in this Agreement are to be construed to be of such gender or number as the circumstances require.
The words “including,” “includes,” or “include” are to be read as listing non-exclusive examples
of the matters referred to, whether or not words such as “without limitation” or “but not limited to”
are used in each instance. The word “extent” in the phrase “to the extent” means the degree to which a
subject or other thing extends, and such phrase will not mean simply “if”. Where this Agreement states that a party
“shall”, “will” or “must” perform in some manner or otherwise act or omit to act, it means
that the party is legally obligated to do so in accordance with this Agreement. Any reference to a statute is deemed also to refer
to any amendments or successor legislation as in effect at the relevant time. Unless otherwise stated, all references to any agreements
will be deemed to include the Exhibits, schedules and annexes to such agreement. Any reference to a Contract or other document
as of a given date means the Contract or other document as amended, supplemented and modified from time to time through such date.

 

Article
2

THE TRANSACTION

 

Section 2.1           Sale
and Purchase of Shares. In accordance with the provisions of this Agreement, at the Closing, the Seller will sell and transfer
to the Purchaser, and the Purchaser will purchase and acquire from the Seller, all of the Shares, free and clear of all Claims
(other than any restrictions on transferability imposed by applicable securities Laws).

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	10

     

    

 

Section 2.2           Purchase
Price. Subject to the terms and conditions of this Agreement, at the Closing, in consideration for the sale of the Shares,
the Purchaser will pay to the Seller an aggregate amount in cash equal to US Dollars 140,000,000 (the “Initial Purchase
Price”), as adjusted pursuant to Section 2.3 (the “Closing Date Payment”). The Closing Date Payment
is subject to adjustment following the Closing pursuant to Section 2.4. The Initial Purchase Price as adjusted pursuant to Section
2.3 and Section 2.4(f) will be the “Purchase Price”.

 

Section 2.3           Closing
Date Adjustment. 

 

(a)          Estimated
Closing Net Cash. No later than two Business Days prior to the Closing Date, the Seller will provide to the Purchaser an estimate
of the Closing Net Cash (such estimate, the “Estimated Closing Net Cash”). To the extent the Estimated Closing
Net Cash is positive (i.e., the Closing Cash exceeds the Closing Indebtedness), the Purchaser will add the absolute value
of such amount to the Initial Purchase Price paid at the Closing. To the extent the Estimated Closing Net Cash is negative (i.e.,
the Closing Indebtedness exceeds the Closing Cash), the Purchaser will deduct the absolute value of such amount from the Initial
Purchase Price paid at the Closing.

 

(b)          Estimated
Closing Net Working Capital. No later than two Business Days prior to the Closing Date, the Seller will provide to the Purchaser
an estimate of the Closing Net Working Capital (the “Estimated Closing Net Working Capital”). If the Estimated
Closing Net Working Capital is greater than zero, the Purchaser will add the absolute value of the excess to the Initial Purchase
Price paid at the Closing. If the Estimated Closing Net Working Capital is less than zero, the Purchaser will deduct the absolute
value of the shortfall from the Initial Purchase Price paid at the Closing.

 

Section 2.4           Post-Closing
Adjustment. 

 

(a)          Within
45 days after the Closing Date, the Purchaser will prepare and deliver to the Seller a written notice (the “Adjustment
Notice”) containing (i) an unaudited consolidated balance sheet of the Acquired Companies as at immediately prior to
the Closing (the “Closing Balance Sheet”), (ii) the Purchaser’s calculation of the Closing Net Working
Capital based on the Closing Balance Sheet (the “Closing Net Working Capital Statement”), (iii) the Purchaser’s
calculation of Closing Net Cash based on the Closing Balance Sheet (the “Closing Net Cash Statement”) and (iv)
the Purchaser’s calculation of the amount of any payments required pursuant to Section 2.4(g) (the “Adjustment Calculation”).
The Closing Balance Sheet, the Closing Net Working Capital Statement and the Closing Net Cash Statement will be prepared in accordance
with GAAP applied in a manner consistent with the methods and practices used to prepare the Company Interim Balance Sheet.

 

(b)          During
the preparation of the Adjustment Notice, at the Purchaser’s request, the Seller will, and will cause each of the Acquired
Companies to, (i) provide the Purchaser and the Purchaser’s Representatives with reasonable access to the books, records,
facilities and Employees of the Acquired Companies to the extent not otherwise already acquired as of the Closing Date, (ii) provide
the Purchaser, within ten Business Days after the Closing Date, with normal month-end closing financial information for the period
ending as of the close of business on the Closing Date and (iii) reasonably cooperate with the Purchaser and the Purchaser’s
Representatives, including by providing on a timely basis all information reasonably necessary or useful in preparing the Adjustment
Notice and any other information reasonably requested by the Purchaser. Following delivery of the Adjustment Notice, at the Seller’s
request, the Purchaser (i) shall reasonably cooperate and assist, and shall cause its Representatives to assist, the Seller
and its Representatives in the review of the Adjustment Notice and (ii) shall provide the Seller and its Representatives with
any information reasonably requested by them.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	11

     

    

 

(c)          Within
30 days after delivery of the Adjustment Notice, the Seller will either:

 

(i)          agree
in writing with the Adjustment Calculation, in which case such calculation will be final and binding on the parties for purposes
of Section 2.4(g); or

 

(ii)         dispute
the Adjustment Calculation by delivering to the Purchaser a written notice (a “Dispute Notice”) which shall
specify which items are being disputed and set forth in reasonable detail the basis for each disputed item therein.

 

(d)          If
the Seller fails to take either of the foregoing actions within 30 days after delivery of the Adjustment Notice, then the Seller
will be deemed to have irrevocably accepted the Adjustment Calculation, in which case, the Adjustment Calculation will be final
and binding on the parties for purposes of Section 2.4(g).

 

(e)          If
the Seller timely delivers a Dispute Notice to the Purchaser, then the Purchaser and the Seller will attempt in good faith, for
a period of 30 days following the Purchaser’s receipt of such Dispute Notice (the “Resolution Period”),
to agree on the Adjustment Calculation for purposes of Section 2.4(g). Any resolution by the Purchaser and the Seller memorialized
in writing and signed by both the Purchaser and the Seller during the Resolution Period as to any disputed items set forth in such
Dispute Notice will be final and binding on the parties for purposes of Section 2.4(g). If the Purchaser and the Seller do not
resolve all disputed items by the end of the Resolution Period, then the Purchaser and the Seller will submit the remaining items
in dispute to PricewaterhouseCoopers LLP for resolution, or if that firm is unwilling or unable to serve, the Purchaser and the
Seller will engage another mutually agreeable independent accounting firm of recognized international standing, which firm is not
the regular auditing firm of the Purchaser or the Acquired Companies. If the Purchaser and the Seller are unable to jointly select
such independent accounting firm within 10 days after the Resolution Period, the Purchaser, on the one hand, and the Seller, on
the other hand, will each select an independent accounting firm of recognized international standing and such selected accounting
firms will select a third independent accounting firm of recognized international standing, which firm is not the regular auditing
firm of the Purchaser or the Acquired Companies; provided, however, that if either the Purchaser, on the one hand,
or the Seller, on the other hand, fails to select such independent accounting firm during this 10-day period, then the parties
agree that the independent accounting firm selected by the other party will be the independent accounting firm selected by the
parties for purposes of this Section 2.4 (such selected independent accounting firm, whether pursuant to this sentence or the preceding
sentence, the “Independent Accounting Firm”).

 

(i)          The
Independent Accounting Firm will (A) act as an expert in accounting, and not as an arbitrator, to resolve only those items specifically
set forth on a timely delivered Dispute Notice that remain in dispute as of such time, and that have not been deemed pursuant to
Section 2.4(c), Section 2.4(d) or Section 2.4(e) to be final and binding on the Parties, (B) render its determination in accordance
with this Agreement and otherwise in accordance with GAAP applied in a manner consistent with the methods and practices used to
prepare the Company Interim Balance Sheet, (C) not determine an Adjustment Calculation that would result in a Purchase Price (1)
in excess of the applicable amount in the Adjustment Notice or (2) that is less than the applicable amount in the Dispute Notice
and (D) render its determination with respect to the items in dispute in a written report that specifies the conclusions of the
Independent Accounting Firm as to each item in dispute and the resulting Adjustment Calculation. The Independent Accounting Firm
will only render its determination with respect to the specific remaining accounting differences submitted to it and may rely only
upon information submitted to it by or on behalf of the Purchaser or the Seller. The Purchaser and the Seller will each use their
commercially reasonable efforts to cause the Independent Accounting Firm to render its

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	12

     

    

 

determination
within 30 days after referral of the disputed items on a timely delivered Dispute Notice to such firm or as soon thereafter as
reasonably practicable. The decision of the Independent Accounting Firm will be final, conclusive and binding on the Parties and
will not be subject to appeal or further review. The costs and expenses of the Independent Accounting Firm will be allocated between
the Parties based upon the percentage which the portion of the contested amount not awarded to each party bears to the amount actually
contested by such party, as determined by the Independent Accounting Firm. The Buyer and the Representative agree to execute, if
requested by the Independent Accounting Firm, a reasonable engagement letter, including customary indemnities in favor of the Independent
Accounting Firm.

 

(ii)         For
purposes of complying with this Section 2.4, the Purchaser and the Seller will furnish to the Independent Accounting Firm
such work papers and other documents and information relating to the disputed items on a timely delivered Dispute Notice as the
Independent Accounting Firm may reasonably request and are available to that party (or its Representatives). A copy of any such
work papers and other documents and information provided by a party to the Independent Accounting Firm will be provided concurrently
to the other party free of charge. Each party will be afforded the opportunity to present to the Independent Accounting Firm any
material related to the disputed items on a timely delivered Dispute Notice and to discuss such items with the Independent Accounting
Firm, with any such presentation or discussion to be held in the presence of both the Purchaser and the Seller and/or their respective
Representatives.

 

Notwithstanding anything
herein to the contrary, the dispute resolution mechanism contained in this Section 2.4(e) will be the exclusive mechanism for resolving
any disputes regarding the Adjustment Calculation.

 

(f)          The
“Final Closing Net Working Capital” will be the calculation of the Closing Net Working Capital contained in
the Closing Net Working Capital Statement, as adjusted pursuant to the mutual agreement of the Seller and the Purchaser, or as
adjusted by the Independent Accounting Firm, in each case, pursuant to Section 2.4(e), together with any other modifications to
the Closing Net Working Capital Statement mutually agreed upon by the Seller and the Purchaser. The “Final Closing Net
Cash” will be the calculation of the Closing Net Cash contained in the Closing Net Cash Statement, as adjusted pursuant
to the mutual agreement of the Seller and the Purchaser, or as adjusted by the Independent Accounting Firm, in each case, pursuant
to Section 2.4(e), together with any other modifications to the Closing Net Cash Statement mutually agreed upon by the Seller and
Purchaser.

 

(g)          If
the Final Closing Net Working Capital is less than the Estimated Closing Net Working Capital, then the Seller will pay to the Purchaser
the absolute value of such difference in cash in accordance with Section 2.4(h). If the Final Closing Net Working Capital is greater
than the Estimated Closing Net Working Capital, then the Purchaser will pay to the Seller the absolute value of such difference
in cash in accordance with Section 2.4(h). If the Final Closing Net Cash is less than the Estimated Closing Net Cash, then the
Seller will pay to the Purchaser the absolute value of such difference in cash in accordance with Section 2.4(h). If the Final
Closing Net Cash is greater than the Estimated Closing Net Cash, then the Purchaser will pay to the Seller the absolute value of
such difference in accordance with Section 2.4(h).

 

(h)          Any
amounts due and payable by one party to the other pursuant to Section 2.4(g) will be paid to the applicable party by means of a
wire transfer of immediately available funds in US Dollars within three Business Days after the determination of the Final Closing
Net Working Capital and the Final Closing Net Cash, as applicable, pursuant to Section 2.4(f).

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	13

     

    

 

(i)          Notwithstanding
anything to the contrary set forth in this Agreement, in no event will the Seller be obligated to indemnify any Purchaser Indemnified
Party for any Loss as a result of, based upon or arising from, any Liability to the extent such Liability is reflected in the calculation
of the Final Closing Net Working Capital or the Final Closing Net Cash as determined pursuant to Section 2.4(f). Any payment made
pursuant to this Section 2.4 will be treated by the Parties for all purposes as an adjustment to the Initial Purchase Price and
will not be subject to offset for any reason.

 

Section 2.5           Closing.
The closing of the transactions contemplated by this Agreement (the “Closing”) will take place at the offices
of Baker & McKenzie LLP, 300 East Randolph Street, Suite 5000, Chicago, Illinois, 60601, at 10:00 a.m., local time, as soon
as practicable, but in any event not later than the third Business Day immediately following the date on which the last of the
conditions set forth in Article 6 has been satisfied or waived (other than those conditions that by their nature can only be satisfied
at the Closing), or at such other time and place as the Seller and the Purchaser may agree in writing; provided, however,
that in no event with the Closing occur prior to June 1, 2016. The date on which the Closing actually occurs is referred to in
this Agreement as the “Closing Date.”

 

Section 2.6           Closing
Deliveries.  

 

(a)          At
the Closing, the Seller will deliver or cause to be delivered to the Purchaser:

 

(i)          written
resolutions or copies of the minutes of the meeting of the Board of Directors of each of the Company and the Seller approving the
transfer of the Shares;

 

(ii)         a
certificate or certificates representing the Shares, duly endorsed or accompanied by a stock power duly endorsed in blank and with
all required stock transfer tax stamps affixed, together with such other documents and instruments necessary to vest in the Purchaser
all of the Seller’s right, title and interest in and to the Shares;

 

(iii)        a
short form acceptance letter signed by the Company approving the transfer of its shares;

 

(iv)        a
certificate, dated as of the Closing Date, executed by the Seller confirming the satisfaction of the conditions specified in Section
6.2(a) and Section 6.2(b);

 

(v)         the
Ancillary Agreements to which the Seller or its Affiliates are a party, duly executed by the Seller or the applicable Affiliate
of the Seller; and

 

(vi)        resignations
effective as of the Closing Date of each director and officer of each Acquired Company as the Purchaser may have requested in writing
within ten (10) Business Days prior to the Closing Date.

 

(b)          At
the Closing, the Purchaser will deliver or cause to be delivered to the Seller:

 

(i)          the
Closing Date Payment by wire transfer of immediately available funds in US Dollars to the account or accounts specified by the
Seller;

 

(ii)         a
certificate, dated as of the Closing Date, executed by the Purchaser confirming the satisfaction of the conditions specified in
Section 6.3(a) and Section 6.3(b); and

 

(iii)        the
Ancillary Agreements to which the Purchaser or its Affiliates are a party executed by the Purchaser or the applicable Affiliate
of the Purchaser.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	14

     

    

 

Article
3

REPRESENTATIONS AND WARRANTIES OF THE SELLER

 

The Seller represents
and warrants to the Purchaser that all of the statements contained in this Article 3 are true and correct as of the date hereof
and as of the Closing Date or, if made as of a specific date, as of such date, subject to such exceptions as are specifically set
forth in the Seller disclosure schedule to this Agreement (the “Seller Disclosure Schedule”) supplied by the
Seller to the Purchaser on the date hereof:

 

Section 3.1           Organization
and Good Standing.

 

(a)          The
Seller is an Exempted Limited Partnership duly registered and validly existing under the Laws of the Cayman Islands. ARIAD US is
a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 

(b)          Each
Acquired Company is a corporation, limited liability company or other legal entity duly organized, validly existing and in good
standing (to the extent such concepts are recognized under applicable Law) under the Laws of the jurisdiction of its formation
and has all requisite corporate, limited liability company or similar power and authority to conduct its business as presently
conducted. Each Acquired Company is duly qualified to do business and is in good standing (to the extent such concepts are recognized
under applicable Law) as a foreign corporation, limited liability company or otherwise in each jurisdiction in which the nature
of its activities requires such qualification, except where the failure to so qualify would not have a Material Adverse Effect.

 

(c)          The
Seller has delivered to the Purchaser a complete and accurate copy of the Organizational Documents for each Acquired Company as
in effect on the date hereof and no Acquired Company is in breach or violation of or default under its Organizational Documents.
The Books and Records of each Acquired Company accurately reflect in all material respects and in a manner consistent with the
historical practices of the Acquired Companies the material actions taken by written consent or resolution and meetings held by
their respective voting equityholders and directors (or equivalent governing bodies), as the case may be, and copies of such material
actions taken by written consent or resolutions and meetings have been made available to the Purchaser.

 

(d)          ARIAD
Pharmaceuticals (Canada) ULC is a non-operating company, and it owns no assets or holds any Liabilities.

 

Section 3.2           Authority
and Enforceability. Each of the Seller and ARIAD US has all requisite corporate power and authority to execute and deliver
this Agreement and each Ancillary Agreement to which it is a party and to perform its obligations under this Agreement and each
such Ancillary Agreement. The execution, delivery and performance of this Agreement and each Ancillary Agreement to which the
Seller or ARIAD US is a party and the consummation of the transactions contemplated hereby and thereby by the Seller and ARIAD
US have been duly authorized by all necessary action on the part of the Seller and ARIAD US. Each of the Seller and ARIAD US has
duly and validly executed and delivered this Agreement and, on or prior to the Closing, each of the Seller and ARIAD US will have
duly and validly executed and delivered each Ancillary Agreement to which it is a party. Assuming the due authorization, execution
and delivery of this Agreement and the Ancillary Agreements by the Purchaser, Incyte US and the other parties thereto, this Agreement
constitutes, and at the Closing each Ancillary Agreement to which the Seller or ARIAD US is a party will constitute, the valid
and binding obligation of the Seller or ARIAD US, as applicable, enforceable against the Seller or ARIAD US, as applicable, in
accordance with its terms, subject to (a) Laws of general application relating to bankruptcy, insolvency

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	15

     

    

 

and the relief of debtors
and (b) Laws governing specific performance, injunctive relief and other equitable remedies.

 

Section 3.3           No
Conflict. Except for the requirements of any Antitrust Law (if applicable), and except in any case that would not have a Material
Adverse Effect, neither the execution, delivery and performance by the Seller or ARIAD US of this Agreement and any Ancillary
Agreement to which it is a party, nor the consummation of the transactions contemplated by this Agreement, will (a) conflict with
or violate the Organizational Documents of any of the Acquired Companies, (b) result in a breach or default under, or create in
any Person the right to terminate, cancel, accelerate or modify, or require any notice, consent or waiver under, any Material
Contract (with or without due notice or lapse of time or both), (c) violate any Law or Judgment applicable to any of the Acquired
Companies, (d) require any of the Acquired Companies to obtain any Governmental Authorization or make any filing with any Governmental
Authority, (e) result in the creation of any Claims upon the Shares or the Subsidiary Shares or (f) result in the imposition of
any Lien or other Encumbrance on any of the assets of the Acquired Companies.

 

Section 3.4           Capitalization
and Ownership.

 

(a)          The
share capital (or equivalent) of the Acquired Companies, the number of shares (or equivalent equity interest) and the beneficial
and record ownership thereof, is set forth in Section 3.4(a) of the Seller Disclosure Schedule. Except as set forth in Section
3.4(a) of the Seller Disclosure Schedule, the Seller is the sole record holder and beneficial owner of all of the Shares, free
and clear of all Claims. Upon payment in full of the Purchase Price, good and valid title to the Shares will pass to the Purchaser,
free and clear of any Claims (other than any restrictions or transferability imposed by applicable securities Laws), and with no
restrictions on the voting rights or other incidents of record and beneficial ownership of such Shares. All of the Shares are duly
authorized, validly issued, fully paid and nonassessable and were issued in compliance with all applicable Laws.

 

(b)          Section
3.4(b) of the Seller Disclosure Schedule sets forth for all Acquired Companies (a) its name and jurisdiction of incorporation,
(b) its authorized share capital (or equivalent) and (c) the number of issued and outstanding shares of share capital (or equivalent)
and the record holders and beneficial owners thereof. No Acquired Company owns or has any rights to acquire, directly or indirectly,
any capital stock or other equity interests of any Person, except for the Subsidiaries set forth in Section 3.4 of the Seller Disclosure
Schedule. All of the issued and outstanding equity securities of each Subsidiary of the Company (the “Subsidiary Shares”)
are duly authorized, validly issued, fully paid and nonassessable, and are owned of record and beneficially by one or more of the
Acquired Companies in the respective amounts set forth in Section 3.4(b) of the Seller Disclosure Schedule.

 

(c)          There
are no Contracts to which either the Seller or any other Person is a party or bound with respect to the voting (including voting
trusts or proxies) of the Shares or the Subsidiary Shares. Other than the Shares and the Subsidiary Shares, there are no outstanding
or authorized shares of capital stock, options, warrants, rights or Contracts to which any Acquired Company is a party or which
are binding upon any Acquired Company obligating any Acquired Company to (i) issue, deliver, grant or sell, or cause to be issued,
delivered, granted or sold, additional shares of capital stock of, or other equity or voting interests in, or options, warrants
or other securities or subscription, preemptive or other rights convertible into, or exchangeable or exercisable for, shares of
capital stock of, or other equity or voting interests in, any Acquired Company, or any “phantom stock” right, stock
appreciation right or other similar right with respect to any Acquired Company, (ii) repurchase, redeem or otherwise acquire any
shares of capital stock of, or other equity or voting interests in any Acquired Company or (iii) to enter into any Contract with
respect to (i) or (ii).

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	16

     

    

 

(d)          Upon
consummation of the transactions contemplated by this Agreement, the Purchaser will own all of the issued and outstanding capital
stock of the Company, free and clear of all Claims.

 

Section 3.5           Brokers
Fees.  Neither the Seller nor any Acquired Company has any Liability to pay any
fees or commissions to any broker, finder or agent in connection with any of the transactions contemplated by this Agreement or
any Ancillary Agreement to which the Purchaser would become liable or obligated or for which any Acquired Company, after the Closing
Date, will have any continuing obligation.

 

Section 3.6           Financial
Statements.  

 

(a)          Attached
as Section 3.6 of the Seller Disclosure Schedule are the following:

 

(i)          an
audited balance sheet of ARIAD SWISSCO as of December 31, 2015 (the “ARIAD SWISSCO Balance Sheet”) and the related
audited statement of income for the years then ended, including any notes thereto, together with the report thereon of Deloitte,
independent certified public accountants;

 

(ii)         an
unaudited consolidated balance sheet of the Company as of December 31, 2015 and the related unaudited consolidated statement of
income for the years then ended (the “Company Balance Sheet”);

 

(iii)        an
unaudited consolidated balance sheet of the Company as of March 31, 2016 (the “Company Interim Balance Sheet”)
and the related unaudited consolidated statement of income for the year-to-date period then ended; and

 

(collectively
(i), (ii) and (iii) the “Financial Statements”)

 

(iv)        a
reconciliation between the ARIAD SWISSCO Balance Sheet and the related statement of income under Swiss generally accepted accounting
principles to GAAP.

 

(b)          The
Financial Statements fairly present in all material respects the financial condition and results of operations of the Acquired
Companies as of the respective dates thereof and for the periods indicated therein, in accordance with Swiss generally accepted
accounting principles with respect to the ARIAD SWISSCO Balance Sheet and in accordance with GAAP with respect to the Company Balance
Sheet and the Company Interim Balance Sheet (except that the Company Interim Balance Sheet is subject to normal year-end adjustments
and does not contain all footnotes or other presentation items as required by GAAP).

 

(c)          The
Seller maintains a system of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange
Act) sufficient to provide reasonable assurance (i) that transactions of the Acquired Companies are made in accordance with management’s
authorization, (ii) that transactions of the Acquired Companies are recorded as necessary to permit the preparation of Seller’s
consolidated financial statements in conformity with GAAP and (iii) regarding prevention or timely detection of the unauthorized
acquisition, use or disposition of the properties or assets of the Acquired Companies.

 

Section 3.7           No
Undisclosed Liabilities. No Acquired Company has any Liabilities as of the date of this Agreement that would be required to
be reflected on a consolidated balance sheet prepared in accordance with GAAP except for (a) Liabilities reflected, reserved against
or otherwise disclosed in the Financial Statements, (b) Liabilities arising in the ordinary course of business consistent with
past

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	17

     

    

 

practice after the date
of the Company Interim Balance Sheet, (c) Liabilities disclosed herein or in the Seller Disclosure Schedule, including Section
3.7 of the Seller Disclosure Schedule or (d) Liabilities in an amount that do not exceed US Dollars 500,000 in the aggregate.

 

Section 3.8           Absence
of Certain Changes and Events. From the date of the ARIAD SWISSCO Balance Sheet to the date of this Agreement, the Acquired
Companies have operated their business in the ordinary course of business and there has not been with respect to any Acquired
Company any:

 

(a)          amendment
to its Organizational Documents;

 

(b)          change
in its authorized or issued share capital (or equivalent), declaration, setting aside or payment of a dividend or other distribution
(whether in cash, stock or property) in respect of any share capital (or equivalent), or issuance, sale, grant, repurchase or redemption
of any shares of its share capital (or equivalent) or any securities convertible, exchangeable or redeemable for, or any options,
warrants or other rights to acquire, any such securities;

 

(c)          incurrence
of any Indebtedness in amounts in excess of US Dollars 50,000 individually or US Dollars 500,000 in the aggregate, that would be
outstanding immediately following the Closing;

 

(d)          sale,
lease, license or transfer of, or Encumbrance on, any material portion of its assets other than in the ordinary course of business;

 

(e)          damage
to, or destruction or loss of, any of material asset of the Acquired Company not covered by insurance;

 

(f)          except
as required by Law, adoption of, material amendment to or material increase in the payments to or benefits under, any Company Plan;

 

(g)          waiver
or release of any material right or claim other than in the ordinary course of business;

 

(h)          change
in the accounting methods used by the Acquired Companies;

 

(i)          making
or rescission of any Tax election, settlement or compromise of any Tax Liability or amendment of any Tax Return;

 

(j)          payment,
discharge or satisfaction of any claim, liability or obligation (absolute, accrued, asserted or unasserted, contingent or otherwise
of the Acquired Company), other than payments, discharges or satisfactions in the ordinary course of business of Liabilities or
arising in the ordinary course of business since the date of the ARIAD SWISSCO Balance Sheet;

 

(k)          revaluation
by the Acquired Company of any of its assets (whether tangible or intangible), including writing down the value of inventory or
writing off notes or accounts receivable;

 

(l)          loan
by the Acquired Company to any Person, or purchase by the Acquired Company of any debt securities of any Person, except for advances
to Employees for travel and business expenses in the ordinary course of business; or

 

(m)          agreement
in writing by any Acquired Company to do any of the foregoing.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	18

     

    

 

Section 3.9           Tangible
Personal Property.

 

(a)          The
Acquired Companies, as applicable, have good and marketable title to, or in the case of leased assets, valid leasehold interests
in, all of their tangible personal property, free and clear of all Encumbrances except as set forth in Section 3.9(a) of the Seller
Disclosure Schedule.

 

(b)          Section
3.9(b) of the Seller Disclosure Letter sets forth an accurate and complete list of leases of personal property or equipment having
a value in excess of US Dollars 50,000.

 

Section 3.10         Leased
Real Property.

 

(a)          Section
3.10 of the Seller Disclosure Schedule sets forth an accurate and complete description (by street address of the subject leased
real property, the date and term of the lease, the name of the parties thereto and the aggregate annual rent payable thereunder)
of all real property that is leased by any Acquired Company (the “Leased Real Property”). The Seller has made
available to the Purchaser complete copies of the leases in effect as of the date hereof relating to the Leased Real Property (the
“Real Property Leases”) and there has not been any sublease or assignment entered into by any Acquired Company
in respect of the leases relating to such Leased Real Property. No Acquired Company is in default of any material provision of
any lease of any of the Leased Real Property.

 

(b)          Each
applicable Acquired Company has peaceful, undisturbed and exclusive possession of the Leased Real Property at Section 3.10(b) of
the Seller Disclosure Schedule (the “Warranted Leased Real Property”), and no Acquired Company has assigned
(collaterally or otherwise) or granted any other security interest in the Warranted Real Property Leases or any interest therein,
and there are no Liens on the estate or interest created by the Warranted Real Property Leases. The full amount of security deposit
required under each lease of Warranted Leased Real Property, if any, is on deposit thereunder.

 

(c)          The
use of the Warranted Leased Real Property, or any portion thereof, and the improvements erected thereon, do not violate or conflict
in any material respect with (i) any Law, Permit, covenants, conditions or restrictions applicable thereto; or (ii) the terms and
provisions of any Contract relating thereto.

 

(d)          Except
in any case that would not reasonably be expected to be material to the business of the Acquired Companies, take as a whole, (i)
there is no pending, or to the Knowledge of the Seller, threatened, appropriation, condemnation or like Proceeding affecting the
Warranted Leased Real Property or any part thereof; and (ii) no Acquired Company has received written notice that is in violation
of any applicable zoning law, regulation or other applicable Law, related to or affecting the Warranted Leased Real Property.

 

(e)          The
Warranted Leased Real Property is in good operating condition and repair and is suitable for the conduct of the Acquired Companies’
business as presently conducted therein, except where the failure of the property to be in good operating condition would not have
a Material Adverse Effect.

 

(f)          No
Person other than an Acquired Company is in possession of the Warranted Leased Real Property or any portion thereof, and there
are no leases, licenses, subleases, concessions or other Contracts, written or oral, granting to any other Person the right to
use or occupy the Warranted Leased Real Property or any portion thereof.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	19

     

    

 

Section 3.11         Intellectual
Property.

 

(a)          The
Acquired Companies own all rights, title and interest in, or otherwise have the right to use, make, have made, sell, have sold,
develop, commercialize and import the Compound and Product under all Intellectual Property used in the operation of their business
as presently conducted (the “Company Intellectual Property”), except where the failure to own or have the right
to use such Company Intellectual Property would not have a Material Adverse Effect.

 

(b)          To
the Seller’s Knowledge, the claims of the issued patents listed in Section 3.11(b) of the Seller Disclosure Schedule are
not invalid and the issued patents included in Section 3.11(b) of the Seller Disclosure Schedule are not unenforceable in the Territory.
No Third Party has challenged in writing, or, to the Company’s Knowledge, has threatened to challenge, the enforceability
or validity of any issued patents included in Section 3.11(b) of the Seller Disclosure Schedule or any claims therein, respectively
in the Territory through the institution of legal proceedings in a court or through revocation, opposition, interference, reexamination,
nullity or similar invalidity proceedings before a patent office or any equivalent entity in the Territory. To the Seller’s
Knowledge, no Third Party is infringing the patents listed in Section 3.11(b) of the Seller Disclosure Schedule.

 

(c)          No
Third Party has challenged in writing, or, to the Seller’s Knowledge, has threatened to challenge, the Company’s right
to use and license the trademarks listed in Section 3.11(c) of the Seller Disclosure Schedule in the Territory.

 

(d)          There
are no claims asserted in writing, Judgments, or settlements in effect against, or amounts with respect thereto owed by, the Acquired
Companies relating to the patents listed in Section 3.11(b) of the Seller Disclosure Schedule in the Territory. No claim or litigation
is pending or, to the Seller’s Knowledge, threatened alleging that the manufacture, development, use or sale of the Product
in the Territory as of the date of this Agreement infringes or would infringe any issued patent in the Territory existing as of
the date of this Agreement.

 

(e)          The
patents listed in Section 3.11(b) of the Seller Disclosure Schedule have been filed and maintained, and are being diligently prosecuted,
in the respective patent offices where filed in the Territory in accordance with applicable Laws. All applicable and material fees
that are finally due prior to the date of this Agreement in connection with the prosecution and maintenance of the patents listed
in Section 3.11(b) of the Seller Disclosure Schedule in the Territory have been paid.

 

(f)          Section
3.11(f) of the Seller Disclosure Schedule lists each written Contract under which any of Seller, ARIAD US or Acquired Company has
granted a license to a Third Party to, make, have made, sell, have sold, develop, commercialize and import the Compound and Product
in the Territory under the Intellectual Property of the Seller, ARIAD US or any Acquired Company.

 

This Section 3.11
constitutes the sole and exclusive representations and warranties of the Seller with respect to any matters relating to Intellectual
Property.

 

Section 3.12         Contracts.
 

 

(a)          Section
3.12(a) of the Seller Disclosure Schedule sets forth an accurate and complete list as of the date hereof of each Contract to which
any Acquired Company is a party, which:

 

(i)          is
an executory Contract for the purchase or sale of materials, supplies, goods, equipment or services that involves the payment by
or to any Acquired Company of more than US Dollars 250,000 in any twelve (12) month period;

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	20

     

    

 

(ii)         is
for capital expenditures in excess of US Dollars 250,000;

 

(iii)        is
a mortgage, indenture, guarantee, loan or credit agreement, security agreement or other Contract relating to indebtedness for borrowed
money, other than accounts receivables and payables in the ordinary course of business;

 

(iv)        is
a written Contract under which any Acquired Company has granted to or received from a Third Party a license to use, make, have
made, sell, have sold, develop, commercialize and import the Compound and Product under the Intellectual Property of such Acquired
Company or Third Party (except for any license implied by the sale of a product, licenses for use of Trademarks in marketing or
promotional materials and licenses for commonly available software programs with a value of less than US Dollars 250,000);

 

(v)         is
a Contract that limits or purports to limit the ability of the Acquired Companies to compete in any line of business or with any
Person or in any geographic area;

 

(vi)        is
a written Contract with a Transferred Employee that provides for payments in excess of US Dollars 250,000 per annum (excluding
any Contract that does not provide severance or termination payments);

 

(vii)       is
a lease of personal property or equipment having a value in excess of US Dollars 100,000; or

 

(viii)      is
an agreement of indemnification or guaranty, but excluding agreements of indemnification or guaranty that are contained in the
Company’s written Contracts with its customers, suppliers and service providers that have been entered into in the ordinary
course of business.

 

The Contracts listed
in Section 3.12(a) of the Seller Disclosure Schedule are referred to in this Agreement as the “Material Contracts.”

 

(b)          The
Seller has made available to the Purchaser an accurate and complete copy of each Material Contract. With respect to each such Material
Contract, neither any Acquired Company party to the Material Contract, nor, to the Seller’s Knowledge, any other party to
the Material Contract is in breach or default under the Material Contract, except for such breaches or defaults as to which requisite
waivers or consents have been obtained or which would not have a Material Adverse Effect. Each Material Contract is enforceable
as to the applicable Acquired Company party thereto in accordance with its terms except to the extent it has previously expired
in accordance with its terms and subject to (i) Laws of general application relating to bankruptcy, insolvency and the relief of
debtors, and (ii) rules of Law governing specific performance, injunctive relief and other equitable remedies. To the Seller’s
Knowledge, no party to a Material Contract intends to terminate such Material Contract with the applicable Acquired Company party
thereto.

 

Section 3.13         Tax
Matters.

 

(a)          (i)
All material Tax Returns required to be filed by the Acquired Companies have been timely filed, (ii) all Taxes shown on such Tax
Returns have been paid, (iii) no Governmental Authority has proposed formally in writing to make or has made any material adjustment
with respect to such Tax Returns, (iv) no Acquired Company has any Liability for any Tax obligation of any other taxpayer (including
any Affiliated Group), including any obligation under any Tax sharing agreement or under

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	21

     

    

 

Section 1.1502-6 of the
Treasury Regulations or any similar provision of any Law, (v) no Section 280G (or similar foreign tax provision) will be triggered
by the transactions contemplated by this Agreement, (vi) any unpaid Taxes do not exceed the reserves for Taxes as set forth in
the Company Interim Balance Sheet, and (vii) the Acquired Companies have no Tax liens. The Seller has made available to the Purchaser
accurate and complete copies of all Tax Returns filed by the Acquired Companies for the years ended December 31, 2014, and December
31, 2013.

 

(b)          All
Taxes that each Acquired Company is required by Law to withhold or collect have been properly withheld or collected, and, to the
extent required by applicable Law, have been paid over to the proper Governmental Authority.

 

(c)          To
the Seller’s Knowledge, no federal, state, local or foreign Tax Contests or other Proceedings are pending or being conducted,
nor has any Acquired Company received any written notice from any Governmental Authority that any such Tax Contest or other Proceeding
is pending, threatened or contemplated. No Acquired Company has waived any statute of limitations with respect to Taxes or agreed
to an extension of time with respect to a Tax assessment or deficiency affecting the Acquired Company, which waiver or extension
of time is currently outstanding.

 

This Section 3.13
constitutes the sole and exclusive representations and warranties of the Seller with respect to any matters relating to Taxes.

 

Section 3.14         Employee
Benefit Matters.  

 

(a)          Section
3.14(a) of the Seller Disclosure Schedule sets forth an accurate and complete list of all Company Plans.

 

(b)          The
Seller has made available to the Purchaser an accurate, up-to-date and complete copy of each Company Plan that has been reduced
to writing.

 

(c)          The
Acquired Companies have performed all of their obligations under each Company Plan in all material respects in accordance with
the terms of such Company Plan. The Acquired Companies have complied with all obligations under applicable Law to inform and consult
the Transferred Employees or their representatives about the transaction contemplated in this Agreement.

 

(d)          Section
3.14(d) of the Seller Disclosure Schedule sets forth an accurate and complete list of: (i) any employment, severance and change
of control agreement with any Transferred Employee the benefits of which are contingent upon the occurrence of a transaction involving
the Company of the nature of the transactions contemplated by this Agreement (either alone or upon termination of employment following
such transactions); and (ii) any agreement or plan binding upon any Acquired Company, including, any Company Plan, any of the benefits
of which will be increased, or the vesting of the benefits of which will be accelerated, by the consummation of the transactions
contemplated by this Agreement (either alone or upon the termination of employment following such transactions).

 

This Section 3.14
constitutes the sole and exclusive representations and warranties of the Seller with respect to any matters relating to Employee
Benefit Matters.

 

Section 3.15         Employment
and Labor Matters.

 

(a)          Except
as set forth in Section 3.15 of the Seller Disclosure Schedule, no Acquired Company is a party to or bound by any collective bargaining
agreement, works council agreement or any

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	22

     

    

 

other agreement with
a body representing any or all of the Transferred Employees and, to the Seller’s Knowledge, no petition has been filed or
Proceedings instituted by any Transferred Employee or group of Transferred Employees of any Acquired Company seeking recognition
of a bargaining representative or other works council agreement or any other agreement with a body representing any or all of the
Transferred Employees. There is no labor strike, picketing, slowdown, lockout, or other work stoppage or labor dispute pending
or, to the Seller’s Knowledge, threatened between any Acquired Company, on the one hand, and any of its Transferred Employees,
on the other hand, except for such disputes with individual Transferred Employees arising in the ordinary course of business.

 

(b)          The
Acquired Companies are in compliance in all material respects with all applicable Laws pertaining to the employment of their Transferred
Employees, including all such Laws relating to equal employment opportunities, prohibited discrimination and other similar employment
activities. Section 3.15 of the Seller Disclosure Schedule sets forth an accurate and complete list (as at the date of this Agreement)
of all Transferred Employees of any Acquired Company, together with their salary, job title, notice period, benefits, start date
of employment and role and place of work. There has been no material change to such compensation or benefits during the 120 days
preceding the date of this Agreement. The Seller has provided to the Purchaser an accurate and complete list (as at the date of
this Agreement) of all equity awards granted to Transferred Employees.

 

(c)          Section
3.15(c) of the Seller Disclosure Schedule sets forth an accurate and complete list as of the date hereof of each Contract providing
for the grant of any severance or termination pay or benefits (in cash or otherwise) to any Transferred Employee (in excess of
a payment in respect of their notice period or any severance payment required by Law).

 

This Section 3.15
constitutes the sole and exclusive representations and warranties of the Seller with respect to any matters relating to Employment
and Labor Matters.

 

Section 3.16         Environmental,
Health and Safety Matters. The Acquired Companies are in compliance in all material respects with (a) all Environmental Laws
applicable to the conduct of their business as presently conducted and the occupancy of the Warranted Leased Real Property as
presently occupied and (b) all Governmental Authorizations required of the Acquired Companies under Environmental Laws to conduct
their business as presently conducted or to occupy the Warranted Leased Real Property as presently occupied. No Acquired Company
has received any written notice stating that the conduct of its business or the condition of any of its Warranted Leased Real
Property is currently in violation of any Environmental Law (including, to the Seller’s Knowledge, any claim or complaint
from any Employee alleging exposure to Hazardous Material). To the Seller’s Knowledge, no Acquired Company has (i) disposed
of, emitted, discharged, handled, stored, transported, used or released any Hazardous Material, arranged for the disposal, discharge,
storage or release of any Hazardous Material, or (ii) entered into any written Contract that may require it to guarantee, reimburse,
pledge, defend, hold harmless or indemnify any other party with respect to Liabilities arising out of Environmental Laws or the
Hazardous Material related activities. No Proceeding is pending or, to the Seller’s Knowledge, threatened against any Acquired
Company that alleges a material violation by any Acquired Company of any applicable Environmental Laws.

 

This Section 3.16
constitutes the sole and exclusive representations and warranties of the Seller with respect to any matters relating to Environmental,
Health and Safety Matters.

 

Section 3.17         Governmental
Authorizations. Except as set forth in Section 3.17 of the Seller Disclosure Schedule or as would not reasonably be expected
to have a Material Adverse Effect, the Acquired Companies have all Governmental Authorizations that are necessary for them to
conduct their

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	23

     

    

 

business in the manner
in which it is presently conducted, the Acquired Companies are in compliance with all such Governmental Authorizations and all
such Governmental Authorizations are in full force and effect. Neither the Seller nor the Acquired Companies have received any
written notice that any Governmental Authority with jurisdiction in the Territory over the Products has commenced or will commence
any action: (i) to suspend, revoke, not renew or materially amend any Governmental Authorizations in the Territory; or (ii) prohibit
production, marketing or sale of any Product in the Territory.

 

Section
3.18         Compliance with Laws. The
Acquired Companies are in compliance in all material respects with all Laws applicable to them or the conduct of their business
or the ownership or use of their properties and assets in the Territory. To the Seller’s Knowledge, neither the Acquired
Companies nor, any of their respective directors, officers, employees or agents have in the last three (3) years and in any material
respect related to the business of the Acquired Companies, directly or indirectly, made, offered, promised or authorized any payment
or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined
in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official
thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official,
party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision
of a foreign Governmental Authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order
to assist the Company or any of its Affiliates obtain or retain business and in violation of the FCPA. Neither the Acquired Companies
nor, to the Seller’s Knowledge, any of their respective directors, officers, employees or agents have made or authorized
any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in
violation of any applicable Law. Neither the Acquired Companies nor, to the Seller’s Knowledge, any of their respective
officers, directors or employees, have received any written notice from any Governmental Authority stating that they are the subject
of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other
anti-corruption law.

 

Section 3.19         Product
Liability. Except as would not have a Material Adverse Effect, the Products sold by the Acquired Companies have complied in
all material respects with all applicable product specifications contained in the relevant Marketing Authorizations. Except as
would not have a Material Adverse Effect, none of the Products after being sold have been the subject of any product recall ordered
by any Government Authority and, to the Seller’s Knowledge, no circumstances currently exist which are reasonably likely
to cause any such product recall to be initiated.

 

Section 3.20         Legal
Proceedings. There is no material Proceeding pending or, to the Seller’s Knowledge, threatened against any Acquired Company,
any of its officers or directors or any of its properties or assets. No Acquired Company is subject to any outstanding Judgment.

 

Section 3.21         Insurance.
The Company maintains, and through the Closing will continue to maintain, in full force and effect, policies of insurance against
fire, theft and other casualties, and covering such other Liabilities and business risks and properties of the Acquired Companies
which are customarily insured against by companies of similar size and in the industry in which the Acquired Companies operate.
There is no claim by the Company pending under any of such policies as to which coverage has been denied by the underwriters of
such policies. All premiums due and payable under all such policies have been paid (or if installment payments are due, will be
paid if incurred prior to the Closing Date) and the Company is otherwise in material compliance with the terms of such policies.
Such policies are in full force and effect.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	24

     

    

 

Section 3.22         Customers.

 

(a)          Section 3.22(a)
of the Seller Disclosure Schedule sets forth a complete and accurate list of the 10 largest customers of the Acquired Companies
based on net sales during each of the calendar years ended 2015 and 2014 and the calendar-year-to-date period ended March 31, 2016
(the “Material Customers”). Such net sale amounts are also set forth on Section 3.22(a) of the Seller Disclosure
Schedule. No Material Customer has canceled, terminated or otherwise materially and adversely modified, or, to the Seller’s
Knowledge, threatened to cancel, terminate, or otherwise materially and adversely modify, its relationship with any Acquired Company
and no Acquired Company has received written notice that any Material Customer may take such action or limit its purchases from
any Acquired Company, either as a result of the consummation of the transactions contemplated by this Agreement or otherwise.

 

(b)          Since
the date of the ARIAD SWISSCO Balance Sheet, no Acquired Company has taken, or permitted any Representative to take, any action
that was designed to have the effect of accelerating the timing of sales or the provision of products or services by any Acquired
Company or of invoicing therefore. Without limitation of the foregoing, since the date of the ARIAD SWISSCO Balance Sheet, no Acquired
Company has sold or provided any amount of products or services (a) with payment terms longer than terms customarily offered
by such Acquired Company for such product, (b) at a discount from the listed price materially differing from any discounts
customarily offered by such Acquired Company, or (c) with shipment or similar terms materially differing from the shipment
or similar terms customarily offered by such Acquired Company.

 

(c)          Section 3.22(c)
of the Seller Disclosure Schedule sets forth a description of all incentives (including coupon, discount, allowance, rebate, bill-back,
price concession or advertising fund payment activities or programs and the like) and pricing allowances (including slotting allowances,
retailer or distributor ads, store display allowances and similar items) offered by the Acquired Companies to its customers that
are in effect as of the date hereof.

 

Section 3.23         Interested
Party Transactions. To the Seller’s Knowledge, no officer or director of any Acquired Company (or any Affiliate or member
of the immediate family (as such term is defined in Rule 16a-1 of the Exchange Act) of such officer or director) has or has had:
(a) an interest in any entity which furnished or sold or licensed, or furnishes or sells or licenses, Products or right to Company
Intellectual Property that any Acquired Company furnishes or sells or (ii) any interest in any entity that purchases from or sells
or furnishes to the any Acquired Company, any goods or services; provided, however, that ownership of no more than one percent
(1%) of the outstanding voting stock of a publicly traded corporation shall not be deemed to be an “interest in any entity”
for purposes of this Section 3.23.

 

Section 3.24         Bank
Accounts. Section 3.24 of the Seller Disclosure Schedule lists (a) all bank accounts, lock boxes and safe deposit boxes relating
to the business and operations of the Acquired Companies (including the name of the bank or other institution where such account
or box is located and the name of each authorized signatory thereto) and (b) the name and address of each Person who has a power
of attorney to act on behalf of any Acquired Company.

 

Section 3.25         No
Other Representations or Warranties. Except for the representations and warranties set forth in this Article 3, neither the
Seller, nor any other Person, makes any other express or implied representation or warranty on behalf of the Seller or any of its
Affiliates with respect to the Shares, the Seller, the Acquired Companies or any other matter relating to the transactions contemplated
by this Agreement. The Seller makes no representations or warranties to the Purchaser regarding the probable success or profitability
of the Acquired Companies. The disclosure of any matter or item in any

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	25

     

    

 

schedule hereto shall
not be deemed to constitute an acknowledgement that any such matter is required to be disclosed.

 

Article
4

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

The Purchaser represents
and warrants to the Seller as of the date of this Agreement and as of the Closing Date:

 

Section 4.1           Organization
and Good Standing. The Purchaser is an entity duly organized, validly existing and in good standing under the Laws of Switzerland.
Incyte US is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 

Section 4.2           Authority
and Enforceability. Each of the Purchaser and Incyte US has all requisite corporate power and authority to execute and deliver
this Agreement and each Ancillary Agreement to which it is a party and to perform its obligations under this Agreement and each
such Ancillary Agreement. The execution, delivery and performance of this Agreement and each Ancillary Agreement to which the Purchaser
or Incyte US is a party and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all
necessary action on the part of the Purchaser and Incyte US. Each of the Purchaser and Incyte US has duly and validly executed
and delivered this Agreement and, on or prior to the Closing, each of the Purchaser and Incyte US will have duly and validly executed
and delivered each Ancillary Agreement to which it is a party. Assuming the due authorization, execution and delivery of this Agreement
and the Ancillary Agreements by the Seller, ARIAD US and the other parties thereto, this Agreement constitutes, and at the Closing
each Ancillary Agreement to which the Purchaser or Incyte US is a party will constitute, the valid and binding obligation of the
Purchaser or Incyte US, as applicable , enforceable against the Purchaser or Incyte US, as applicable, in accordance with its terms,
subject to (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) Laws governing
specific performance, injunctive relief and other equitable remedies.

 

Section 4.3           No
Conflict. Except for the requirements of any Antitrust Law (if applicable), and except in any case that would not have a material
adverse effect on the ability of the Purchaser or Incyte US to perform its obligations under this Agreement or on the ability of
the Purchaser or Incyte US to consummate the transactions contemplated by this Agreement, neither the Purchaser’s or Incyte
US’s execution, delivery and performance of this Agreement and any Ancillary Agreement to which the Purchaser or Incyte US
is a party, nor the consummation of the transactions contemplated by this Agreement, will (a) conflict with or violate the Purchaser’s
or Incyte US’s Organizational Documents, (b) result in a breach or default under or create in any Person the right to terminate,
cancel, accelerate or modify, or require any notice, consent or waiver under, any Contract to which the Purchaser or Incyte US
is a party or by which the Purchaser or Incyte US is bound, in any case with or without due notice or lapse of time or both, (c)
result in the imposition of any lien or other encumbrance on any of the assets of the Purchaser or Incyte US, (d) violate any Law
or Judgment applicable to the Purchaser or Incyte US or (e) require the Purchaser or Incyte US to obtain any Governmental Authorization
or make any filing with any Governmental Authority.

 

Section 4.4           Legal
Proceedings. There is no Proceeding pending, or, to the Purchaser’s knowledge, threatened against the Purchaser that
questions or challenges the validity of this Agreement or that may prevent, delay, make illegal or otherwise interfere in any material
respect with the ability of the Purchaser to consummate any of the transactions contemplated in this Agreement.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	26

     

    

 

Section 4.5           Investment
Intent. The Purchaser is acquiring the Shares for the Purchaser’s own account and investment purposes and is not acquiring
the Shares with a view to, or for sale in connection with, any distribution thereof within the meaning of any federal or state
securities Laws. The Purchaser is an “accredited investor” within the meaning of Rule 501(a) of Regulation D as promulgated
by the Securities and Exchange Commission under the Securities Act of 1933, as amended, and has sufficient business and financial
knowledge and experience to protect its own interests and to evaluate the merits and risks in connection with the purchase of the
Shares.

 

Section 4.6           Brokers
Fees. Neither the Purchaser nor any Person acting on its behalf has incurred any Liability to pay any fees or commissions to
any broker, finder or agent in connection with any of the transactions contemplated by this Agreement.

 

Section 4.7           Financial
Capacity. The Purchaser has, or will have on the Closing Date, immediately available cash in an amount sufficient to pay the
Purchase Price.

 

Section 4.8           Independent
Investigation. The Purchaser has conducted its own independent investigation, review and analysis of the business, operations,
assets, liabilities, results of operations, financial condition and prospects of the business of the Acquired Companies as it has
deemed appropriate, which investigation, review and analysis was done by the Purchaser and its Affiliates and Representatives.
The Purchaser acknowledges that it and its Affiliates and Representatives have been provided adequate access to the personnel,
properties, premises and records of the Acquired Companies for such purpose. In entering into this Agreement, the Purchaser acknowledges
that it has relied solely upon the aforementioned investigation, review and analysis and not on any factual representations or
opinions of the Seller, the Acquired Companies or their Representatives (except the representations and warranties set forth in
Article 3). The Purchaser hereby acknowledges and agrees that other than the representations and warranties set forth in Article
3, none of the Seller, the Acquired Companies, or any other Person makes or has made any other express or implied representation
or warranty on behalf of the Seller or any of its Affiliates with respect to the Shares, the Seller, the Acquired Companies or
any other matter relating to the transactions contemplated by this Agreement.

 

Article
5

PRE-CLOSING COVENANTS

 

Section 5.1           Access
and Investigation; Notice. Until the Closing and upon reasonable advance notice from the Purchaser, the Seller will and will
cause the Acquired Companies to allow the Purchaser and its Representatives reasonable access during normal business hours and
without unreasonable interference with the operation of the business of the Acquired Companies to (a) such materials and information
about the Acquired Companies as the Purchaser may reasonably request and (b) specified members of management of the Acquired Companies
as the Parties may reasonably agree. Notwithstanding the foregoing, the Seller will not be required to disclose (or cause the Acquired
Companies to disclose) any information to the Purchaser or its Representatives if such disclosure would be reasonably likely to:
(x) cause significant competitive harm to the business of the Acquired Companies if the transactions contemplated hereby are not
consummated, (y) jeopardize any attorney-client or other legal privilege or (z) contravene any applicable Laws (including Antitrust
Laws), fiduciary duty or binding agreement entered into prior to the date hereof. The Purchaser will, and will cause its Representatives
to, hold confidentially all information so obtained in accordance with the terms of the Confidentiality Agreement. Seller will
provide prompt written notice to the Purchaser of any event, circumstance, development, material or other information that the
Seller reasonably determines would have a Material Adverse Effect.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	27

     

    

 

Section 5.2           Operation
of the Businesses of the Acquired Companies.  

 

(a)          Until
the Closing, except as otherwise set forth in this Agreement or Section 5.2(a) of the Seller Disclosure Schedule, required by Law
or as otherwise consented to by the Purchaser (which consent will not be unreasonably withheld, conditioned or delayed), the Seller
will cause the Acquired Companies to conduct their business in the ordinary course of business in substantially the same manner
as heretofore conducted, and, to the extent consistent therewith, use commercially reasonable efforts to preserve the relationships
of the Acquired Companies with their customers, suppliers, distributors, licensors, licensees, and others doing business with them
and to preserve the goodwill and ongoing operations of the Acquired Companies.

 

(b)          Until
the Closing, except as otherwise set forth in this Agreement or Section 5.2(b) of the Seller Disclosure Schedule or as otherwise
consented to by the Purchaser (which consent will not be unreasonably withheld, conditioned or delayed), the Seller will not cause
or permit any Acquired Company to:

 

(i)          amend
its Organizational Documents;

 

(ii)         issue,
sell or pledge additional shares of its capital stock or securities convertible into any such shares, or any options, warrants
or rights to acquire any such shares or other convertible securities;

 

(iii)        purchase,
redeem or otherwise acquire any outstanding shares of its capital stock;

 

(iv)        declare,
set aside or pay any dividend or other distribution in respect of its capital stock, other than in cash in the ordinary course
of business in connection with the Company’s cash management practices;

 

(v)         pay,
discharge, waive or satisfy, any Indebtedness other than in the ordinary course of business;

 

(vi)        adopt
or change accounting methods or practices (including any change in depreciation or amortization policies), except as required by
GAAP or applicable Law;

 

(vii)       make
or change any Tax election, adopt or change any Tax accounting method, enter into any closing agreement with respect to Taxes,
settle or compromise any material Tax claim or assessment, consent to any extension or waiver of the limitation period applicable
to any material Tax claim or assessment or file any material Tax Return or any amended Tax Return unless a copy of such Tax Return
has been delivered to the Purchaser for review a reasonable time prior to filing;

 

(viii)      make
any loan to any Person or purchase debt securities of any Person or amend the terms of any outstanding loan agreement;

 

(ix)         incur
any Indebtedness, guarantee any Indebtedness of any Person, issue or sell any debt securities, or guarantee any debt securities
of any Person;

 

(x)          commence
or settle any lawsuit, threat of any lawsuit or proceeding or other investigation against the Company involving an amount in dispute
greater than US Dollars 50,000;

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	28

     

    

 

(xi)         enter
into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into
any lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify or terminate
any of the terms of any Real Property Leases;

 

(xii)        terminate
or materially and adversely amend any Material Contract;

 

(xiii)       waive
or release any right or claim of a material value to the Acquired Companies other than in the ordinary course of business;

 

(xiv)      sell,
lease or license, or permit any Encumbrance on, any material portion of its assets other than in the ordinary course of business;

 

(xv)       acquire,
by merger or consolidation with, or by purchase of all or a substantial portion of the assets or stock of, or by any other manner,
any business or entity, or enter into any joint venture, partnership or other similar arrangement for the conduct of its business;

 

(xvi)      change
in any material respect the remuneration or terms of employment of any of its Employees or make offers to employ or engage any
other personnel (other than to replace any Employees who have resigned or served or been served with notice to end their employment)
other than (A) in the ordinary course of business, (B) as required by Law or (C) for retention, incentive and similar payments
relating to the consummation of the transactions contemplated by this Agreement;

 

(xvii)     except
in cooperation with the Purchaser, make any representations regarding offers of employment from the Purchaser or the terms thereof;

 

(xviii)    alter,
or enter into any commitment to alter, its interest in any corporation, association, joint venture, partnership or business entity
in which any Acquired Company directly or indirectly holds any interest;

 

(xix)       cancel,
amend or renew any insurance policy; or

 

(xx)        agree
in writing to take any of the foregoing actions.

 

Section 5.3           Consents
and Filings; Commercially Reasonable Efforts.

 

(a)          Subject
to the terms and conditions of this Agreement and unless otherwise specified in this Agreement, each of the parties will use their
respective commercially reasonable efforts (i) to take promptly, or cause to be taken, all actions, and to do promptly, or cause
to be done, all things reasonably necessary to consummate and make effective the transactions contemplated by this Agreement and
(ii) as promptly as practicable after the date of this Agreement, to obtain all Governmental Authorizations from, and make all
filings with, all Governmental Authorities (including Antitrust Approvals), and to obtain all other consents, waivers, approvals
and other authorizations from, all other third parties, that are reasonably necessary in connection with the authorization, execution
and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement.

 

(b)          The
Purchaser will be solely responsible for all filing fees due under antitrust or other competition Laws (“Antitrust Laws”)
in connection with any Antitrust Approvals and neither the Seller nor any Acquired Company will have any Liability with respect
to the payment of such filing fees.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	29

     

    

 

(c)          The
Seller and the Purchaser will promptly notify the other of any communication it or any of its Affiliates receives from any Governmental
Authority relating to the transactions contemplated by this Agreement, and will permit the other party to review in advance any
proposed communication by such party to any Governmental Authority. Neither party will agree to participate in any meeting with
any Governmental Authority in respect of any filings, investigation or other inquiry unless it consults with the other party in
advance and, to the extent permitted by such Governmental Authority, gives the other party the opportunity to attend and participate
at such meeting. The Seller and the Purchaser will coordinate and cooperate fully with each other in exchanging such information
and providing such assistance as the other party may reasonably request in connection with the foregoing and in seeking early termination
of any applicable waiting periods under any Antitrust Laws. The Seller and the Purchaser will provide each other with copies of
all correspondence, filings or communications between them or any of their Representatives, on the one hand, and any Governmental
Authority or members of its staff, on the other hand, with respect to this Agreement and the transactions contemplated by this
Agreement.

 

(d)          The
Purchaser and the Seller will use commercially reasonable efforts to respond to any request for additional information received
from any Governmental Entity under the Antitrust Laws and to resolve the objections, if any, that could be asserted by any Governmental
Entity under Antitrust Laws with respect to the transactions contemplated by this Agreement.

 

Section 5.4           Financing.
Notwithstanding anything contained in this Agreement to the contrary, the Purchaser expressly acknowledges and agrees that the
Purchaser’s obligations under this Agreement are not conditioned in any manner whatsoever upon the Purchaser obtaining any
financing and any failure to fulfill any obligation under this Agreement arising from the failure of the Purchaser to obtain financing
or the unavailability of such financing will be deemed to be intentional for purposes of this Agreement.

 

Section 5.5           Public
Announcements. Each party agrees not to issue any press release or make any other public announcement relating to this Agreement
without the prior written approval of the other party, except that each of the Seller and the Purchaser reserves the right,
without the other party’s prior consent, to make any public disclosure it believes in good faith is required by applicable
securities Laws or securities listing standards (in which case the disclosing party agrees to consult with the other party prior
to making the disclosure and allow the other party reasonable time to comment thereon prior to issuance or release; provided, that,
the disclosing party will consider the other party’s comments in good faith, but it is not required to accept all comments).
Following execution and delivery of this Agreement, ARIAD US and the Purchaser shall issue a joint press release substantially
in the form set forth in Exhibit C.

 

Section 5.6           Intragroup
Agreements. The Seller shall terminate prior to or effective as of the Closing all Intragroup Agreements (including the ARIAD
Intragroup Indebtedness), settle all outstanding financial obligations arising thereunder and cause each Person party thereto to
be unconditionally released and irrevocably discharged from any and all further covenants, undertakings, warranties and other obligations
contained in such Intragroup Agreements.

 

Section 5.7           Carve
Out Restructuring. Prior to the Closing, the Seller shall transfer to a member of the Seller’s Group the Australian Business
in substantially the manner described in Section 5.7 of the Seller Disclosure Schedule (the “Carve Out Restructuring”).

 

Section 5.8           Financial
Statements. Prior to the Closing, the Seller shall provide to the Purchaser an audited consolidated balance sheet for the Company
for each of the fiscal years ending December 31, 2015 and 2014 (collectively, the “Audited Consolidated Balance Sheets”)
and the related statements of income, changes in equity and cash flow, for each such fiscal year (collectively, with the Audited
Consolidated Balance Sheets, the “Audited Consolidated Financial Statements”) and unaudited consolidated interim
financial statements for the Company for the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	30

     

    

 

period ending March 31,
2016 (the “Other Consolidated Financial Statements”), in each case prepared in accordance with the requirements
of Regulation S-X of the SEC and in form and substance sufficient to permit the Purchaser to comply with its obligations under
Item 9.01 of Form 8-K under the Exchange Act. The Seller shall use commercially reasonable efforts to obtain all necessary auditor
reports and consents from the Seller’s independent auditors required by the SEC to file such Audited Consolidated Financial
Statements and Other Consolidated Financial Statements with the SEC. The fees, costs and expenses incurred by the Seller or its
Affiliates in connection with the delivery of the Audited Consolidated Financial Statements and any auditor reports or consents
required pursuant to this Section 5.8 shall reduce dollar-for-dollar the amount of the current liabilities of the Acquired Companies
for the purposes of calculating Closing Net Working Capital.

 

Section 5.9           CSC
Guarantee. The Purchaser and the Seller will use commercially reasonable efforts to provide financial assurances reasonably
acceptable to CSC in substitution of the CSC Guarantee or to otherwise obtain the full release of the CSC Guarantee, in each case
at or prior to the Closing. In the event that the CSC Guarantee is not substituted or released at or prior to the Closing, (a)
the Purchaser and the Seller will continue to use commercially reasonable efforts to provide financial assurances reasonably acceptable
to CSC in substitution of the CSC Guarantee or to otherwise obtain the full release of the CSC Guarantee as promptly as practicable
and (b) until such time as the CSC Guarantee is substituted or released, the Purchaser will indemnify and hold harmless the Seller
and its Affiliates (including ARIAD US) against and from any and all Liabilities arising out of or relating to CSC Guarantee.

 

Article
6

CONDITIONS PRECEDENT TO OBLIGATION TO CLOSE

 

Section 6.1           Joint
Condition. The obligation of the Purchaser and the Seller to consummate the transactions contemplated by this Agreement is
subject to the satisfaction, on or before the Closing Date, of the following condition (any of which may be waived by the mutual
agreement between the parties, in whole or in part): there must not be in effect any Law or Judgment that would prohibit or make
illegal the consummation of the transactions contemplated by this Agreement or cause the transactions contemplated by this Agreement
to be rescinded following consummation.

 

Section 6.2           Conditions
to the Obligation of the Purchaser. The obligation of the Purchaser to consummate the transactions contemplated by this Agreement
is subject to the satisfaction, on or before the Closing Date, of each of the following conditions (any of which may be waived
by the Purchaser, in whole or in part):

 

(a)          The
representations and warranties of the Seller in Article 3 must be true and correct in all respects as at Closing (except to the
extent any such representation or warranty speaks as of the date of this Agreement or any other specific date, in which case such
representation or warranty must have been true and correct in all respects as of such date), except where the failure of
such representations and warranties to be so true and correct (without regard for any “material,” “Material Adverse
Effect” or similar qualification) would not, individually or in the aggregate, constitute a Material Adverse Effect;

 

(b)          All
of the covenants and obligations that the Seller is required to perform or comply with under this Agreement on or before the Closing
Date must have been duly performed and complied with in all material respects;

 

(c)          The
Seller must have delivered or caused to be delivered each document that Section 2.6(a) requires it to deliver;

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	31

     

    

 

(d)          The
Required Contracts shall not have been amended, modified or rescinded and shall be in full force and effect; and

 

(e)          There
shall not have occurred any event or condition of any character that has had, or is reasonably likely to have, a Material Adverse
Effect since the date of this Agreement.

 

Section 6.3           Conditions
to the Obligation of the Seller. The obligation of the Seller to consummate the transactions contemplated by this Agreement
is subject to the satisfaction, on or before the Closing Date, of each of the following conditions (any of which may be waived
by the Seller, in whole or in part):

 

(a)          The
representations and warranties of the Purchaser in Article 4 must be true and correct in all material respects as of the Closing
(except to the extent any such representation or warranty speaks as of the date of this Agreement or any other specific date, in
which case such representation or warranty must have been true and correct in all material respects as of such date);

 

(b)          All
of the covenants and obligations that the Purchaser is required to perform or comply with under this Agreement on or before the
Closing Date must have been duly performed and complied with in all material respects; and

 

(c)          The
Purchaser must have delivered or caused to be delivered to the Seller each document that Section 2.6(b) requires it to deliver.

 

Article
7

TERMINATION

 

Section 7.1           Termination
Events. This Agreement may, by written notice given before or at the Closing, be terminated:

 

(a)          by
mutual consent of the Purchaser and the Seller;

 

(b)          by
either the Purchaser or the Seller if any Governmental Authority has issued a nonappealable final Judgment or taken any other nonappealable
final action, in each case having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated
by this Agreement; provided, however, that the right to terminate this Agreement under this Section 7.1(b) will not
be available to any party whose failure to fulfill any material covenant under this Agreement, including the obligations of the
Purchaser under Section 5.3, has been the cause of or resulted in the action or event described in this Section 7.1(b) occurring;

 

(c)          by
the Purchaser if the Closing has not occurred (other than through the failure of the Purchaser to comply fully with its obligations
under this Agreement) on or before June 30, 2016; or

 

(d)          by
the Seller if the Closing has not occurred (other than through the failure of the Seller or the Company to comply fully with its
obligations under this Agreement) on or before June 30, 2016.

 

Section 7.2           Effect
of Termination. If this Agreement is terminated pursuant to Section 7.1, this Agreement and all rights and obligations of the
parties under this Agreement automatically end without Liability against any party or its Affiliates, except that (a) Section 12.1
(Confidentiality), Section 5.5 (Public Announcements), Section 7.3 (Certain Effects of Termination), Article
13 (General Provisions) (except for Section 13.12 (Specific Performance)) and this Section 7.2 will remain in full
force and survive any termination of this Agreement and (b) if this Agreement is terminated by a party because of

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	32

     

    

 

the knowing and intentional
breach of this Agreement by the other party or because one or more of the conditions to the terminating party’s obligations
under this Agreement is not satisfied as a result of the other party’s knowing and intentional failure to comply with its
obligations under this Agreement, the terminating party’s right to pursue all legal remedies will survive such termination
unimpaired.

 

Section 7.3           Certain
Effects of Termination. If the Purchaser or the Seller terminates this Agreement pursuant to Section 7.1, the Purchaser will
comply with the Confidentiality Agreement regarding the return and/or destruction of any information furnished to the Purchaser
in connection with this Agreement.

 

Article
8

INDEMNIFICATION

 

Section 8.1           Indemnification
by the Seller. If the Closing occurs, and subject to the limitations expressly set forth in Section 8.4 and Section 8.5, the
Seller will indemnify and hold harmless the Purchaser and its directors, officers, employees, agents, representatives, stockholders
and Affiliates (collectively, the “Purchaser Indemnified Parties”) from and against any and all Losses (other
than Losses with respect to Taxes, for which the provisions of Section 9.2 will govern) incurred by the Purchaser Indemnified Parties
arising or resulting from (a) any breach of any representation or warranty set forth in Article 3, (b) any breach of any covenant
of the Purchaser set forth in this Agreement, (c) any Indebtedness to the extent not taken into account in the determination of
the Final Closing Net Cash and (d) the Deferred Refund Obligations. The amount of indemnified Losses will be determined without
regard to any “materiality” or “Material Adverse Effect” qualification contained in the applicable provisions
hereof.

 

Section 8.2           Indemnification
by the Purchaser. If the Closing occurs, and subject to the limitations expressly set forth in Section 8.4 and Section 8.5,
the Purchaser will indemnify and hold harmless the Seller and its directors, officers, employees, agents, representatives, stockholders
and Affiliates (collectively, the “Seller Indemnified Parties”) from and against any and all Losses (other than
Losses with respect to Taxes, for which the provisions of Section 9.2(b) will govern) incurred by the Seller Indemnified Parties
arising or resulting from (a) any breach of any representation or warranty set forth in Article 4 and (b) any breach of any covenant
of the Purchaser set forth in this Agreement. The amount of indemnified Losses will be determined without regard to any “materiality”
or “Material Adverse Effect” qualification contained in the applicable provisions hereof.

 

Section 8.3           Claim
Procedure.  

 

(a)          A
party that seeks indemnity under this Article 8 (an “Indemnified Party”) will give written notice (a “Claim
Notice”) to the party from whom indemnification is sought (an “Indemnifying Party”) whether the Losses
sought arise from matters solely between the parties or from Third Party Claims described in Section 8.3(b). The Claim Notice must
contain (i) a description and, if known, the estimated amount of any Losses incurred or reasonably expected to be incurred by the
Indemnified Party, (ii) a reasonable explanation, accompanied by reasonable supporting documentation, of the basis for the Claim
Notice to the extent of the facts then known by the Indemnified Party and (iii) a demand for payment of those Losses.

 

(b)          If
the Indemnified Party seeks indemnity under this Article 8 in response to a claim or Proceeding by another Person not a party to
this Agreement (a “Third Party Claim”), then the Indemnified Party will give a Claim Notice to the Indemnifying
Party within ten days after the Indemnified Party has received notice or otherwise learns of the assertion of such Third Party
Claim and will include in the

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	33

     

    

 

Claim Notice (i) the
facts constituting the basis for such Third Party Claim and the amount of the damages claimed by the other Person, in each case
to the extent known to the Indemnified Party, accompanied by reasonable supporting documentation submitted by such third party
(to the extent then in the possession of the Indemnified Party) and (ii) the assertion of the claim or the notice of the commencement
of any Proceeding relating to such Third Party Claim; provided, however, that no delay or deficiency on the part
of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any Liability under this
Agreement except to the extent such delay or deficiency prejudices or otherwise adversely affects the rights of the Indemnifying
Party with respect thereto.

 

(c)          The
Indemnifying Party will have 30 days after receipt of notice of such Third Party Claim to elect to assume control of the defense
of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party by giving to the Indemnified Party written
notice of the intention to assume control of such defense. If the Indemnifying Party elects not to assume control of such defense,
the Indemnified Party will control such defense.

 

(d)          The
party not controlling the defense of the Third Party Claim (the “Non-controlling Party”) may participate in
the defense thereof at its own expense. However, if the Indemnifying Party assumes control of such defense as permitted above and,
based upon the reasonable opinion of counsel to the Indemnified Party reasonably acceptable to the Indemnifying Party, a conflict
or potential conflict of interest exists between the Indemnified Party and the Indemnifying Party which makes the representation
of both parties inappropriate under applicable standards of professional conduct, then the reasonable fees and expenses of counsel
to the Indemnified Party will be considered and included as “Losses” for purposes of this Agreement. The Non-controlling
Party will furnish the party controlling the defense of the Third Party Claim (the “Controlling Party”) with
such information as it may have with respect to the Third Party Claim (including copies of any summons, complaint or other pleading
which may have been served on such party and any written claim, demand, invoice, billing or other document evidencing or asserting
the same) and will otherwise cooperate with and assist the Controlling Party and its counsel in the defense of such Third Party
Claim. The Controlling Party will keep the Non-controlling Party reasonably advised of the status of such Third Party Claim and
will consider in good faith recommendations made by the Non-controlling Party with respect thereto.

 

(e)          The
Indemnifying Party will not agree to any settlement of, or consent to the entry of any Judgment (other than a Judgment of dismissal
on the merits without costs) arising from, any such Third Party Claim without the prior written consent of the Indemnified Party;
provided, however, that the consent of the Indemnified Party will not be required if the Indemnifying Party agrees
in writing to pay any amounts payable pursuant to such settlement or any Judgment and such settlement or Judgment includes a full,
complete and unconditional release of the Indemnified Party from further Liability. The Indemnified Party will not agree to any
settlement of, or the entry of any Judgment (other than a Judgment of dismissal on the merits without costs) arising from, any
such Third Party Claim without the prior written consent of the Indemnifying Party.

 

Section 8.4           Survival.
Other than the Seller Fundamental Representations and the representations and warranties set forth in Section 3.13 (Tax Matters),
all representations and warranties contained in this Agreement will survive the Closing until the twelve-month anniversary of the
Closing Date. The Seller Fundamental Representations and the representations and warranties set forth in Section 3.13 (Tax Matters)
will survive the Closing until sixty days after the expiration of the applicable statute of limitations. None of the covenants
or other agreements contained in this Agreement shall survive the Closing Date other than those which by their terms contemplate
performance after the Closing Date, and each such surviving covenant and agreement shall survive the Closing for the period contemplated
by its terms or in accordance with the applicable statute of limitations with respect thereto, whichever is shorter.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	34

     

    

 

All claims for indemnification
under this Agreement must be asserted pursuant to a Claim Notice given prior to the expiration of the applicable survival period
set forth in this Section 8.4; provided, however, that any representation, warranty or covenant that is the subject
of a claim for indemnification which is asserted pursuant to a Claim Notice given after the Closing Date within the survival period
specified in this Section 8.4 will survive until, but only for purposes of, the resolution of such claim.

 

Section 8.5           Limitations
on Liability.

 

(a)          Notwithstanding
anything to the contrary contained in this Agreement:

 

(i)          no
indemnification payments will be made by or on behalf of an Indemnifying Party in respect of any breaches of representations and
warranties made by such party, as applicable, under this Agreement (other than with respect to Seller Fundamental Representations)
until the aggregate amount of Losses for which such Indemnifying Party would (but for this clause) be liable thereunder exceeds
1% of the Initial Purchase Price, in which event the Indemnifying Party will be liable for all Losses from the first dollar;

 

(ii)         the
aggregate total amount for which an Indemnifying Party will be liable to indemnify and hold harmless the Indemnified Parties with
respect to any breaches of representations and warranties made by the Indemnifying Party under this Agreement (other than with
respect to Seller Fundamental Representations) will not exceed 10% of the Initial Purchase Price;

 

(iii)        the
aggregate total amount for which an Indemnifying Party will be liable to indemnify and hold harmless the Indemnified Parties under
this Agreement will not exceed the Initial Purchase Price; and

 

(iv)        any
indemnity provided hereunder shall be so applied as to avoid any double counting and no Indemnified Party shall be entitled to
obtain indemnification more than once for the same matter or Losses.

 

(b)          An
Indemnified Party’s right to indemnification or other remedies based upon the representations, warranties, covenants and
agreement of the Indemnifying Party contained in this Agreement will not be affected or deemed waived by reason of the fact that
the Indemnified Party, based solely upon its own investigation and without regard to any information provided by the Indemnifying
Party, knew or should have known that any representation or warranty might be inaccurate or that the Indemnifying Party filed to
comply with any agreement or covenant.

 

The limitations on
liability set forth in this Section 8.5 shall not apply to Losses resulting from fraud with respect to any breach of any representation
or warranty or willful breach with respect to any covenant, in each case as contained in this Agreement.

 

Section 8.6           Tax
Refunds, Insurance Proceeds and Other Payments. The amount of any and all Losses for which indemnification is provided pursuant
to this Article 8 or Article 9 will be net of any Tax benefit to which an Indemnified Party is entitled by reason of payment of
such Liability and any amounts of any insurance proceeds, indemnification payments, contribution payments or reimbursements receivable
by, or payable in kind to, the Indemnified Party with respect to such Losses or any of the circumstances giving rise thereto. In
connection therewith, if, at any time following payment in full by the Indemnifying Party of any amounts of Losses due under this
Agreement, the Indemnified Party receives any insurance proceeds, indemnification payments, contribution payments or reimbursements
relating to

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	35

     

    

 

the circumstances giving
rise to such Losses, the Indemnified Party will promptly remit to the Indemnifying Party such proceeds, payments or reimbursements
in an amount not to exceed the amount of the corresponding indemnification payment made by the Indemnifying Party. The Purchaser
will use (and will cause its Affiliates to use) commercially reasonable efforts to collect the proceeds of any available insurance
which would have the effect of reducing any Losses (in which case the net proceeds thereof will reduce the Losses).

 

Section 8.7           Subrogation.
If the Purchaser or any Purchaser Indemnified Party is indemnified for any Losses pursuant to this Agreement with respect to any
claim by a Person not party to this Agreement, then the Seller will be subrogated to all rights and remedies of the Purchaser or
the Purchaser Indemnified Party against such third party, and the Purchaser will, and will cause each of the Purchaser Indemnified
Parties to, cooperate with and assist the Seller in asserting all such rights and remedies against such third party.

 

Section 8.8           Exclusive
Remedy From and after the Closing, except for the availability of injunctive or other equitable relief and claims relating
to fraud, the sole and exclusive remedy of the Purchaser for any matter arising out of the transactions contemplated by this Agreement
will be pursuant to the indemnification obligations set forth in Article 8 and Article 9 and, except to the extent the Purchaser
has asserted a claim for indemnification by giving a Claim Notice in accordance with Section 8.3 prior to the expiration of the
applicable survival period set forth in Section 8.4, the Purchaser will have no remedy against the Seller for any breach of any
provision of this Agreement. In no event will the Seller have any Liability for Losses arising from the conduct of the business
of the Acquired Companies after the Closing.

 

Article
9

TAX MATTERS

 

Section 9.1           Swiss
Tax Rulings.

 

(a)          As
soon as reasonably practicable and in any event within thirty days following the execution and delivery of this Agreement, the
Seller shall prepare and file with the Swiss Tax Authorities the requests for tax rulings listed in Section 9.1(a) of the Seller
Disclosure Schedule with respect to the applicable federal stamp tax and or income or withholding tax that may arise as a result
of the Pre-Sale Restructuring (the “Swiss Tax Rulings”).

 

(b)          The
Seller and the Purchaser will each use their respective reasonable best efforts to take, or cause to be taken, all actions and
to do, or cause to be done, all things necessary, proper or advisable to obtain the Swiss Tax Rulings. Subject to this Section
9.1(b), the Seller will control and be responsible for the filing of the Swiss Tax Rulings and the submission of any information,
documentation, responses or communication with the Swiss Tax Authority relating thereto. The parties will provide to each other
such assistance, information and cooperation as is reasonably required to obtain the Swiss Tax Rulings (including providing necessary
information, assisting in responding to any inquiries and attending meetings with the applicable Swiss Tax Authority) and, in connection
therewith, each party will (i) promptly notify the other party of any material communication between such party and any Swiss Tax
Authority relating to the Swiss Tax Rulings; (ii) consult with the other party in advance of participating in any meeting or discussion
with any Swiss Tax Authority relating to the Swiss Tax Rulings and, to the extent permitted by such Swiss Tax Authority, give the
other party (and its counsel and tax advisors) the opportunity to attend and participate thereat; and (iii) subject to applicable
Law, discuss with and permit the other party (and its counsel and tax advisors) to review in advance, and consider in good faith
the other party’s reasonable comments in connection with, any proposed filing, submission or

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	36

     

    

 

communication to any
Swiss Tax Authority relating to the Swiss Tax Rulings. For the avoidance of doubt, the provisions of this Section 9.1(b) shall
govern with respect to the interactions of the parties with the Swiss Tax Authority in connection with the Swiss Tax Ruling and
Section 5.3(c) will not apply to the matters addressed in this Section 9.1(b).

 

Section 9.2           Liability
and Indemnification for Taxes.

 

(a)          If
the Closing occurs, and subject to Section 8.5(a)(iii) and the limitations expressly set forth in Section 9.2(d), and except to
the extent any Taxes are reserved or accrued on the Closing Balance Sheet, the Seller will indemnify the Purchaser Indemnified
Parties against: (i) all Losses for all Taxes of the Acquired Companies that are attributable to the Pre-Closing Period or as a
result of the Pre-Sale Restructuring or Carve-out Restructuring, and (ii) all Losses for all Taxes attributable to any breach of
the Company’s representations and warranties set forth in Section 3.13.

 

(b)          If
the Closing occurs, the Purchaser will indemnify the Seller Indemnified Parties against all Losses (i) for all Taxes of the Acquired
Companies that are attributable to any Post-Closing Period, except to the extent that such Losses for Taxes are attributable to
any breach of the Company’s representations and warranties set forth in Section 3.13 and (ii) for all Taxes arising solely
out of or due to any breach of any covenant of the Purchaser set forth in this Agreement.

 

(c)          With
respect to any Straddle Period, any Losses for Taxes will be allocated between the Pre-Closing Period and the Post-Closing Period
by closing the books of the Acquired Companies at the end of the Closing Date, except that (i) Tax items of a periodic nature,
such as property taxes or depreciation allowances calculated on an annual basis, will be allocated by apportioning a pro-rata portion
of such Taxes to each day in the relevant Straddle Period, and (ii) Liabilities relating to Tax associated with the Pre-Sale Restructuring
will fall into the Pre-Closing Period.

 

(d)          The
Seller will not be required to indemnify the Purchaser Indemnified Parties for reductions in any Tax Attributes. The Seller will
not be required to indemnify the Purchaser Indemnified Parties against Losses for Taxes attributable to the Pre-Closing Period
or the Pre-Sale Restructuring or Carve-out Restructuring to the extent such Losses for Taxes could be reduced under applicable
Law by reason of net operating loss carryovers, Tax credits and similar Tax attributes arising in the Pre-Closing Period (assuming
for the purposes of this sentence that such attributes are not used to reduce Taxes in the Post-Closing Period).

 

Section 9.3           Tax
Return Filing; Audit Responsibilities.  

 

(a)          Except
as set forth in Section 9.3(b), the Purchaser will control and be responsible for the filing of all Tax Returns required to be
filed with respect to the Company after the Closing Date. All such Tax Returns will be completed in accordance with past practice
to the extent permitted by applicable Law. The Purchaser will make all payments required with respect to any such Tax Return.

 

(b)          The
Seller will control and be responsible for the preparation and filing of all Tax Returns due after the Closing Date that relate
to the Company or any Affiliate of the Company and are Affiliated Group Tax Returns which include Pre-Closing Period operations.
All such Tax Returns will be completed in accordance with past practice to the extent permitted by applicable Law. The Seller will
make all payments required with respect to any such Tax Return.

 

(c)          In
the event that the Seller or the Purchaser is liable under this Agreement for any Taxes paid by the other party with respect to
any Tax Return, prompt reimbursement will be made.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	37

     

    

 

(d)          If
the Purchaser receives notice of a Tax Contest with respect to any Acquired Company which could reasonably be expected to cause
the Seller to have an indemnification obligation under this Article 9, then the Purchaser will notify the Seller in writing of
such Tax Contest within five Business Days of receiving such notice. The Seller will have the right to control the conduct and
resolution of such Tax Contest; provided, however, that the Seller may decline to participate in such Tax Contest.
If the Seller controls the conduct of such Tax Contest, the Seller will not resolve such Tax Contest, to the extent such Tax Contest
relates to Post-Closing Period Taxes, without the Purchaser’s written consent, which consent will not be unreasonably withheld,
conditioned or delayed. If the Seller declines to control such Tax Contest, then the Purchaser will have the right to control the
conduct of such Tax Contest; provided, however, that the Purchaser will not resolve such Tax Contest without the
Seller’s written consent, which consent will not be unreasonably withheld, conditioned or delayed. Each party will bear its
own costs for participating in such Tax Contest.

 

(e)          Any
net refunds and credits attributable to the payment of Taxes for a Pre-Closing Period will be for the account of the Seller, and
the Purchaser will promptly pay to the Seller any such refund or credit.

 

(f)          To
the extent not inconsistent with the provisions of this Section 9.3, the procedures of Article 8 will apply in the case of any
claim for Losses related to Taxes.

 

Section 9.4           Cooperation.
Each of the Seller and the Purchaser agree that it will:

 

(a)          provide
assistance to the other party as reasonably requested in preparing and filing Tax Returns and responding to Tax Contests;

 

(b)          make
available to the other party as reasonably requested all information, records, and documents relating to Taxes concerning the Acquired
Companies; and

 

(c)          retain
any books and records that could reasonably be expected to be necessary or useful in connection with any preparation by any other
party of any Tax Return or for any Tax Contest or other examination or Proceeding relating to Taxes. Such books and records will
be retained until the expiration of the applicable statute of limitations (including extensions thereof). Thereafter, the Purchaser
will not dispose of any such Tax Returns, books and records unless it first offers in writing such Tax Returns, books and records
to the Seller and the Seller fails to accept such offer within 60 days of it being made.

 

Section 9.5           No
Code Section 338 Election. Neither the Purchaser, the Company, nor any of their Affiliates will make any election under Section
338 of the Code with respect to the transactions contemplated by this Agreement.

 

Section 9.6           Tax
Treatment of Indemnity Payments. Any indemnity payment under this Agreement shall be treated as an adjustment to the Purchase
Price for Tax purposes unless otherwise required by applicable Tax Law. Each party shall notify the other party if it receives
notice that any Governmental Authority proposes to treat any indemnification payment as other than an adjustment to the Purchase
Price for Tax purposes, or if it otherwise determines that an indemnification payment is required by applicable Tax Law to be treated
as other than an adjustment to the Purchase Price for Tax purposes.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	38

     

    

 

Article
10

EMPLOYEE MATTERS

 

Section 10.1         Employees.
 

 

(a)          For
the one-year period commencing on the Closing Date (or such longer period as may be required by applicable Law) (the “Continuation
Period”), the Purchaser will provide, or cause the Acquired Companies to provide, those employees employed by any Acquired
Company at Closing, including those employees on vacation, leave of absence, disability (including long-term disability), military,
parental or sick leave or layoff (whether or not such employees return to active employment with the Acquired Company) (the “Transferred
Employees”), with employee benefits that in the aggregate are substantially equivalent to, and no less favorable than,
those provided to such Transferred Employees immediately prior to the Closing, subject to any variations agreed with such Transferred
Employees. During the Continuation Period or such longer period as may be required under the terms of any applicable employee benefit
plan or arrangement, the Purchaser will continue to provide, or cause the Acquired Companies to provide, those former employees
of any Acquired Company who left employment prior to the Closing and who retain a benefit in any applicable Company Plan (the “Transferred
Former Employees”) and their dependents, beneficiaries and join annuitants, with employee/retiree benefits that in the
aggregate are substantially equivalent to, and no less favorable than, the benefits to which such Transferred Former Employees
were entitled under the Company Plans in effect immediately prior to the Closing, subject to any variations agreed with such Employees.
These obligations are not intended to limit any provisions of applicable Law or Contracts which are more favorable to Transferred
Employees or Transferred Former Employees.

 

(b)          To
the extent that service is relevant for purposes of eligibility, vesting or benefit accrual under any employee benefit plan, program
or arrangement established or maintained by the Purchaser for the benefit of Transferred Employees or Transferred Former Employees,
such plan, program or arrangement will credit such employees or former employees for service on or prior to the Closing with the
Acquired Companies and their Affiliates.

 

(c)          Upon
the Closing Date, the Purchaser will honor or cause the Acquired Companies to honor in accordance with their terms all individual
employment, severance, retention and other compensation agreements then existing between the Acquired Companies and any employee,
director or officer thereof, except as otherwise agreed in writing by the Purchaser and such Person.

 

(d)          Promptly
after the execution and delivery of this Agreement, the Purchaser and the Seller will cooperate in good faith to prepare a written
communication to the Transferred Employees and written guidance for any verbal communications by or on behalf of either party to
the Transferred Employees regarding the employee benefits (including equity compensation arrangements) to be provided to the Transferred
Employees by the Acquired Companies following the Closing.

 

(e)          The
Purchaser shall cause the applicable Retention Payment to paid to each individual identified on Schedule 1.1(c) to the Seller Disclosure
Schedules on the first regularly scheduled payroll date for such individual following the Closing Date.

 

Section 10.2         Indemnity.
From and after the Closing and subject to Sections 8.3 and 8.5(a)(iii), the Purchaser will indemnify and hold harmless the Seller
Indemnified Parties against all Losses that are incurred from and after the Closing arising or resulting from (a) any Company Plan
maintained or sponsored directly by any Acquired Company that transfers with the Acquired Companies by operation of Law, (b) any
claim with respect to any Company Plan which transfers in whole, or in part, by operation of

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	39

     

    

 

this Article 10 and (c)
any failure of the Purchaser to discharge its obligations under this Article 10.

 

Article
11
 POST-CLOSING COVENANTS

 

Section 11.1         Confidentiality.

 

(a)          The
parties agree to continue to abide by that certain Confidentiality Agreement between ARIAD US and Purchaser dated January 19, 2016
(the “Confidentiality Agreement”), which will survive until the Closing, at which time the Confidentiality Agreement
will terminate; provided, however, that if this Agreement is, for any reason, terminated prior to the Closing, the
Confidentiality Agreement will continue in full force and effect in accordance with its terms.

 

(b)          For
a period of [***] years after the Closing, the Seller will, and will instruct its Representatives to, hold in confidence, unless
compelled to disclose by judicial or administrative process or by other requirements of Law, all non-public documents and information
to the extent relating to the Acquired Companies (the “Company Information”), except to the extent that such
the Company Information (i) must be disclosed in connection with the obligations of the Seller pursuant to this Agreement or any
Ancillary Agreement, (ii) can be shown to have been in the public domain through no fault of the Seller or (iii) was later lawfully
acquired by the Seller from sources other than those related to its prior ownership of the Acquired Companies. Notwithstanding
the foregoing, in no event will this Section 12.1(b) limit or otherwise restrict the right of the Seller to disclose such the Company
Information (w) to its and its Affiliates’ respective Representatives to the extent reasonably required to facilitate the
negotiation, execution, delivery or performance of this Agreement and the Ancillary Agreements, (x) to any Governmental Authority
or arbitrator to the extent reasonably required in connection with any Proceeding relating to the enforcement of this Agreement
or any Ancillary Agreement, (y) in connection with its indemnification obligations under this Agreement, including the defense
of any Third Party Claim, and (z) as permitted in accordance with Section 5.5.

 

Section 11.2         Indemnification.
The Purchaser will not, for a period of six years after the Closing, take or permit any action to alter or impair any exculpatory
or indemnification provisions now existing in the Organizational Documents of any Acquired Company for the benefit of any individual
who served as a director or officer of any Acquired Company at any time prior to the Closing (each an “Affiliate Indemnified
Party”), except for any changes which may be required to conform with changes in applicable Law and any changes which
do not affect the application of such provisions to acts or omissions of such individuals prior to the Closing. Without limiting
the generality of this Section 12.2, the provisions of this Section 12.2 are intended for the benefit of, and may be enforced by,
each of the Affiliate Indemnified Parties and their respective heirs.

 

Section 11.3         Seller’s
Group Marks.

 

(a)          As
soon as practicable after Closing, and in any event by no later than the date falling six months following the Closing Date, remove
all Seller’s Group Marks from, or otherwise destroy, all sales or promotional materials, stationery, buildings, signage,
vehicles or internet websites in its possession or control bearing any Seller’s Group Marks.

 

(b)          As
soon as practicable after Closing, and in any event by no later than the date falling six months following the Closing Date, change
the name of all Acquired Companies so that it no longer includes any Seller’s Group Marks.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	40

     

    

 

Section 11.4         Standstill.

 

(a)          Except
as permitted by Section 12.4(b), for a period of [***] following the execution and delivery of this Agreement, without the prior
written consent of the Board of Directors of ARIAD US, no Controlled Person shall (or assist or encourage others to) directly or
indirectly in any manner: (i) acquire, announce an intention to acquire, or agree to acquire, directly or indirectly, alone or
in concert with others, by purchase, gift or otherwise, any direct or indirect beneficial ownership (within the meaning of Rule
13d-3 under the Exchange Act) or interest in any securities or direct or indirect rights, warrants or options to acquire, or securities
convertible into or exchangeable for, any securities of ARIAD US; (ii) make, or in any way participate in, directly or indirectly,
alone or in concert with others, any “solicitation” of “proxies” to vote (as such terms are used in the
proxy rules of the SEC promulgated pursuant to Section 14 of the Exchange Act) any securities of ARIAD US with respect to any business
combination, restructuring, recapitalization or similar transaction; (iii) form, join or in any way participate in a “group”
within the meaning of Section 13(d)(3) of the Exchange Act with respect to any voting securities of ARIAD US; (iv) acquire, announce
an intention to acquire, or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, exchange or
otherwise, (x) any of the assets, tangible or intangible, of ARIAD US or (y) direct or indirect rights, warrants or options to
acquire any assets of ARIAD US, other than in the ordinary course of business; (v) enter into any arrangement or understanding
with others to do any of the actions restricted or prohibited under clauses (i), (ii), (iii) or (iv) of this Section 12.4(a); (vi)
otherwise act in concert with others, to seek to offer to ARIAD US or any of its stockholders any business combination, restructuring,
recapitalization or similar transaction to or with ARIAD US, or (vii) take any action to control or influence the management, Board
of Directors or policies of ARIAD US.

 

(b)          The
provisions of Section 12.4(a) shall not apply (i) in the event that ARIAD US announces publicly that it is seeking purchasers for
ARIAD US, (ii) upon the commencement by a third party of a tender or exchange offer for more than 50% of the voting power of the
outstanding voting securities of ARIAD US, provided that if such third party withdraws its tender or exchange offer, Section 11.4(a)
shall again apply as of the date of such withdrawal, (iii) if a third party acquires beneficial ownership of more than 20% of the
outstanding common stock of ARIAD US, (iv) if ARIAD US publicly announces a transaction, or an intention to effect any transaction,
which would result in (A) the sale by ARIAD US or one or more of its subsidiaries to a third party of assets representing more
than 50% of the consolidated earning power or assets of ARIAD US and its subsidiaries, (B) the common shareholders of ARIAD US
immediately prior to such transaction owning less than 50% of the outstanding common stock of the acquiring entity or, in the case
of a merger transaction, the surviving corporation (or, if the surviving corporation is a subsidiary of a parent company, the parent
company) or (C) a third party acquiring beneficial ownership of more than 20% of the outstanding common stock of ARIAD US. For
clarity, the foregoing provisions shall prohibit the Controlled Persons from acquiring shares of common stock of ARIAD US pursuant
to a public tender offer for all outstanding common stock of ARIAD US in consideration for cash unless one of the exceptions in
the preceding sentence applies. Notwithstanding the above, cumulative acquisitions by the Controlled Persons of less than [***]
of ARIAD US’s outstanding common shares shall not be deemed a breach of this provision.

 

(c)          Nothing
in this Section 11.4 shall prevent a Controlled Person from privately approaching ARIAD US to make an offer for the acquisition
solely by the Controlled Persons of ARIAD US or any assets of ARIAD US, including ARIAD US’s rights to Products; provided
that, (i) in the event ARIAD US does not accept any such offer, no Controlled Person shall take any action in contravention of
Section 11.4(a), which shall continue to apply in all respects in accordance with the provision thereof and (ii) no Controlled
Person shall make any public announcement regarding any such private approach by a

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	41

     

    

 

Controlled Person or
otherwise take any action that would reasonably require ARIAD US to make a public announcement regarding such offer or any of the
types of matters set Section 11.4(a).

 

Section 11.5         Further
Actions. Subject to the other express provisions of this Agreement, upon the request of any party to this Agreement, the other
parties will execute and deliver such other documents, instruments and agreements as the requesting party may reasonably require
for the purpose of carrying out the intent of this Agreement and the transactions contemplated by this Agreement.

 

Section 11.6         Books
and Records and Cooperation with Litigation. 

 

(a)          As
soon as reasonably practical after the Closing, and in no event later than 30 days after the Closing Date, the Seller shall, or
shall cause its Affiliates to, deliver to the Purchaser or an Affiliate of the Purchaser as directed in writing by the Purchaser
all Books and Records not kept at the Leased Real Properties.

 

(b)          For
a period of six years after the Closing Date or such longer time as may be required by Law (i) the Purchaser shall not, and shall
cause its Affiliates not to, intentionally dispose of or destroy any of the Books and Records without first offering to turn over
possession thereof to the Seller by written notice to the Seller at least 60 days prior to the proposed date of such disposition
or destruction and (ii) upon reasonable advance notice, the Purchaser shall, and shall cause its Affiliates to, give the Seller
and its Representatives reasonable access, during normal business hours and without unreasonable interruption of the Purchaser’s
business, to, at the Seller’s sole cost and expense, make copies of any Books and Records at reasonable times at the Purchaser’s
principal place of business or at any location where any Books and Records are stored. The provisions of Section 11.6(b)(i) shall
not prohibit or restrict, and shall not require the Purchaser to provide any notice to the Seller in connection with, the deletion
of electronic mail messages or other information stored in an electronic format in the ordinary course of business in a manner
consistent with the Purchaser’s electronic records retention policies and applicable Law. The Seller’s access to the
Books and Records after the Closing Date pursuant to Section 11.6(b)(ii) shall be limited to access that is reasonably required
to permit the Seller to comply with its financial and Tax reporting obligations, to defend against any Proceeding or claim by a
Third Party in which the Seller or its Affiliates are involved relating to or in connection with the Acquired Companies, or otherwise
to comply with any requirement of applicable Law, in each case, subject to the Purchaser’s reasonable policies restricting
access by Third Parties to the Purchaser’s and its Affiliates’ (including, following the Closing, the Acquired Companies’)
information technology systems or assets.

 

(c)          For
a period of six years after the Closing Date, each of the Purchaser and the Seller shall, and shall cause its Affiliates to, make
available upon reasonable advance notice and at reasonable times upon written request any personnel whose assistance or participation
is reasonably required in anticipation of, or preparation for, existing or future Proceedings or claims by a Third Party in which
such party or any of its Affiliates are involved relating to or in connection with the Acquired Companies.

 

(d)          The
requesting party shall reimburse the other party for its reasonable out-of-pocket expenses incurred in performing the covenants
contained in this Section 11.6.

 

Article
12

GENERAL PROVISIONS

 

Section 12.1         Notices.
All notices and other communications under this Agreement must be in writing and are deemed duly delivered when (a) delivered if
delivered personally or by nationally recognized overnight courier service (costs prepaid), (b) sent by facsimile with confirmation
of

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	42

     

    

 

transmission by the transmitting
equipment (or, the first Business Day following such transmission if the date of transmission is not a Business Day) or (c) received
or rejected by the addressee, if sent by United States of America certified or registered mail, return receipt requested; in each
case to the following addresses or facsimile numbers and marked to the attention of the individual (by name or title) designated
below (or to such other address, facsimile number or individual as a party may designate by notice to the other parties):

 

If to the Seller or
ARIAD US:

 

ARIAD Pharmaceuticals,
Inc.

26 Landsdowne
Street

Cambridge,
MA 02139

Facsimile:     [***]

Attention:    Chief
Executive Officer

                      Chief
Legal Officer

 

with a copy (which
will not constitute notice) to:

 

Baker
& McKenzie LLP

100 New
Bridge Street

London,
EC4V 6JA

United
Kingdom

Facsimile:     [***]

Attention:    Jane Hobson

 

and

 

Baker & McKenzie
LLP

300 East Randolph Street, Suite 5000

Chicago, Illinois 60601

United States of America

Facsimile:     [***]

Attention:    Andrew J. Warmus

 

If to the Purchaser
or Incyte US:

 

Incyte Corporation

1801 Augustine
Cut-Off

Wilmington, DE 19803

United States of
America

Facsimile:     [***]

Attention:    General
Counsel

 

with a copy (which will
not constitute notice) to:

 

Morgan, Lewis
& Bockius LLP

502 Carnegie
Center

Princeton ,
NJ 08540

United States
of America

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	43

     

    

 

Facsimile:     [***]

Attention:     Randall
Sunberg

                     Emilio Ragosa

 

Section 12.2         Amendment.
this Agreement may not be amended, supplemented or otherwise modified except in a written document signed by each party to be bound
by the amendment and that identifies itself as an amendment to this Agreement.

 

Section 12.3         Waiver
and Remedies. The parties may (a) extend the time for performance of any of the obligations or other acts of any other party
to this Agreement, (b) waive any inaccuracies in the representations and warranties of any other party to this Agreement contained
in this Agreement or (c) waive compliance with any of the covenants or conditions for the benefit of such party contained in this
Agreement. (i) any such extension or waiver by any party to this Agreement will be valid only if set forth in a written document
signed on behalf of the party or parties against whom the extension or waiver is to be effective; (ii) no extension or waiver will
apply to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any covenant or condition,
as the case may be, other than that which is specified in the written extension or waiver; and (iii) no failure or delay by any
party in exercising any right or remedy under this Agreement or any of the documents delivered pursuant to this Agreement, and
no course of dealing between the parties, operates as a waiver of such right or remedy, and no single or partial exercise of any
such right or remedy precludes any other or further exercise of such right or remedy or the exercise of any other right or remedy.
Except as provided in Section 8.8, any enumeration of a party’s rights and remedies in this Agreement is not intended to
be exclusive, and a party’s rights and remedies are intended to be cumulative to the extent permitted by law and include
any rights and remedies authorized in law or in equity.

 

Section 12.4         Entire
Agreement. This Agreement (including the Schedules and Exhibits hereto and the documents and instruments referred to in this
Agreement that are to be delivered at the Closing) constitutes the entire agreement among the parties and supersedes any prior
understandings, agreements or representations by or among the parties, or any of them, written or oral, with respect to the subject
matter of this Agreement. Notwithstanding the foregoing, the Confidentiality Agreement will remain in effect in accordance with
its terms as modified pursuant to Section 12.1.

 

Section 12.5         Assignment,
Successors and No Third Party Rights. This Agreement binds and benefits the parties and their respective successors and assigns,
except that the Purchaser may not assign any rights under this Agreement, whether by operation of law or otherwise, without the
prior written consent of the Seller. No party may delegate any performance of its obligations under this Agreement, except that
the Purchaser may at any time delegate the performance of its obligations (other than the obligation to pay the Purchase Price)
to any Affiliate of the Purchaser so long as the Purchaser remains fully responsible for the performance of the delegated obligation.
Nothing expressed or referred to in this Agreement will be construed to give any Person, other than the parties to this Agreement,
any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement except
such rights as may inure to a successor or permitted assignee under this Section 12.5.

 

Section 12.6         Severability.
If any provision of this Agreement is held invalid, illegal or unenforceable, the remaining provisions of this Agreement remain
in full force and effect, if the essential terms and conditions of this Agreement for each party remain valid, binding and enforceable.

 

Section 12.7         Exhibits
and Schedules. The Exhibits and Schedules to this Agreement are incorporated herein by reference and made a part of this Agreement.
The Seller Disclosure Schedule and

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	44

     

    

 

the Purchaser Disclosure
Schedule are arranged in sections and paragraphs corresponding to the numbered and lettered sections and paragraphs of Article
3 and Article 4, respectively. The disclosure in any section or paragraph of the Seller Disclosure Schedule, and those in any amendment
or supplement thereto, qualifies other sections and paragraphs in this Agreement to the extent it is reasonably apparent that a
given disclosure is applicable to such other sections and paragraph.

 

Section 12.8         Interpretation.
In the negotiation of this Agreement, each party has received advice from its own attorney. The language used in this Agreement
is the language chosen by the parties to express their mutual intent, and no provision of this Agreement will be interpreted for
or against any party because that party or its attorney drafted the provision.

 

Section 12.9         Expenses.
Except as set forth in this Agreement, whether or not the transactions contemplated by this Agreement are consummated, each party
will pay its own direct and indirect expenses incurred by it in connection with the preparation and negotiation of this Agreement
and the consummation of the transactions contemplated by this Agreement, including all fees and expenses of its Representatives.

 

Section 12.10         Governing
Law. Unless any Exhibit or Schedule specifies a different choice of law, the internal laws of the State of New York (without
giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction)
govern all matters arising out of or relating to this Agreement and its Exhibits and Schedules and the transactions contemplated
by this Agreement, including its validity, interpretation, construction, performance and enforcement and any disputes or controversies
arising therefrom or related thereto.

 

Section 12.11         Limitation
on Liability. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT OR ANY ANCILLARY AGREEMENT TO THE CONTRARY, IN NO EVENT
WILL ANY PARTY OR ANY OF ITS AFFILIATES BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES
(INCLUDING LOST PROFITS, LOSS OF REVENUE OR LOST SALES) IN CONNECTION WITH ANY CLAIMS, LOSSES, DAMAGES OR INJURIES ARISING OUT
OF THE CONDUCT OF SUCH PARTY PURSUANT TO THIS AGREEMENT REGARDLESS OF WHETHER THE NONPERFORMING PARTY WAS ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES OR NOT.

 

Section 12.12         Specific
Performance. The parties agree that irreparable damage would occur and the parties would have no adequate remedy at Law in
the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. The parties accordingly agree that, prior to the termination of this Agreement pursuant to Section 7.1, in addition to
any other remedy to which a party is entitled at law or in equity, such party is entitled to injunctive relief to prevent breaches
of this Agreement by the other party and otherwise to enforce specifically the provisions of this Agreement against the other party.
Each party (a) expressly waives any requirement that the other party obtain any bond or provide any indemnity in connection with
any action seeking injunctive relief or specific enforcement of the provisions of this Agreement (b) agrees it will not oppose
the granting of such remedy.

 

Section 12.13         Jurisdiction
and Service of Process. Any action or proceeding arising out of or relating to this Agreement or the transactions contemplated
by this Agreement must be brought in the New York State Court located in the City of New York, Borough of Manhattan, or, if it
has or can acquire jurisdiction, in the United States District Court for the Southern District of New York located in the City

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	45

     

    

 

of New York, New York.
Each of the parties knowingly, voluntarily and irrevocably submits to the exclusive jurisdiction of each such court in any such
action or proceeding and waives any objection it may now or hereafter have to venue or to convenience of forum. Any party to this
Agreement may make service on another party by sending or delivering a copy of the process to the party to be served at the address
and in the manner provided for the giving of notices in Section 12.1. Nothing in this Section 12.13, however, affects the right
of any party to serve legal process in any other manner permitted by law.

 

Section 12.14         Waiver
of Jury Trial. EACH OF THE PARTIES KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT
OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR THE ACTIONS OF ANY PARTY TO THIS AGREEMENT
IN NEGOTIATION, EXECUTION AND DELIVERY, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT.

 

Section 12.15         No
Joint Venture. Nothing in this Agreement creates a joint venture or partnership between the parties. This Agreement does not
authorize any party (a) to bind or commit, or to act as an agent, employee or legal representative of, another party, except as
may be specifically set forth in other provisions of this Agreement, or (b) to have the power to control the activities and operations
of another party. The parties are independent contractors with respect to each other under this Agreement. Each party agrees not
to hold itself out as having any authority or relationship contrary to this Section 12.15.

 

Section 12.16         Non
Recourse. No past, present or future Representative, incorporator, member, partner, equity holder or Affiliate of the Seller,
any Acquired Company or any of their respective Affiliates shall have any liability for any Liabilities of the Seller, as applicable,
under this Agreement or for any claim based on, in respect of, or by reason of, the transactions contemplated hereby.

 

Section 12.17         Guaranty.

 

(a)          ARIAD
US irrevocably guarantees all representation, warranty, covenant and obligations of the Seller and the performance of its obligations
under the provisions of this Agreement. This is a guarantee of payment and performance, and not of collection, and ARIAD US acknowledges
and agrees that this guarantee is full and unconditional, and no release or extinguishments of the Seller’s Liabilities (other
than in accordance with the terms of this Agreement), whether by decree in any bankruptcy proceeding or otherwise, will affect
the continuing validity and enforceability of this guarantee. ARIAD US hereby waives, for the benefit of the Purchaser any right
to require the Purchaser as a condition of payment or performance of ARIAD US to proceed against the Seller.

 

(b)          Incyte
US irrevocably guarantees all representation, warranty, covenant and obligations of the Purchaser and the performance of its obligations
under the provisions of this Agreement. This is a guarantee of payment and performance, and not of collection, and Incyte US acknowledges
and agrees that this guarantee is full and unconditional, and no release or extinguishments of the Purchaser’s Liabilities
(other than in accordance with the terms of this Agreement), whether by decree in any bankruptcy proceeding or otherwise, will
affect the continuing validity and enforceability of this guarantee. Incyte US hereby waives, for the benefit of the Seller any
right to require the Seller as a condition of payment or performance of Incyte US to proceed against the Purchaser.

 

Section 12.18         Counterparts.
The parties may execute this Agreement in multiple counterparts, each of which constitutes an original as against the party that
signed it, and all of which together

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	46

     

    

 

constitute one agreement.
This Agreement is effective upon delivery of one executed counterpart from each party to the other parties. The signatures of all
parties need not appear on the same counterpart. The delivery of signed counterparts by facsimile or email transmission that includes
a copy of the sending party’s signature(s) is as effective as signing and delivering the counterpart in person.

 

[Signature page follows.]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	47

     

    

 

IN WITNESS WHEREOF,
the parties have executed and delivered this Agreement as of the date indicated in the first sentence of this Agreement.

 

	 	ARIAD PHARMACEUTICALS (CAYMAN) L.P.
	 	 
	 	BY:	ARIAD Pharmaceuticals (Cayman) Inc., its General Partner
	 	 	 	 
	 	 	By:	/s/ Manmeet S. Soni
	 	 	 	Manmeet S. Soni
	 	 	 	Director
	 	 
	 	ARIAD PHARMACEUTICALS, INC., solely as guarantor
	 	 	 
	 	By:	/s/ Manmeet S. Soni
	 	 	Manmeet S. Soni
	 	 	Executive Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to Stock Purchase Agreement]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed and delivered this Agreement as of the date indicated in the first sentence of this Agreement.

 

	 	Incyte Europe S.à r.l.
	 	 	 
	 	By:	/s/ Laurent Chardonnet
	 	 	Name: Laurent Chardonnet
	 	 	Title: Head of Finance
	 	 
	 	Incyte CORPORATION, for the purposes of Section 11.4 and 12.7(b)
	 	 	 
	 	By:	/s/ Hervé Hoppenot
	 	 	Name: Hervé Hoppenot
	 	 	Title: President and Chief Executive Officer

 

[Signature Page to Stock Purchase Agreement]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

For acknowledgment
and consent of the transfers of the Shares in accordance with the provisions of this Agreement and for the purpose of article 1690
of the Luxembourg Civil code and 190 of the Luxembourg law dated 10 August 1915 on commercial companies, as amended:

 

	 	ARIAD Pharmaceuticals (luxembourg) S.à r.l.
	 	 	 
	 	By:	/s/ Jonathan Dickinson
	 	 	Jonathan Dickinson
	 	 	Class A Manager

 

[Signature Page to Stock Purchase Agreement]

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

EXHIBIT A

 

Amended and Restated
Buy-In License Agreement

 

Attached.

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

EXHIBIT B

 

Territory

 

	European Union Countries	 	[***]
	 	 	
	1.    Austria	 	[***]
	2.    Belgium	 	37. Israel
	3.    Bulgaria	 	[***]
	4.    Croatia	 	43. Norway
	5.    Cyprus	 	44. Russia
	6.    Czech Republic	 	[***]
	7.    Denmark	 	47. Switzerland
	8.    Estonia	 	48. Turkey
	9.    Finland	 	[***]
	10.  France	 	 
	11.  Germany	 	 
	12.  Greece	 	 
	13.  Hungary	 	 
	14.  Ireland	 	 
	15.  Italy	 	 
	16.  Latvia	 	 
	17.  Lithuania	 	 
	18.  Luxembourg	 	 
	19.  Malta	 	 
	20.  Netherlands	 	 
	21.  Poland	 	 
	22.  Portugal	 	 
	23.  Romania	 	 
	24.  Slovakia	 	 
	25.  Slovenia	 	 
	26.  Spain	 	 
	27.  Sweden	 	 
	28.  United Kingdom	 	 

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	 

     

    

 

EXHIBIT C

 

Joint Press Release

 

    	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
 Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment
 pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]